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New small-molecule drugs are needed, both to address existing disease and to combat the rise of 
antibiotic resistance in pathogenic microbes. A major source of antibiotics and other valuable 
therapeutic agents remains the natural products produced by Streptomyces and allied bacteria. The 
advent of genome-level sequencing has changed how such bioactive products are identified in two 
ways: first, by enabling new approaches to engineering of known clusters to obtain new analogues; 
and secondly by enabling mining of their large (8-12 Mbp) genomes to make rapid links between 
valuable compounds and the gene clusters responsible for their biosynthesis; as well as a complete 
inventory of orphan clusters for decryption. In this work, both of these aspects were explored.  
 Accelerated Evolution (AE) is a new method of induced recombination in Streptomyces that 
produces libraries of analogues of a parent compound in a single experiment. It has been previously 
applied to a typical assembly-line biosynthetic pathway involving a multimodular polyketide synthase, 
that for the immunosuppressant rapamycin. Here, the utility of AE was initially explored with several 
polyketide antibiotics, before focussing on the polyene filipin. Unfortunately, this system proved 
refractory to the AE method, since only recombinants which had either lost filipin production, or which 
maintained some level of filipin production, were recovered. These results suggested that deeper 
understanding of the fundamental processes of recombination in Streptomyces are now needed to 
allow the AE approach to flourish. 
 A genome mining approach was taken to identify and analyse the gene cluster in Streptomyces 
albus DMS40763 for pseudouridimycin (PUM), a rare C-nucleoside antibiotic and a newly-recognised 
selective inhibitor of bacterial RNA polymerase. The fully-sequenced genome (8.01 Mbp) of S. albus 
was analysed and 27 biosynthetic gene clusters were found, including those for 11 novel assembly-
line systems. A strong candidate for the PUM gene cluster was identified through BLAST searches with 
a gene probe (truD) found in the gene cluster for a different C-nucleoside in other Streptomyces spp., 
hinting at a common mechanism for formation of the C-nucleoside moiety. Identification of the 
enzymes predicted to be encoded by the gene cluster allowed a detailed biosynthetic pathway to be 
proposed. Several genes from the PUM cluster were expressed and purified as recombinant proteins 
in Escherichia coli, and the proposed enzymatic roles of two of them were verified. One of these, a 
pseudouridine oxidase, also showed activity against uridine. Consistent with this finding, feeding of 
uracil to a mutant S. albus lacking the pseudouridine synthase-like gene truD gave production of the 
novel N-linked analogue of PUM, suggesting that the biosynthetic enzymes may be sufficiently flexible 
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Chapter 1: Introduction 
 
1.1: Actinomycete Natural Products and their Targets 
1.1.1: The Role of Natural Products in Medicine 
 
Natural products, and the field of research that attempts to understand and eventually control them, 
lie at the interface between chemistry and biology. Their complex, diverse structures have captured 
the imagination of chemical scientists and led to a flowering of modern methods of stereoselective 
total synthesis 1–3. Meanwhile, the exquisite specificity of action of many natural products has been 
invaluable in the mapping of metabolic pathways and regulatory cascades. Last but not least, natural 
products have been a continuing source of leads and inspiration in drug discovery 4–6  
 The simplest definition of a natural product is a small molecule that is produced by a biological 
source 7. The term natural product generally refers to secondary metabolites. These are non-essential 
molecules; they are not required for the growth, development and reproduction of the producing 
organism. The function of secondary metabolites has been widely discussed and there have been a 
number of views as to why they exist at all; Bu’Lock, who coined the term ‘secondary metabolite’ 
stated “it is the process of secondary biosynthesis which is seen as advantageous, and not, in the 
general case, its products, and in my opinion this is still the general type of explanation” 8; Zähner et 
al held the view that we should “rid ourselves of the simplistic idea that antibiotics are formed as a 
defence mechanism, and recognise instead that antibiotics are nothing more than secondary 
metabolites which possess, more or less incidentally, an antibiotic effect” 9; while Williams et al argue 
that “all natural products have evolved under the pressure of natural selection to bind to specific 
receptors” 10. Perhaps the most widely-accepted view now is that of Firn and Jones 11, who identify 
the ability to produce such bioactive specialised metabolites as the valuable selectable trait, rather 
than the ability to produce a particular molecule and that the secondary metabolism will have evolved 
such that traits that optimise the production and retention of chemical diversity at a minimum cost 
will have been selected for. 
 
 The earliest records of natural products have been found on clay tablets from Mesopotamia, 
dated at 2600 BC. These documented oils from Cupressus sempervirens (Cypress) and Commiphora 
(Myrrh) species, which are still used to treat colds, coughs and inflammation 12. Studies of the ancient 
Egyptian Ebers Papyrus identified about 800 complex prescriptions and over 700 natural agents such 
as Aloe vera, Boswellia carteri (frankincense) and the oil of Ricinus communis (castor oil) 13. The first 
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treatise written on the concepts and practice of Indian Ayurveda was written almost 3000 years ago 
and contains hundreds of plant derived medicines 14. Some of the most important drugs in use today 
have ancient roots; the anti-inflammatory agent, acetylsalicyclic acid (aspirin) is derived from salicin, 
isolated from the bark of Salix alba (willow tree) 15 and the alkaloid morphine is derived from the plant 
Papaver somniferum (opium poppy) 15 (Figure 1.1). 
 
 
Figure 1.1: Historical and modern examples of therapeutic natural products. (1) β-boswellic acid, one of the 
active ingredients in frankincense (2) A trimester of glycerol and ricinoleic acid, the major component of castor 
oil (3) acetylsalicyclic acid (4) morphine (5) benzylpenicillin (6) amphotericin B (7) gentamicin. 
 
 The development of modern medicine has also been shaped in part by the impact of natural 
products. In 1929 Alexander Fleming famously discovered penicillin, derived from the fungus 
Penicillium notatum. The clinical studies and commercialisation of synthetic penicillins that followed 
revolutionised drug discovery and the practice of medicine, allowing operations to be performed at 
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much lower risk, and the treatment of previously life-threatening diseases. Anti-infectives remain an 
important class of natural products, as in 2016 three of the top ten global causes of death were 
infections, including tuberculosis and respiratory infections. Many of these compounds are found in 
the World Health Organisation (WHO) Model List of Essential Medicines, including amphotericin B, 
rifampicin, vancomycin, and gentamicin. Natural products possess a vast chemical diversity and have 
had a profound impact on the development of antitumour, immunosuppressnt and cholesterol-
lowering compounds 16,17, however the focus of the work described here is on anti-infective natural 
products, their producers, and the genes and enzymes responsible for their biosynthesis. 
 Sixteen years after Alexander Fleming’s discovery of penicillin, he shared the 1945 Nobel Prize 
in Physiology or Medicine for the discovery of penicillin. Then, in 1952, Selman A. Waksman received 
the Nobel Prize for the discovery of streptomycin 18, an antibiotic with activity against penicillin-
resistant bacteria, and importantly exhibiting activity against Mycobacterium tuberculosis, the 
causative agent of tuberculosis. This was the first time natural products were systematically sought 
through screening, and it heralded the age of antibiotics and what is known as ‘the Golden Age’ of 
natural product drug discovery. Half of the drugs commonly used today and many of the recognised 
classes `of antibiotics were discovered during this period 19 (Figure 1.1). 
 
1.1.2: Producers of Natural Products 
 
Antibiotic-producing organisms are primarily bacterial, but it is important to note that plants and fungi 
also have specialised secondary metabolic pathways that can generate huge chemical diversity. 
Indeed, penicillin, one of the best known and most influential antibiotics, is derived from a fungus, 
Penicillium notatum. There are approximately 100,000 fungal species known, although the total 
expected number is far in excess of one million. The variety of species and their diversity means fungi 
are a rich source of new natural products. An extension of screening from traditionally used 
saprophytic terrestrial strains to marine and endophytic strains, accompanied by new screening 
strategies, has led to the discovery of many novel fungal metabolites 20. Hypocreolide, a nonenolide 
derived from the terrestrial ascomycete Hypocrea lactea, shows antibacterial, antifungal, and 
cytotoxic activities21. Benzophomopsin A, a new benzoxepin isolated from an endophytic Phomopsis 
strain derived from a Japanese cherry tree, potently inhibits Ca2+ signalling 22. The novel compounds; 
JBIR-37 and JBIR-38, isolated from the marine sponge-derived fungus Acremonium sp., do not exhibit 
any bioactivities, but they are the first examples of glycosyl benzenes from fungi 23, showing that 
advances in chemical screening techniques continue to identify interesting chemotypes. 
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 Plants have historically been a primary source of medicines. In a pre-synthetic era it is 
estimated that 80% of medicines were obtained from roots, bark and leaves 24. With an estimated 
200,000 natural products being generated by plants25, including many valuable alkaloids and 
terpenoids, such as artemisinin, plants are an important source of novel chemical diversity. Plant 
natural product biosynthesis tends to focus on the generation of key intermediate scaffolds which are 
then tailored, or enzymatically decorated, by a small collection of enzymatic transformations, to form 
different classes of natural products. The most widely used drug for the treatment of breast cancer is 
paclitaxel (Taxol), isolated from the bark of Taxus brevifolia (Pacific Yew). Initial screenings of the 
compound required the bark from three 100 year old trees to produce 1 gram of paclitaxel 26. A total 
synthetic route has been developed to help meet the current annual demand for 100 to 200 kg of the 
compound 15, but it is expensive. Fortunately, baccatin III was found to be present in the needles of T. 
brevifolia in much higher quantities and can be used as a starting point for paclitaxel semi-synthesis. 
Unfortunately, only a handful of plant secondary metabolic pathways are fully defined 25, and this lack 
of knowledge of the genes and enzymes involved in bioynthesis has hindered progress. However there 
have been success stories, such as artemisinin. This potent antimalarial was first isolated from 
Artemisia annua, which was originally used in traditional Chinese medicine. The supply of plant-
derived artemisinin is unstable, resulting in complications for drug manufacturers, but through huge 
effort, the pathway for a precursor to artemisinin, artemisinic acid, has been successfully engineered 
into Saccharomyces cerevisiae 27, and an elegant chemical conversion devised to turn this into the 




Figure 1.2: Natural products derived from fungi and plants. (1) hypocreolide A (2) benzophomopsin A (3) JBIR-
37 (4) artemisinin (5) paclitaxel. 
 
 Actinomycetes are prolific producers of natural products. More than 5000 antibiotics have 
been identified from this order of organisms, with over 90% of those coming from the genus 
Streptomyces 28. The discoveries of streptothricin and streptomycin in the 1940s led to large scale 
screening of candidates, but it has been estimated that only a small percentage of Streptomyces 
antibiotics have been discovered 29. A number of other genera are also important contributors to 
natural product diversity. The genus Bacillus produces, for example, lanthionine-containing 
antibiotics, bacteriocin, and gramicidin 30,31. The order Myxococcales are also recognised as prolific 
producers of natural products. They contain some of the largest genomes of all bacteria 32 which 
together encode over 500 natural products, mostly the products of polyketide synthase (PKS), non-
ribosomal peptide synthase (NRPS), or hybrid PKS-NRPS pathways 33,34. Pathogenic species of the 
genus Burkholderia are also a rich source of new natural products, producing for example enacyloxins, 
which are active against Gram-positive and Gram-negative pathogens 35; rhizoxin, an antimitotic agent 
36; and the glidobactins, antitumor antibiotics 37. 
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 After the ‘Golden Age’ of natural product drug discovery, it was assumed that the diversity of 
natural products had been fully evaluated and since the 1990s pharmaceutical companies have largely 
abandoned natural product screening in favour of combinatorial chemistry, structure-assisted drug 
design, and antibody-based therapies. However, new technologies and screening strategies can 
uncover many more promising drug candidates from natural products. For example, new screening 
methods have identified many new β-lactams, which as of 2003 held approximately 65% of the global 
antibiotics market. β-lactams remain at the forefront of the fight against antibiotic resistance with the 
development of the current 5th generation β-lactam derived cephalosporins, ceftaroline 38, and 
ceftobiprole 39 which are both highly active against MRSA and other Gram-positive bacteria. 
 Considering that an estimated 99% of all bacteria species are uncultured 40, bacteria still represent a 
largely untapped reservoir of novel chemical diversity. 
 
1.1.3: The Life Cycle of Streptomyces and related actinomycetes 
 
Streptomyces are filamentous actinomycetes, Gram-positive and of characteristically high G+C% 
content. They are abundant in soil and are believed to have had a last common ancestor around 400 
million years ago 41, about the same time at which the land was being colonised by plants. Their major 
role in wider ecosystems was probably the solubilisation of cell walls, or surface components of plants, 
fungi and insects 42, composting early organic material and helping to form primeval soil. This 
ecological function can be seen still at the genome level. Streptomyces reticuli has an estimated 456 
genes encoding proteins involved in degradation and utilisation of cellulose and other carbohydrates 
43. This is a common situation among Streptomyces and suggests that they may have evolved to live in 
mixed communities 44. 
 The developmental cycle of Streptomyces on a surface begins with formation of substrate 
mycelium, a vegetative tip growth phase that produces branching filaments that only septate 
occasionally so that each cell contains multiple chromosomes. In response to nutrient depletion, 
typical Streptomyces alter their growth pattern, producing specialised aerial hyphae, or aerial 
mycelium, which undergoes septation to generate a series of compartments each containing a single 
copy of the (linear) chromosome. Finally, the compartments differentiate to create a chain of heat-
labile but desiccation-resistant spores for dispersion 45 (Figure 1.3). A complex signalling cascade 
controls the transition from vegetative growth to reproduction 46, and might provide checkpoints for 
the coordination of secondary metabolism 47.  
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 The developmental cycle in liquid cultures is different to growth on a surface and has not been 
as extensively studied. This is mainly because most Streptomyces do not sporulate in liquid medium. 
Most industrial processes involving Streptomyces are performed in liquid cultures, so the majority of 
the work in this area has focused on mycelial morphology, medium composition, and bioreactor 
design 48–50. Mycelial morphology, for example, is correlated with secondary metabolite production in 
at least some cases 51,52, but not in others 53. In practice, each strain requires individual optimisation, 
which normally accompanies successive rounds of mutation and selection for improved production. 
 
 








1.1.4: Antibiotic modes of action and bacterial mechanisms of resistance 
 
The chemical structure of an antibiotic determines its class, which in turn determine the bacterial 
physiology or biochemistry of the drug’s target. The primary modes of action for antibiotics are 
illustrated in Figure 1.4. Common examples of antibiotic classes and their biological targets are; -
lactams which target cell walls, fluoroquinolones which target DNA and RNA synthesis, sulphonamides 
which target folate synthesis, lipopeptides which target the cell membrane, and aminoglycosides 
which target protein synthesis. 
 
Figure 1.4: Mechanisms of action of antibiotics. 
 
 Self-resistance is an evidently important feature for antibiotic-producing organisms. Self-
resistance is closely connected to acquired resistance, the ability of target organisms to modify 
themselves in some way to overcome the effects of an antibiotic. The development and/or 
recruitment of genes that confer resistance is of clear value for survival. Many genes responsible for 
resistance against several classes of antibiotics have been identified, most systematically by high-
throughput screens of high-density mutant libraries created by targeted insertion or random 
transposon mutagenesis 54,55. An example of intrinsic resistance (Figure 1.5) is given by daptomycin, a 
clinically-used lipopeptide which is effective against Gram-positive, but not Gram-negative bacteria. 
Gram-negative bacteria have fewer phospholipids in the cytoplasmic membrane significantly reducing 
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daptomycin uptake 56. Other mechanisms by which bacteria protect themselves include: minimising 
intracellular concentration of the antibiotic by dedicated active efflux systems; modification of the 
intracellular target by genetic mutation or post-translational modification; or inactivation of the 
antibiotic by hydrolysis or covalent modification. 
 
 
Figure 1.5: Intrinsic mechanisms of resistance. Antibiotic A can enter the cell via a cell membrane spanning pore 
and inhibit peptidoglycan synthesis. Antibiotic B can also enter the cell but is removed by efflux. Antibiotic C 
cannot cross the membrane. Adapted from Blair et al. 56. 
  
Bacterial efflux pumps actively transport molecules out of cells and are major factors to the 
intrinsic resistance to antibiotics for many Gram-negative bacteria. Some pumps are highly substrate 
specific, such as the Tet family efflux pumps, which are specific for tetracycline antibiotics 57. Others 
have a wider substrate specificity, such as AcrB in E. coli. AcrB forms a protein complex with two 
adapter proteins, and resides in the inner cell membrane. Structural studies have shown a large, 
flexible binding pocket which can accommodate molecules of different sizes and structures, allowing 
the transport of a wide range of antibiotics from the cell 58.  
 Antibiotic modifying enzymes are another important factor in resistance. Penicillins and 
cephalosporins are hydrolysed by a range of β-lactamase enzymes 56,59. These enzymes were first 
detected in 1979 after analysis of bacterial isolates resistant to cefamandole, a cephalosporin 60. 
Newer examples have been found to follow, with increasing rapidity, upon the introduction into 
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clinical use of improved β-lactams 56. This type of resistance mechanism is particularly dangerous. The 
resistance can be provided by a single gene carried on a plasmid, meaning the risk of horizontal 
transfer is especially high, which can have serious implications for the treatment of severe infections. 
 Resistance genes have been present in the environment long before the modern development 
of antibiotics 61 but antibiotic resistance is now one of the biggest threats to global health, food 
security and development. A particularly striking example of the dangers of antibiotic resistance was 
the isolation of a strain of methicillin-resistant Staphylococcus aureus (MRSA) with resistance to 
vancomycin, normally used as a drug of last resort 62. The rapid spread of resistance genes across 
bacterial populations has been driven by the widespread and poorly managed use of antibiotics in 
human health, and increasingly in agriculture and aquaculture, leading to increased concentrations of 
antibiotics in the environment and creating perfect conditions for the development of resistance. To 
combat microbial infections in the era of multi-drug resistance bacteria the traditional approaches to 
drug discovery need to change. Economic incentives designed to encourage pharmaceutical 
investment into new antibiotics, and a focus on accurate, personalised diagnosis and narrow spectrum 
antibiotics are steps in the right direction to treat serious infections in the resistance era 63. 
 
1.2: Biosynthetic Genes and Enzymes of Actinomycetes  
1.2.1: Biosynthetic Gene Cluster Organisation and Regulation. 
 
One of the most important discoveries in the early days of actinobacterial gene sequencing was that 
the genes required for the biosynthesis of secondary metabolites are clustered together on the 
bacterial chromosome, although that clustering is highly variable across and within organisms 64. Most 
gene clusters are organised into several operons, each under the control of a single upstream 
promoter, ensuring tight coupling of transcription and translation 65. Within a biosynthetic gene 
cluster, the core biosynthetic genes encode enzymes that generate the scaffold of the metabolite. Its 
structure will depend on the class of metabolite, for example polyketide, non-ribosomal peptide, or 
terpene. In addition to the core biosynthetic genes, there are genes that encode tailoring enzymes 
that modify the scaffold and generate diversity and bioactivity, such as oxidoreductases, 
methyltransferase, acyltransferases, and glycosyltransferases. Many gene clusters will also contain 
cluster-specific regulatory (CSR) genes, as well as genes conferring self-resistance, and genes encoding 
mechanisms to transport the product out of the cell. As discussed above, the mechanisms for self-
resistance are very important for an organism. Erythromycin A is a potent inhibitor of protein synthesis 
and causes this inhibition in susceptible bacteria by binding to their ribosome. The erythromycin 
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biosynthetic gene cluster contains a gene, ermE, which confers self-resistance to erythromycin by the 
dimethylation of a specific adenine base in its ribosomal RNA 66. One of the first actinobacterial 
antibiotic biosynthetic gene clusters to be identified was that for the coloured isochromanequinone 
actinorhodin 67. The gene cluster has been characterised in detail and is illustrated in Figure 1.6, 
showing that the core minimal PKS genes form only a small component of a complex system. 
 
Figure 1.6: The actinorhodin gene cluster. The functions of genes are indicated by colour. Adapted from 
Osbourn 64. 
 
 In Streptomyces, and in other actinobacteria, the expression of secondary metabolic pathways 
is typically controlled by complex regulatory cascades that send signals to pathway-specific regulators 
and are often coordinated with morphological changes in the organism, or environmental stimuli 68. 
While the pathway-specific regulators, such as the SARP 69 or LAL 70 families of regulators, are 
responsible for transcriptional control of individual gene clusters, there are also global, or pleiotropic 
regulators that control multiple gene clusters. The highly phosphorylated guanosine nucleotide, 
ppGpp, has received attention for its role in antibiotic production in Streptomyces. It has been shown 
that ppGpp is required for activating the transcription of genes required for antibiotic biosynthesis 
under nitrogen limited conditions, although the exact mechanism is elusive 71. γ-butyrolactones are 
produced by many Streptomyces 72, and have also been implicated in the onset of secondary 
metabolism 68. A-factor, a typical γ-butyrolactone from S. griseus, has been implicated in both the 
activation of secondary metabolism and morphological differentiation 73. 
 
1.2.2: Evolution and Function of Biosynthetic Gene Clusters  
 
The clustered organisation of biosynthetic genes suggests that at some point in their evolution they 
were selected for as a group, rather than as individual genes. If the production of the natural product 
were favoured for the producing organism then it would be beneficial for them to be close together, 
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increasing the probability of them being transferred to subsequent generations of the organism 74. 
This does not explain the origins of the core biosynthetic genes however, which are often considered 
the founders of the gene cluster. Three types of evolutionary pathway are possible: linear, divergent 
and convergent 74. A linear pathway is the easiest to imagine. The first catalytic enzyme of the 
primordial gene cluster could have arisen from random mutation of an enzyme involved in the primary 
metabolism of the starting material. If the product of that enzyme could be secreted from the cell, 
and provided some advantage to the organism, for instance by interacting with a receptor from 
another organism, then the producing organism will be selected for over others. Subsequent 
duplication, or mutation of that first enzyme, or the occurrence of a new enzyme may result in the 
transformation of the product, which may provide additional advantage over the original mutant 
organism. It can be imagined that repeated steps of this process could generate a multi-step 
biosynthetic pathway where each step provides further advantage over the previous steps. A 
divergent evolutionary pathway can be described by a slight modification of the linear one. If, at the 
point of divergence, two mutations of an enzyme are generated that can perform different reactions 
on the same substrate and providing they both provide greater advantage than the original organism, 
then both will be selected for. At that point one can imagine two parallel linear evolutionary pathways 
that diverge as they improve upon the original biosynthesises. Convergent pathways are more difficult 
to imagine occurring randomly, they require a mutation resulting in an enzyme that can bring together 
two different biosynthetic pathways, with the condensed product of the new pathway conferring 
greater advantage to the organism than the previous two products. An example of this kind of 
evolutionary pathway may be dynemicin, an antibiotic with both enediyne and anthracycline 
structural features 75. 
 
1.2.3: Polyketides and Polyketide Synthases 
 
Polyketides are a large and diverse class of biologically active natural product polymers, which can be 
broadly divided into aromatic compounds, in which the carbon skeleton that is built up is then 
stabilised by dehydration and aromatic ring formation; and complex reduced polyketides, in which the 
more chemically stable reduced chain adopts a wide range of structures including linear products, 
macrocycles, and polyethers, and may also be found covalently linked to amino acid units within 
hybrid polyketide-peptide compounds 17 Polyketides have been harvested from a number of 
organisms besides bacteria, including most importantly fungi. In the case of insects, marine sponges, 
and plants the actual producing organism is very often a commensal microorganism 17. Between them 
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polyketides have provided clinically useful compounds with antibacterial, antifungal, antiviral, and 
antitumour activity, as well as immunosuppressant and cholesterol-lowering compounds. This family 
of natural products also includes toxins such as the potent fungal carcinogen aflatoxin from Aspergillus 
spp. 76; macrolide mycolactone produced by Mycobacterium ulcerans 77, the causative agent of the 
necrotizing skin disease Buruli ulcer; and the potent respiratory toxin bongkrekic acid produced by 
Burkholderia gladioli, a notorious contaminant of the traditional Indonesian dish, tempe bongkrek 78. 
  
 Polyketides are an exciting source of drug candidates as they cover a region of chemical space 
that appears to interact with biological targets very effectively 79,80. Over 7000 known polyketide 
structures have led to more than 20 commercial drugs, a hit rate of 0.3%, far greater than the hit rate 
of <0.001% typically found for synthetic compound libraries 81. These drugs have also proved very 
successful commercially, with annual peak sales of the top six totalling $15 billion. Over the last thirty 
years, fundamental research on the genes and enzymes of polyketide biosynthesis has transformed 
our understanding of the pathways and mechanisms involved, and this in turn has presented new 
opportunities to exploit natural products as leads in drug discovery. 
 
Figure 1.7: Examples of polyketide natural products. (1) modular type I PKS product erythromycin A; (2) 
modular type I PKS product amphotericin B; (3) iterative type I PKS product lovastatin; (4) type II PKS product 





Polyketide synthases (PKSs) are the key enzymes catalysing the biosynthesis of polyketide polymers. 
They use a mechanism for chain assembly that closely resembles that of fatty acid synthases (FASs), 
in which simple carboxylic acid extender units provided by primary metabolism are linked together by 
iterative Claisen-like condensation reactions 17 (see Figure 1.8). Assembly on a typical fatty acid 
synthase starts by transfer of an acetyl unit from acetyl-CoA onto the active site of a ketosynthase (KS) 
enzyme as a thioester. The transfer is catalysed by an acyltransferase (AT) which in FAS systems also 
transfers a malonyl unit from malonyl-CoA to the 4'-phosphopantetheinyl prosthetic group of an acyl 
carrier protein (ACP). The KS catalyses Claisen-like condensation to give the 3-ketoacyl-ACP product, 
after which reductive processing takes place catalysed by, successively, a β-ketacyl-ACP reductase 
(KR); a dehydratase (DH); and an enoylreductase to give a fully reduced butyryl thioester, which the 
KS transfers back to its active site, freeing the ACP for attachment of a further malonate extender unit. 
This iterative process continues until the chain length is such that chain termination catalysed by a 
thioesterase (TE) or transferase competes effectively with back-transfer of the chain to the KS. In E. 
coli and most other bacteria, the individual enzymatic activities of the FAS are housed on individual 
proteins (a Type II system), while in yeast and animal FAS the enzymes are domains within a covalently-
linked multifunctional enzyme (a Type I system) 17. 
 
 
Figure 1.8: Claisen-like condensation of an ACP-bound malonyl extender unit with the growing polyketide 
backbone. An activated malonyl extender unit, bound to an ACP domain by a phosphopantetheine prosthetic 
group reacts with the polyketide intermediate held by the KS domain, expelling carbon dioxide and forming a 





The major difference between FAS and PKS is that in the latter type of synthase reductive 
processing is not complete. In Type II dissociated PKSs of bacteria, and in the iterative Type I PKS 
multienzymes of fungi, reduction may take place rarely or not at all, giving a full-length, highly-reactive 
poly--oxo-thioester intermediate which is stabilised by formation of aromatic rings. In bacterial 
modular PKSs reduction is variable and usually incomplete, as discussed below. Table 1.1 summarises 
these different types of synthase and their characteristic products. 
Table 1.1: Summary of polyketide synthase types (adapted from Weissman 82). 
 






Typical product Typical 
organisms 
I Modular ACP Reduced Bacteria 




II Iterative ACP Aromatic Bacteria 
III Iterative CoA Aromatic Bacteria, Fungi 
and Plants 
 
 Type III PKSs are relatively simple homodimeric enzymes, with a single KS-like multifunctional 
active site which interacts with CoA-bound substrates (no ACP is involved) to catalyse the iterative 
condensations of acetate units to the CoA-bound starter units. They are found in bacteria, fungi and 
plants 83, typically yielding mono- and bi-cyclic aromatic products 84 formed through intramolecular 
condensations and aromatisation of the linear intermediate within the same PKS active site cavity. 
The type III PKSs were originally discovered in plants 83, where they include chalcone synthases and 
stilbene synthases. They generate a vast array of small polyphenolic molecules important to plant 
survival and fitness. The phenolic compounds were likely early adaptations in plants, involved in the 
transition of plants from aquatic to terrestrial environments 85. These compounds are involved in UV 
protection, flower colour, pollen development, root nodulation, plant architecture and chemical 
defence 86. These systems provide diversity through the choice of CoA-bound starter molecules, the 
number of elongation steps and the mechanisms of cyclisation. Downstream tailoring enzymes can 
then further increase diversity, transforming the initial scaffolds into a huge range of different 
compounds 87. The relatively simple architecture of the type III enzymes has allowed for a mechanistic 
framework to be developed, offering insights into the factors involved in starter unit selection, chain 
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extension and control of ring formation 82. These insights can be helpful when considering similar 
factors in the more complex type II and type I systems. 
 Type II PKSs consist of several different enzymes, each expressed from a distinct gene. Marine- 
and soil-dwelling actinomycetes are the only known organism to employ the type II system. They are 
a rich source of bioactive polyphenols such as tetracyclines and produce doxorubicin, an anthracycline, 
one of the most effective classes of anticancer drugs ever developed 88. Chain initiation, most 
commonly starting with acetate, and elongation, using malonyl-CoA extension units, are achieved by 
a “minimal PKS” which consists of a complex of two ketosynthase-like condensing enzymes (KSα and 
KSβ), and an ACP to which the polyketide intermediate is tethered. The folding of the growing 
polyketide intermediate can be modified by additional enzymes such as a KR, cyclases and aromatases, 
to generate an aromatic product. Once released these polyphenols are often extensively modified by 
hydroxylases, glycosylases and other tailoring enzymes 89. A malonyl-CoA:ACP transferase (MCAT) 
activity to recruit new malonyl extension units is thought a necessary component of the minimal PKS, 
however genes encoding proteins with this activity are absent in most type II PKS gene clusters and it 
was proposed that an endogenous MCAT is recruited from fatty acid biosynthesis 90. An alternative 
model for the recruitment of malonyl extender units was proposed by Simpson et al. that ACP self-
malonylates. Although they demonstrated this activity in vitro, it unfortunately required elevated 
concentrations of malonyl-CoA unlikely to be found in vivo 91. The multienzyme complexes of type II 
PKS have been notoriously hard to study and only recently, through structural studies, has there been 
direct evidence for the KSα, KSβ heterodimer 92. 
 Type I PKSs have proven to be the most complicated and most versatile class of PKS. Iterative 
Type I PKSs are commonly found in fungi where they use a single set or module of enzymes acting 
iteratively to generate the diverse polyketide structures found in fungi natural products. Fungal 
polyketides can broadly be grouped into three classes, based on the extent to which the enzymes 
make use of reducing domains. These are illustrated in Figure 1.9. The classes of non-reduced 
compounds such as orsellinic acid, and partially reduced compounds such as 6-MSA were 
characterised first from the limited set of known fungal PKS genes. Degenerate primers, designed to 
amplify the conserved β-ketoacyl synthase domains identified many new fungal PKS genes, which also 




Figure 1.9: Examples of iterative Type I PKS products. (1) orsellinic acid; (2) 6-MSA; (3) lovastatin. 
 
1.2.4: Modular Type I Polyketide Synthases and the Assembly-line Paradigm 
 
The modular PKS for the 14-membered macrolide erythromycin A 
 
Macrolides are glycosylated polyketides with potent antibacterial activity (via inhibition of protein 
biosynthesis) and a ring size between 12 and 18, including the 16-membered spiramycin produced by 
Streptomyces ambofaciens 94 and the 12-membered methymycin produced by Streptomyces 
venezuelae 95. Erythromycin A (Figure 1.10) 96 is a prominent member of this class, for together with 
its semi-synthetic derivatives it has been in worldwide clinical use since the 1960s. Erythromycin 
biosynthesis starts with the synthesis of the macrocyclic aglycone precursor 6-deoxyerythronolide B 
(6-dEB) assembled from the successive condensation of the propionyl starter unit with six 
methylmalonyl extender units catalysed by six extension modules housed within three multi-modular 





Figure 1.10: Erythromycin biosynthesis. (1) the biosynthetic intermediate aglycone 6-deoxyerythronolide (6-
dEB) B; (2) erythromycin A. 
 
 In the early 1990s the genes encoding deoxyerythronolide B synthase (DEBS), the PKS 
responsible for the precursor to erythromycin, from the producing organism Saccharopolyspora 
erythraea, were sequenced and characterised by two independent groups 98–101. These were the first 
PKS genes to be sequenced in their entirety and they revealed for the first time the modular 
architecture that became the paradigm for type I PKSs and rationalised the biosynthetic relationship 
between many known reduced polyketides and the PKS multienzymes that produced them. The 
modular architecture of these biological machines has resulted in some of the largest proteins in 
nature. A single subunit of MLSA1, the enzyme responsible for generating nine of the eighteen acyl 
links in the mycolactone polyketide chain, has a molar mass of 1.8MDa 102.  
 A PKS module can be defined as a set of activities (domains) responsible for incorporating a 
particular precursor at a designated point in the nascent acyl chain and for determining its structure 
in the final polyketide produced 103. Figure 1.11 shows the modular organisation of DEBS along with 





Figure 1.11: Schematic of the erythromycin PKS assembly line. Image adapted from Weissman 104. The DEBS 
genes are not to scale, but indicate which modules are encoded by which genes. DEBS 1 = 10.5 kb, DEBS 2 = 10.5 
kb, DEBS 3 = 9.5 kb. 
 
 DEBS is made up of three components, DEBS 1-3, which are encoded respectively by three 
large genes, eryAI-III 100. Each polypeptide contains two modules of FAS-related activities, with DEBS 
1 also containing a loading module comprising a propionyl-CoA specific AT and an ACP, to recruit the 
propionyl starter unit. The remaining six modules contain (2S)-methylmalonyl specific AT domains 105 
and DEBS 3 contains a C-terminal TE domain which is responsible for cleaving and cyclising the 
completed heptaketide to generate 6-dEB 103. Strikingly, each module contains the complement of 
reductive domains needed to achieve the appropriate oxidation state after each cycle of chain 
extension. DEBS proved to be the prototype of a very large number of such multi-modular systems, 
composed of several large enzymes with multiple modules in each enzyme, each module is responsible 
for a given catalytic cycle in the polyketide biosynthesis82. All intermediates remain bound to the 
assembly line throughout chain assembly. 
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 The general reaction scheme is similar for all modular type I PKSs. First, the KS is acylated with 
a polyketide intermediate from the upstream module, and the extender unit is selected by the AT 
domain which then charges the ACP with it. The modular arrangement allows different extender units 
to be utilised at different cycles of chain growth, and natural ATs have been identified that are specific 
respectively for malonyl-CoA, methylmalonyl-CoA, ethylmalonyl-CoA, hydroxymalonyl-CoA, and 
methoxymalonyl-CoA 106,107. This larger pool of extender units helps explain the great molecular 
diversity of complex polyketides obtained from modular systems. Secondly, the (alkyl)malonyl-ACP 
docks to the acylated KS which then catalyses the condensation reaction, extending the polyketide 
chain; the resulting β-ketoacyl-ACP intermediate then migrates to the active sites in turn of the 
processing enzymes of the so-called 'reductive loop' (KR, DH and ER) 108; finally the processed 
polyketide intermediate is ferried either to the adjacent downstream module, or to a TE domain which 
catalyses chain-release 109. The stereospecific action of the reductive loop domains (KR, DH and ER) 
provides exquisite control over the shape of the final product 82.  
 
Extension of the modular paradigm to other major classes of complex polyketide 
 
Polyether ionophores are an abundant class of polyketides with broad-spectrum activity against 
bacteria and parasites 110. More recently, certain polyethers such as salinomycin (Figure 1.9) have 
been shown to be selective killers of cancer stem cells 111 and to be active in an animal model of 
latent TB 112. Unfortunately, their clinical use is limited by their significant toxicity 113, however 
targeted modification of these compounds may provide promising drug leads. They are produced 
exclusively by actinobacteria, with the vast majority produced by the genera Streptomyces and 
Actinomadura 114. Polyethers are characterised by chains of tetrahydrofuran and tetrahydropyran 
rings connected via C-C bonds or spiro linkages (Figure 1.9). The high oxygen content of polyether 
ionophores allow them to chelate monovalent metal ions such as Na+ and K+, and in a minority of 
cases divalent ions such as Mg2+ and Ca2+ 115. The resulting complex has a hydrophobic exterior 
surface, allowing transport of the chelated ions through lipid membranes, resulting in a collapse of 






Figure 1.12: Examples of polyether antibiotics. (1) monensin A, R=C2H5, monensin B, R=CH3 (2) salinomycin. 
 
Monensin (Figure 1.12) is an iconic polyether ionophore 117 which has found a widespread 
application in animal husbandry as a coccidiostat and growth promoter 118. Monensin A differs from B 
by the presence of an ethyl substituent rather than methyl at position C16. Both compounds 
selectively bind Na+ ions 118. The monensin gene cluster from S. cinnamonensis was identified and 
sequenced by Leadlay et al. in 2001 118. It consists of 8 open reading frames (monAI to monAVIII) 
encoding the 12 extension modules of the monensin PKS, flanked by tailoring genes that encode 
enzymes required for post-PKS processing of the monensin carbon backbone, as well as efflux and 
regulatory proteins 82. 
 The difference between monensins A and B arises in module 5, where the acyltransferase (AT) 
domain allows the incorporation of either methyl or ethylmalonyl-CoA. MonCI is a unique epoxidase 
which epoxidises three double bonds in the linear precursor, and monBI and monBII are novel ring-
opening epoxide hydrolases/cyclases responsible for forming the ether rings in a cascade reaction 
119,120. The monensin gene cluster also has additional ketosynthase (KS)-like and ACP-like ORFs. It is 
proposed that the KS-like enzyme transfers the full-length triene intermediate onto the ACP-like 
protein where the oxidative cyclisations occur, followed by further tailoring and final release of 
monensin from the discrete ACP catalysed by thioesterase MonCII 121. Deletion of the monCI epoxidase 
gene results in the accumulation of the shunt product premonensin (Figure 1.13) in which the double 






Figure 1.13: Premonensin, shunt product of monensin biosynthesis. (1) premonensin A, R=C2H5, premonensin 
B, R=CH3. 
 
Macrocyclic polyene polyketides 
 
Amphotericin B and nystatin are valuable macrocyclic polyenes, amphotericin being used in front-line 
treatment of life-threatening systemic fungal infections. Such polyenes are composed of a large 
macrolactone ring with distinct polyol and polyene regions and are often glycosylated with a 
mycosamine sugar residue (see Figure 1.8). Their advantages over other antifungal compounds such 
as azoles is their potent fungicidal action, and the extremely low incidence of resistance 122. Azoles 
disrupt ergosterol biosynthesis, a crucial component of the fungal cell membrane, but are fungistatic 
and resistance can arise more readily 123. Macrocyclic polyenes instead interact directly with 
ergosterol, forming pore-like structures in the cell membrane that lead to cell death 124. Unfortunately 
macrocyclic polyenes also interact with cholesterol in mammalian cell membranes, albeit with much 
lower affinity, and because of this relative toxicity amphotericin is always administered as an 





Figure 1.14: Examples of macrocyclic polyenes. (1) nystatin A1 (2) filipin III. Filipin biosynthesis incorporates an 
unusual hexylmalonyl extender unit in the final chain extension. 
 
 Nystatin, produced by Streptomyces noursei, was the first useful macrocyclic polyene to be 
identified. It is widely used for the topical treatment of oral, gastro-intestinal and genital candidosis. 
Nystatin biosynthesis involves the successive condensation of 19 malonyl and methylmalonyl 
extender units catalysed by separate modules housed within the 6 multimodular enzymes of the 
nystatin type 1 PKS. The polyene region of amphotericin contains a conjugated heptaene, but in 
nystatin this region of the molecule is interrupted into diene and tetraene regions because of the 
presence of an enoylreductase (ER) domain in module 5 (Fig. 1.14). Once the polyketide chain is 
complete, the biosynthesis is completed by oxidation of a methyl group to an exocyclic carboxyl group, 
hydroxylation at C-10 in the polyol region and glycosylation with a mycosamine sugar residue 124.
  
 The macrocyclic antifungal polyene filipin was isolated from Streptomyces filipinensis in 1955 
126. Filipin is synthesised by a type I PKS with five multi-modular enzymes consisting of 14 modules 
condensing both malonyl and methylmalonyl extender units. The final PKS extension module 
introduces a hexylmalonyl unit to generate the unusual extended alkyl chain. Post-assembly steps 
involve specific hydroxylations catalysed by cytochrome P450 monooxygenases 127. Filipin lacks the 
mycosamine moiety found in many other macrocyclic polyenes, but maintains its affinity to membrane 
sterols and can form pore-like structures 128. Filipin is too toxic for clinical use as it has similar affinity 
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to both ergosterol and cholesterol. This property does however make it a valuable probe for the 
detection of cholesterol in cellular membranes 129. 
 
Rapamycin, a macrocyclic hybrid polyketide-nonribosomal peptide 
 
Rapamycin (Figure 1.15) is a classic example of a hybrid polyketide-nonribosomal peptide and 
historically has played an important role in PKS engineering. It is a potent antifungal and 
immunosuppressive and possesses a structural motif which is responsible for the specific binding to 
FK506-binding proteins. This binding triggers subsequent binding of the binary complex to the 
mammalian target of rapamycin (mTOR) which mediates its biological activities 130. In 2001, Rowe and 
colleagues spliced an entire PKS extension module from rapamycin between the first two extension 
modules of DEBS 1 in one of the first attempts at combinatorial biosynthesis 131. When the extended 
DEBS 1 was co-expressed in Sa. erythraea with DEBS 2 and DEBS 3 production of a novel octaketide 
was observed. Due to rapamycin’s (and its analogues’) properties as the only known inhibitor of mTOR, 
and as the most selective inhibitor of kinase activity known to date 132, it has been the target of 
extensive work to build a library of related compounds with desirable therapeutic properties. Some 
of the more promising work has focussed on the exotic start unit of rapamycin or rather, its removal. 
Several rapamycin analogues (rapalogs) that underwent clinical trials contained semisynthetic 
alterations at positions derived from the starter unit 132 and in 2005 Gregory and colleagues showed 
that novel starter units can be efficiently incorporated into rapamycin by feeding them to a rapK-
deleted mutant (rapK is involved in the synthesis of the 4,5-dihydroxycyclohex-1-enecarboxylic acid 
starter unit) 132. The rapamycin scaffold has undergone further modification to generate rapalogs 
lacking the O- and C-linked methyl groups at position 16 and 17, respectively (Figure 1.15) 133. These 
modifications were based on knowledge gained from X-ray structures of rapamycin bound to mTOR 
and aimed at reducing steric constraints and increase positive interactions. The group’s efforts were 
rewarded by the production of rapalogs that displayed enhanced inhibition of cancer cell lines 133. 
Rapamycin and its analogues exemplify the potential modular biosynthetic enzymes have for 







Figure 1.15: Structure of the macrocyclic hybrid polyketide-nonribosomal peptide rapamycin. 
 
The active site specificity of PKS domains  
 
As the number of characterised PKS systems has increased, detailed comparisons have revealed active 
site sequence motifs that correlate with observed chemical and stereochemical outcomes within 
extension modules. This was confirmed with the sequencing of the rapamycin PKS gene cluster in 1995 
134. In many cases these have been validated by biochemical experiments and confirmed by atomic 
resolution X-ray crystal structures of individual domains 104,135. In the erythromycin PKS (DEBS) the 
choice of methylmalonyl-CoA could be identified by the motif of YASH 100 residues downstream of 
the active site serine, while malonyl-CoA specific AT domains would have a HAFH motif 135. The 
presence of structural data, also explained the stereospecificity for the (2S)-isomer of methylmalonyl-
CoA in AT domains with the YASH motif, as there would be a steric clash between the (2R)-methyl 
group and residues in the active site. 
Similar analyses of KR, DH and ER domains have provided explanations for substrate 
specificity. All reductase active KR domain active sites contain a tetrad of Tyr, Ser, Lys, and Asn residues 
136 and bind the NADPH cofactor in the same orientation. Therefore the alternative stereochemical 
outcomes of ketoreduction are thought to arise from opposite modes of binding the substrate into 
the active site 104. Several motifs were identified by comparative sequence analysis that predict the 
directions, referred to as A- and B-type KRs 137. An LDD motif in the region between amino acid 
positions 88 and 103 is a strong indication of a B-type and is absent in the A-type KRs. The role of these 
residues in influencing the direction of substrate binding is still unknown, possibly because as yet no 
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KR has been co-crystallised in a complex with both the polyketide intermediate and the NADPH 
cofactor 104. However there have been two alternative mechanisms to account for substrate positions 
proposed by Keatinge-Clay and Bonnett et al. 138,139.  
 DH domains typically form trans double bonds, although cis double bonds are also present 140. 
By studying the stereochemistry of the evolutionary related DH domains from fatty acid synthesis and 
comparing that with PKS DH domains it appears that control of the stereochemistry of the dehydration 
step is ultimately determined by the KR domain and should always yield a trans double bond because 
the catalytic machinery is not in the correct position to yield a cis double bond 141. The origin of cis 
double bonds is less clear. There is little evidence to show they are generated directly, or if they form 
a trans bond before undergoing isomerisation through post-PKS tailoring reactions 142. The only clear 
evidence for cis bond formation by a specific module comes from the phoslactomycin PKS where it 
was shown that the modules of the PKS could discriminate between cis and trans intermediates and 
that they do not contain domains capable of catalysing double bond isomerisation 143.  
 The final domain with reducing activity is the ER domain which acts on trans double bonds, 
reducing them to generate fully-saturated alkyl groups. This reduction has stereochemical 
consequences when a side chain, such as a C-2 methyl substituent, is present. Reduction can produce 
either (2R)- or (2S)-configuration depending on the side from which the double bond is protonated 104. 
Through similar comparisons of sequences that determined key residues in the previously discussed 
domains, a correlation was identified between ER sequence motifs and the stereochemical outcome 
of their reaction 144. A conserved Y residue predicts a (2S)-configuration, while a conserved V residue 
predicts a (2R)-configuration. However, subsequent mutagenesis experiments revealed that 
additional factors affect stereocontrol of the ER domain. When the conserved Y was replaced with a 
V the stereospecificity swapped from a (2S)- to a (2R)-configuration, as was predicted, however in the 
reciprocal experiment where the conserved V was replaced with a Y there was no observed change in 
stereospecificity. A combination of the solved structure of a KR-ER didomain from the second module 
of the spinosyn PKS 145 and further mutagenesis experiments 146 helped to explain these observations. 
In the active site pocket there is a conserved K residue positioned opposite the conserved Y residue. 
When the Y is present it acts as the proton donor in the double bond protonation reaction, but in its 
absence the K residue acts as a proton donor. However, introducing a Y at the conserved position into 
a (2R)-producing ER domain was not enough to overcome the K proton donor, and more work will be 
required to identify the remaining stereochemical determinants. This result highlights the prevailing 
situation across PKS structural studies, that despite the great progress that has been made since their 
discovery, there is still a lot that remains unknown regarding the architecture of PKSs. However, these 
37 
 
bioinformatic, structural and biochemical insights provided the essential knowledge for rational 
engineering of PKSs to produce novel chemical diversity and predict the possibility of even finer 
control of these molecular assembly lines in the future. 
 The erythromycin PKS has been a model system for many investigations into PKS engineering, 
leading to the discovery of several interesting properties of PKS systems, namely stuttering and 
skipping. Stuttering of a PKS module refers to its ability to catalyse additional extension cycles before 
the growing polyketide chain is transferred to the next module 147. Skipping of a module has the 
opposite effect, it allows a module to be bypassed, passing the polyketide chain onwards without 
catalysing an extension cycle.131  
 Both the stuttering and the skipping properties of the erythromycin producing system were 
discovered as a result of modification of the PKS, where they highlight an important limitation in 
current polyketide engineering techniques. The desired products of a modified system are often found 
as the minor product whereas the major product will be the product of the parent system, despite the 
modifications. Meanwhile, a number of natural modular PKS systems have been described in which 
non-colinearity is an essential feature 148. For example, formation of the antibiotic borrelidin requires 
that module 5 of the bor PKS acts three times (identically) before the chain is handed on 149. In the 
case of the marginolide azalomycin, the iteration of module 1 actually achieves different outcomes, 
as an essential part of producing the natural product 150. Such programmed iteration offers the 
possibility of generating "aberrant" products from a single production line and offers a possible clue 
to a process that might have been important in the natural evolution of these assembly-line systems. 
 In addition to the functional domains of each DEBS module, they contain additional domains 
comprised of short α-helical regions at the N- and C- termini. These have been associated with docking 
to neighbouring modules thanks to solved crystal and NMR structures of these domains 151,152. The 
heptaketide product of DEBS cannot be produced by DEBS alone, it requires additional enzymatic 
activities to generate 6-dEB. When the DEBS was purified and acylated in vitro, it was shown that all 
six AT domains retained their specificity for (2S)-methylmalonyl, however the configuration of the 
methyl branches in the product was different from that produced in vivo. Stereoselection during the 
biosynthesis must also involve epimerisation activities that DEBS is unable to perform. 
 Following the sequencing of DEBS, Leonard Katz and colleagues performed pioneering work 
on the relationship between the arrangement of domains in PKS systems and the structure of the 
resulting polyketide using erythromycin as a model system. First the group disabled the KR domain of 
module 5 by removing a part of the gene; this resulted in a mutant strain which produced two 
erythromycin analogues in which a hydroxyl group was replaced by a keto group 98. The group then 
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disabled the ER domain in module 4 through mutations in the putative NADPH binding site. The 
resulting mutant strain produced an erythromycin analogue with a double bond at the predicted 
position 153. The structure of these analogues had been predicted by knowledge of the function and 
position of the inactivated domains. This was the first signs of what became known as co-linearity, the 
relationship between the arrangement of the modules at the DNA level and their order of use in the 
biosynthesis of the corresponding polyketide. 
 The sequences for other macrolide PKSs, such as tylosin and spiromycin, were among the first 
to appear after the DEBS sequence 154,155. What was remarkable at the time was the similarity of their 
organisation to DEBS, strengthening the evidence for co-linearity, and making it a general rule for type 
I PKS systems 156. The importance of co-linearity is that it allows for predictions of the polyketide 
structure, given the PKS DNA sequence is known. The prediction became more confident as more PKS 
sequence data became available, as discussed above, making the prospect of engineering novel 
polyketides so tempting, since modifications of the organisation of domains within the PKS lead to 
predictable outcomes in the polyketide metabolites. The architecture of modular Type I PKSs has 
encouraged efforts at combinatorial biosynthesis, in which different natural PKS modules are “mixed 
and matched” to create hybrid PKS systems 157. Combinatorial biosynthesis has resulted in several 
hundred new polyketide structures over the last 20 years and plays an important part in current 
polyketide drug discovery 82. 
 As the number of PKSs discovered to follow the DEBS paradigm increased, an increasing 
number of PKSs were identified that didn’t 103. Two major classes of modular PKSs are now 
distinguished: cis-AT PKSs, including DEBS and others, and trans-AT. The defining feature of a trans-
AT is the absence of an AT domain from all extension modules. Instead the acyltransferase activity is 
provided on a single discrete protein that provides each module with the same extender unit 158, as 
illustrated by the virginiamycin PKS (Figure 1.16). Trans-AT PKSs have other characteristic features 
including; irregular domain arrangements, duplicated and inactive domains, atypical enzymatic 
functions, such as integrated methyltransferase domains, and modules distributed between two 
polypeptides 104.  
 Stereochemical control operates similarly in the two systems, as both contain the full suite of 
reducing domains, which act in the same way. There are differences however in the specificity for the 
AT domains. In cis-AT PKSs, the AT domains have a greater range of specificity, some ATs even 
specifying long-chain linear or branched extender units. In contrast, the majority of discrete AT 
domains from trans-AT PKSs only provide malonyl-CoA, although there are exceptions, such as KirCII, 
the trans-AT from kirromycin biosynthesis which is capable of loading ethylmalonyl-CoA onto a 
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specific ACP 159. Methyl branches in the products of trans-AT PKSs are introduced by methyltransferase 
domains during chain elongation 160. 
 
 
Figure 1.16: Schematic of the virginiamycin trans-AT PKS assembly line. Image adapted from Weissman 104. The 
virginiamycin genes are not to scale, but indicate which modules are encoded by which genes. 
 
The differences in architecture suggests independent, or divergent evolutionary pathways for 
the two classes of modular PKS systems. Nguyen et al. argue that while cis-AT PKSs evolved through 
gene duplication, the trans-AT class evolved through horizontal recruitment and assembly of 
substrate-specific KS domains 161. However, recent studies have suggested that at least some trans-AT 
PKSs share a common ancestor with cis-AT PKSs 162. Solved crystal structures have revealed that 






1.3: Genome-level Analysis; Sequencing, Assembly, and Annotation 
1.3.1: Evolution of Sequencing and Assembly Technologies 
 
The initial characterisation of biosynthetic gene clusters from Streptomyces and allied bacteria, 
leading to the uncovering of the assembly line paradigm for both PKS and nonribosomal peptide 
synthetase (NRPS) systems, was made using conventional Sanger sequencing, later automated using 
fluorescent chain terminators. Even several actinomycete genomes were sequenced in this way. The 
first was Mycobacterium tuberculosis in 1998 163, followed several years later by the model organism 
Streptomyces coelicolor 164 and by Streptomyces avermitilis 165 The S. coelicolor sequence was 
generated by sequencing an ordered library of cosmid and BAC clones. In contrast the S. avermitilis 
sequence was the first to attempt a whole-genome shotgun approach. The final assembly had to rely 
on additional sequence data from over 10,000 cosmids, additional cosmid shotgun sequencing, 
hundreds of PCR products and many manually curated sequences 165. The assembly of the S. avermitilis 
genome highlighted issues that any attempt at sequencing actinomycete genomes would encounter; 
high GC% content, and large sections of highly conserved repeats. In 2005 and 2006 the so-called Next 
Generation Sequencing (NGS) technologies were introduced: 454 and Solexa/Illumina sequencing. 
These took advantage of increased processing power to allow for massively parallel sequencing of 
shotgun fragments 166,167. Several other complete actinomycete genomes were reported at this stage, 
including those of Sa. erythraea 168 and S. griseus 169. Rapid improvements in the Illumina platform 
have since then made it the method of choice for genome-scale sequencing of bacterial and small 
fungal genomes. Single Molecule Real Time (SMRT) sequencing 170, usually referred to as PacBio, and 
Nanopore sequencing 171 allow sequencing of single DNA molecules, without amplification and in real 
time, to generate read lengths of up to several kilobases 172. As yet, the high costs of PacBio and the 
high error rate of Nanopore sequencing means that they have yet to supplant Illumina as the method 
of choice outside major sequencing centres. 
A search for actinobacteria in the NCBI database reveals 15,600 genome assemblies, more 
than double the number of entries since 2015, at 7057 173. The most important discovery to come from 
all these sequence data is that actinobacteria contain many more putative biosynthetic gene clusters 
than are expected from compounds isolated under laboratory conditions, in some cases the 
underrepresentation of metabolites is up to 10-fold, with some species dedicating up to 11% of their 
genome to secondary metabolism 174. This realisation has led to much focus on these orphaned gene 




1.3.2: Prediction of Biosynthetic Gene Clusters  
 
To help identify putative orphaned gene clusters, automated BLAST searches 175 can be used to identify 
similarities with proteins in the public databases. The improvement of recognition of characteristic 
protein sequence motifs and prediction of substrate specificity for biosynthetic genes has been the 
main focus for this field, particularly for PKS and NRPS annotation 176. The most commonly used 
software is antiSMASH, which aims to define biosynthetic loci covering the entire range of known 
secondary metabolite classes 177. Its current iteration, antiSMASH 4.0 178, is an extremely useful tool 
for the identification of biosynthetic gene clusters in actinomycetes, but manual curation is often 
required to obtain an accurate assessment of the biosynthetic potential of a gene cluster, as will be 
discussed in following chapters. 
 
1.3.3: Genome and Metagenome Mining 
 
The combination of advances in sequencing technologies and the development of robust biosynthetic 
gene cluster prediction software has led to a new paradigm for natural product discovery. The new 
approach uses sequence data and annotation to identify biosynthetic gene clusters of interest, and 
then study the product, or if it is an orphan gene cluster, attempt to ‘wake up’ the cluster and generate 
the product. There are three strategies used to obtain and characterise unknown products of a 
biosynthetic gene cluster (Figure 1.17): activation of expression in the host strain; heterologous 
cloning and expression; and mutation of key genes followed by metabolic profiling. An example of the 
first approach was the identification of the stambomycins, a family of 51-membered glycosylated 
macrolides, synthesised by an PKS gene cluster spanning almost 150kb found in Streptomyces 
ambofaciens 179. Fermentation extracts showed no evidence for the product of this gene cluster, but 
after constitutive expression of a LuxR activator gene present in the cluster, stambomycins were 
detected and could be characterised. The second strategy was used in the identification and 
characterisation of grisemycin, a peptide natural product produced by S. griseus 180. The gene cluster 
had previously been identified by comparing homologous genes to the characterised cypemycin gene 
cluster and a mass signal could be seen that matched the predicted mass of the unknown compound. 
To verify that the gene cluster was involved in grisemycin biosynthesis the entire gene cluster was 
cloned into a plasmid and transformed into S. coelicolor A3(2) and heterologous production was 
confirmed by mass spectrometry. The third strategy is useful when the gene cluster is expressed, but 
the product is unknown, for example in the identification and characterisation of the cuevaenes, 
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ansamycins from Streptomyces sp. LZ35 181. By identification and subsequent knocking out of key 
biosynthetic genes, such as Cuv10, a putative 3-hydroxybenzoate (3-HBA) synthase, the authors could 
study the metabolic profiles of several mutants and identify the product of the gene cluster. By feeding 
3-HBA to the ΔCuv10 mutant, the authors could also confirm the function of the putative gene. 
 
 
Figure 1.17: Natural products identified through genome mining. (1) stambomycin A (2) grisemycin (3) 
cuevaene A. 
 
Metagenomic mining is an important tool to estimate the total biosynthetic potential of 
organisms in certain complex environments, such as soil, and to identify if there are any gene clusters 
of note and worth pursuing. It has been estimated that over 99% of microorganisms from the 
environment resist cultivation in a laboratory setting with unculturable organisms in every prokaryotic 
group, and even entire divisions with no cultured representative 182. This is an extremely deep 
reservoir of potential novel natural products, and achievements such as the identification of novel 
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pentacyclic type II polyketides 183, and a novel indolotryptoline with antiproliferative activity 184 
encourage further study. The characterisation of the potent cell wall synthesis inhibitor teixobactin 185 
and isolation of other organisms previously thought unculturable 182 have shown the importance of 
non-traditional culturing techniques in this endeavour. 
 
1.4: Engineering of Complex Polyketide Biosynthesis 
1.4.1 Engineering in the native host 
 
Two different experimental approaches are available for the engineering of the biosynthetic pathway 
to complex polyketides, which are encoded by gene clusters typically between 70-150 kbp in size. The 
first of these is the use of homologous recombination between identical sequences to delete, alter, or 
swap segments of genomic DNA in the natural host organism is the first strategy used to attempt 
engineering of PKS systems. This approach ensures the presence of the required precursors and any 
tailoring enzymes. The architecture of PKSs is modular, and the boundaries and active sites of each 
domain have been identified and are increasingly well understood. The hypothesis behind 
combinatorial biosynthesis was that if the component enzymes of a PKS system were sufficiently 
autonomous to carry out their natural functions in alternative contexts and with new substrates then 
it should be possible to create novel PKSs that produce novel polyketide products by rearranging the 
domains. 
 Through the directed manipulation of domains, hybrid PKSs have indeed been produced with 
novel properties including: modified levels of β-keto reduction in the avermectin PKS 186; increased 
and decreased polyketide chain lengths in the erythromycin 131 and spinosyn PKS 187; respectively, and 
changed selection for starter 188 and extension 189 units in model PKS systems based on DEBS. However, 
these experiments have also shown that modular PKSs are not entirely modular, and some are 
markedly less modular than others. Crucially, we do not yet understand well enough the spatial 
architecture of native PKS modules required for non-native domains to function together correctly 157, 
which inevitably leads to slow, inefficient and low yielding enzymatic reactions.  
 Despite these problems, over the last few years several successful examples have also been 
published of a knowledge-based approach to the systematic engineering of the biosynthetic pathways 
to complex polyketides. These have included for example the generation of macbecin analogues which 
combine extreme potency against their Hsp90 target with greater safety thanks to elimination of the 
undesirable quinone moiety in this and other antitumour ansamycins such as geldanamycin 190; and 
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the generation of over 130 different rapalogs from S. rapamycinicus 132,133. It is important to note that 
an integrated approach to engineering the pathway is essential: additional manipulation of precursor 
genes and/or genes for late-stage tailoring maximises the number of new compounds that are 
obtained from PKS engineering. While this approach to engineering organisms does result in new 
insights and in the production of valuable chemicals it has the drawback of requiring detailed 
knowledge of the PKS system and of its target, in order to design the alterations to the molecule 
accordingly. The approach is also slow and labour-intensive, and it requires careful initial exploration 
of the strain to confirm that it is genetically tractable and amenable to engineering. Homologous 
recombination can be very difficult to achieve in organisms such as Streptomyces spp. Also, vectors 
suitable for Streptomyces may not function in rare actinomycetes such as Saccharopolyspora. 
 
1.4.2 Engineering in a heterologous host strain 
 
An alternative engineering strategy is the transfer to, and expression of, the target PKS gene cluster 
in a heterologous host that is more tractable to genetic engineering. Heterologous expression has 
already been discussed as a valuable tool in (meta)genome mining, both of known clusters and of 
orphan clusters (section 1.3.3). S. coelicolor, S. lividans, S. avermitilis and S. albus are often used. S. 
coelicolor can naturally produce high yields of secondary metabolites, but by ‘cleaning’ the strain by 
removing endogenous plasmids, and deleting or inactivating biosynthetic gene clusters, the yields of 
heterologously expressed natural products have been increased 191,192. A derivative of S. avermitilis 
from which endogenous gene clusters have been systematically removed has also been used 
successfully for expression of heterologous polyketides 193. Cleaned strains have the benefit of a 
simpler metabolic profile, easing analysis of any gene cluster introduced to the organism.  
 The general approach to heterologous expression is to amplify the PKS genes from the less 
tractable strain, assemble them in E. coli, and transfer them by conjugation into more tractable strains. 
Once in the new host, the genes can then be integrated into the chromosome by homologous 
recombination or through a suitable attachment site. An example is the successful heterologous 
expression of the gene cluster for FK506, a clinically relevant immunosuppressant. The entire 83.5kb 
FK506 gene cluster was assembled into a 130kb PAC clone and used to transform different S. coelicolor 
derivatives, giving yields approximately five-fold higher than in the wild-type strain, S. tsukubaensis 
194. Progress in this area has focussed on ways to improve the promiscuity of the heterologous hosts, 
and to improve the expression of introduced gene cluster 157. Identifying promoters that function well 
with heterologous systems is an important factor, however it appears that PKS gene clusters prefer 
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their own PKS-associated promoter 195, so creating a single system to support a range of PKS gene 
clusters is unlikely. An important pitfall is the propensity of the tandemly repetitive PKS gene 
sequences to undergo unwanted recombination events during transfer to E. coli and thence to the 
Streptomyces host.  
 E. coli itself has been developed as a host for heterologous expression of PKS genes. However, 
extensive engineering was required to allow production of polyketides. E. coli naturally produces 
acetyl-CoA and malonyl-CoA, but lacks any significant quantity of other precursors, such as propionyl-
CoA, or methylmalonyl-CoA 196. Despite this, a series of modifications has resulted in an E. coli strain 
that can convert exogenous propionate into 6-dEB, the precursor scaffold to erythromycin, with a 
yield comparable to an overproducing mutant strain 196. More recent advances have developed upon 
the 6-dEB producing E. coli strain, introducing 17 new heterologous genes to provide the enzymes 
necessary to glycosylate 6-dEB converting it to erythromycin C 197. This work establishes a basis for 
production of other glycosylated polyketides in E. coli.  
 More recently, the potential for Saccharomyces cerevisiae as a heterologous host has been 
shown. A strain of S. cerevisiae was modified to contain two additional plasmids, carrying the genes 
encoding 6-methylsalicyclic acid (6-MSA) synthase from Penicillium patulum and a PPTase from 
Aspergillus nidulans, respectively. Yields of 6-MSA were increased by replacing the promotor sequence 
of ACC1, the gene encoding acetyl-CoA carboxylase, which catalyses the conversion of acetyl-CoA into 
malonyl-CoA with a strong, constitutive promotor 198. S. cerevisiae is a popular host for cloning thanks 
to the simplicity and high efficiency of homologous recombination in yeast, which requires only short 
overlapping sequences of 29 nucleotides to be able to assembly multiple DNA fragments in a single 
step 199. Developments in yeast heterologous expression have included additional tools to aid with 
cloning in this organism. Using an any-gene-any-plasmid approach 200, a yeast cloning cassette can be 
introduced into any vector, along with multiple DNA fragments, at efficiencies approaching 100%, far 
higher than commonly used ligase-based techniques. This approach could be of great use to the study 
of PKSs, allowing rapid, efficient assembly of PCR products into a yeast or E. coli compatible plasmid. 
Despite this exciting progress, heterologous expression it still remains to be seen whether 







1.4.3: Exploratory approaches to engineering of Streptomyces spp. 
 
Recently, a chance discovery by a group at Isomerase Therapeutics developed into a new method for 
rapidly recombining PKS gene clusters to generate novel polyketide analogues 201. The method, which 
has been termed accelerated evolution (AE), takes advantage of the many highly homologous regions 
within PKS gene clusters to replace, add, or remove modules to generate diversity, in a way that 
mimics a plausible mechanism for the natural evolution of modular PKSs 201. What is particularly 
exciting about AE is that the diversity appears to come from genetic rearrangements induced by the 
relaxation step of the homologous recombination, meaning a single experiment could generate a 
library of analogous molecules. Furthermore, while some knowledge of the target PKS is required, this 
approach is exploratory in that it has the potential to create a range of unpredicted products and by 
studying the crossover points, could reveals new insights into PKS evolution and architecture.  
 Another interesting approach to exploring the potential for combinatorial biosynthesis of 
modular systems is the reconstitution in vitro of (parts of) a biosynthetic pathway using recombinantly 
expressed and purified enzymes. Biochemical experiments were vital to the early development of our 
understanding of assembly-line polyketide synthases. They were used to show, surprisingly, that 
modular PKSs multienzymes are homodimeric 17; to show that the DEBS AT is stereospecific, accepting 
only the (2S) isomer of methylmalonyl-CoA as substrate 105; and to show that individual modules of 
DEBS are autonomously active 202. Now, in vitro reconstitution offers not only critical validation of 
proposed biosynthetic mechanisms but also insight into potential bottlenecks in biosynthesis, and into 
the substrate specificity of individual enzymes, information which can be used to guide in vivo 
engineering. There have been many examples of the application of in vitro reconstitution and the 
insights these attempts can bring 203. One of the first attempts to produce an aromatic polyketide in 
vitro was by Carreras and colleagues when they reconstituted the actinorhodin PKS from its purified 
components 204. Using 14C-labeled malonyl-CoA they observed shunt product intermediates of the 
actinorhodin biosynthetic pathway. Through this work they also observed that the malonyl-CoA:ACP 
transacylase (MAT) is shared by the fatty acid synthase in the natural host, and notably, was the 
discovery that the KS domain and chain length factor (CLF) of type II PKSs formed a heterodimer. The 
insights gained by this in vitro reconstitution paved the way for further mechanistic analyses of the 
how the CLF controls polyketide chain length, and enabled the production of more advanced 
intermediates through in vitro reconstitution 205,206. A more recent example is found in the elucidation 
of the biosynthesis of antifungal C-nucleoside malayamycin which identified the key precursor as 5’-
pseudouridine-monophosphate (5’--MP) and provided the opportunity for engineering through 
mutasynthetic or semisynthetic approaches (Hong et al., (2018) ms. in the press).  
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Aims of the project 
 
This project aimed to evaluate two powerful and complementary approaches to the discovery and 
engineering of biosynthetic gene clusters in actinomycete bacteria, and their potential to deliver novel 
chemical diversity of potential therapeutic value. 
First, the recently introduced (and still poorly-understood) technique termed accelerated evolution 
(AE), for which the published work on rapamycin analogues (rapalogs) provides a worked example, 
would be applied to three other antibiotic producing strains, Saccharopolyspora erythraea, 
Streptomyces filipinensis, and Streptomyces cinamonensis and evaluated for its potential to generate 
not only antibiotic analogues, but potentially also novel insights into PKS evolution. 
Secondly, a genome-level analysis of Streptomyces albus DSM40763, producer of the novel 
antibacterial compound pseudouridimycin (PUM), would be undertaken. This would allow a detailed 
survey of the biosynthetic potential of the strain. In particular, it would provide access to the 
biosynthetic gene cluster for PUM, a remarkable C-nucleoside antibiotic which is now known to target 
a novel site on bacterial RNA polymerase and would allow in vitro and in vivo studies to trace the 




















All chemicals were purchased from Sigma-Aldrich and were of analytical grade. All solvents were 
purchased from Fischer Scientific and were of HPLC grade. Unless stated all water was purified with 
the MilliQ Integral Water Purification system (Merck Millipore). All antibiotics were purchased from 
Sigma-Aldrich and were filtered before being diluted to the stock concentration listed in Table 2.1 and 
were stored at -20°C.  
 
Table 2.1. Antibiotics used in this work 




Ampicillin H2O 100 100 
Apramycin H2O 50 50 
Kanamycin H2O 50 50 
Chloramphenicol EtOH 25 25 
Nalidixic acid 0.15M NaOH 25 25 




Table 2.2 contains a list of all purchased enzymes used in this study. Enzymes were stored at -20°C 





Table 2.2: Enzymes used in this work 
Enzyme Seller 
Fast Digest restriction endonucleases ThermoFisher Scientific 
Phusion High-Fidelity PCR Master Mix  New England Biolabs 
Q5 High-Fidelity DNA Polymerase New England Biolabs 
Gibson Assembly Master Mix New England Biolabs 
NEBuilder HiFi DNA Assembly Master Mix New England Biolabs 
BioMix Red  Bioline 
Proteinase K Sigma-Aldrich 
Lysozyme Sigma-Aldrich 
 
2.1.3 Culture Media 
 
The media found in Table 2.2 were used in this study. Solid phase media were created by adding agar 
to the liquid media at a ratio of 20g/l. 
 
Table 2.3: Components of the media used in this work 
Medium Component Mass per 1L of medium (g) 
TSB Tryptic soya broth (Difco) 30 
 MilliQ water Up to 1L 
TSBY TSB 30 
 Sucrose 103 
 Yeast Extract 5 
 MilliQ water Up to 1L 
LB Tryptone 10 
 Yeast Extract 5 
 NaCl 10 
 MilliQ water Up to 1L, pH 7.0 
2TY Tryptone 16 
 Yeast Extract 10 
 NaCl 5 
 MilliQ Up to 1L, pH 7.0 
50 
 
SFM* Soya flour 20 
 D-Mannitol 20 
 Tap water Up to 1L 
 MgCl2 10 ml/L of 1M stock 
 
*Tap water was added to soya flour and autoclaved. D-Mannitol was added to the mixture which was 




Table 2.4: Buffer used in this work 
Chemically Competent Cell Buffers 
Buffer A 50 mM CaCl2, 10 mM CH3COOK, pH 6.2 
Buffer B 50 mM CaCl2, 10 mM CH3COOK, 20% (v/v) glycerol, pH 6.2 
 
Genomic DNA Isolation Buffers 
SET Buffer 75 mM NaCl, 25 mM EDTA, 20 mM Tris-HCl, pH 7.5 
 
Protein Purification Buffers 
Binding Buffer 20 mM Tris-HCl, 500 mM NaCl, pH 7.9 
Wash Buffer 20 mM Tris-HCl, 500 mM NaCl, 1 M Imidazole, pH 7.9 
Strip Buffer 20 mM Tris-HCl, 500 mM NaCl, 100 mM Imidazole, 100 mM EDTA, pH 7.9 
SDS-PAGE Protein 
Buffer 
10% (w/v) SDS, 10 mM DTT, 20% (v/v) glycerol, 200 mM Tris-HCl, 0.05% (w/v) 











Table 2.5: Vectors created and used in this work 
Plasmid Features  Reference 
pKC1139 oriT, ori (psG5), aac(3)IV, LacZ α  207 
pET28a ori, f1 ori, T7, T7 tag, His tag, T7 term, lacI, kanR  Invitrogen 
pYH7 Derived from pHZ1358, oriT, ori (pIJ101), ori (pBR322), rep, 
sti, tsr, bla, acc(3)IV 
 208 
pKC1139-Fil1 Derived from pKC1139, contains a fragment of module 11 
from the filipin PKS gene cluster in A936 
 This work 
pKC1139-Fil2 Derived from pKC1139, contains a fragment of module 11 
from the filipin PKS gene cluster in A936 
 This work 
pKC1139-Fil3 Derived from pKC1139, contains a fragment of module 11 
from the filipin PKS gene cluster in A936 
 This work 
pKC1139-Fil4 Derived from pKC1139, contains a fragment of module 11 
from the filipin PKS gene cluster in A936 
 This work 
pKC1139-Fil5 Derived from pKC1139, contains a fragment of module 2 
from the filipin PKS gene cluster in A936 
 This work 
pKC1139-Ery1 Derived from pKC1139, contains a fragment of module 6 
from the erythromycin PKS gene cluster in A009 
 This work 
pKC1139-Ery2 Derived from pKC1139, contains a fragment of module 6 
from the erythromycin PKS gene cluster in A009 
 This work 
pKC1139-Ery3 Derived from pKC1139, contains a fragment of module 6 
from the erythromycin PKS gene cluster in A009 
 This work 
pKC1139-Ery4 Derived from pKC1139, contains a fragment of module 6 
from the erythromycin PKS gene cluster in A009 
 This work 
pKC1139-Pre1 Derived from pKC1139, contains a fragment of module 2 
from the monensin PKS gene cluster in A568 
 This work 
pKC1139-Pre2 Derived from pKC1139, contains a fragment of module 2 
from the monensin PKS gene cluster in A568 
 This work 
pKC1139-Pre3 Derived from pKC1139, contains a fragment of module 2 
from the monensin PKS gene cluster in A568 
 This work 
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pKC1139-Pre4 Derived from pKC1139, contains a fragment of module 2 
from the monensin PKS gene cluster in A568 
 This work 
pKC1139-Pre5 Derived from pKC1139, contains a fragment of module 2 
from the monensin PKS gene cluster in A568 
 This work 
pKC1139-Pre6 Derived from pKC1139, contains a fragment of module 2 
from the monensin PKS gene cluster in A568 
 This work 
pET28a-psmH Derived from pET28a, contains the psmH gene from the 
pseudouridimycin gene cluster in A980 
 This work 
pET28a-psmI Derived from pET28a, contains the psmI gene from the 
pseudouridimycin gene cluster in A980 
 This work 
pET28a-psmK Derived from pET28a, contains the psmK gene from the 
pseudouridimycin gene cluster in A980 
 This work 
pET28a-psmM Derived from pET28a, contains the psmM gene from the 
pseudouridimycin gene cluster in A980 
 This work 
pET28a-psmO Derived from pET28a, contains the psmO gene from the 
pseudouridimycin gene cluster in A980 
 This work 
pET28a-yeiN Derived from pET28a, contains the yeiN gene from E. coli 
O81 
 This work 
pYH7-ΔpsmN Derived from pYH7, contains DNA designed for knocking 
out the psmN gene in A980 
 This work 
pYH7-ΔpsmU Derived from pYH7, contains DNA designed for knocking 
out the psmU gene in A980 
 This work 
pYH7-ΔpsmB Derived from pYH7, contains DNA designed for knocking 
out the psmB gene in A980 










2.1.7 Bacterial Strains 
 




DH10B F- endA1 deoR+ recA1 galE15 galK16 nupG rpsL Δ(lac)X74 φ8
0lacZΔM15 araD139 Δ(ara,leu)7697 mcrA Δ(mrr-hsdRMS-
mcrBC) StrR λ- 
Invitrogen 
BL21 E. coli B F– ompT gal dcm lon hsdSB(rB–mB–) [malB+]K-12(λS) NEB 
ET12567/pUZ8002 F- dam-13::Tn9 dcm-6 hsdM hsdR zjj-202::Tn10 recF143 
galK2 galT22 ara-14 lacY1 xyl-5 leuB6 thi-1 tonA31 rpsL136 
hisG4 tsx-78 mtl-1 glnV44 
(MacNeil et 









Filipin-producing wild type strain DSMZ 
S. erythraea NRRL 
2338 (A009) 
Erythromycin-producing wild type strain NRRL 
S. cinnamonensis 
(A568) 
ΔmonCI, ΔmonBI, ΔmonBII, premonensin-producing 
overproducer strain 
PFL 
S. albus DSM40763 
(A980) 
Pseudouridimycin-producing wild type strain DSMZ 
A980:ΔpsmN A980 with psmN knocked out This work 
A980:ΔpsmU A980 with psmU knocked out This work 







2.2 Microbiological Methods 
2.2.1 Growth and Maintenance of E. coli 
 
E. coli strains were grown and maintained in solid or liquid LB or 2TY supplemented with the 
appropriate antibiotics. Unless stated all E. coli cultures were grown at 37°C overnight in Falcon tubes 
or on plates. Liquid cultures were shaken at 220 rpm. 
 
2.2.2 Growth and Maintenance of Streptomyces 
 
Streptomyces cultures were grown and maintained in solid or liquid TSB, TSBY or SFM. All 
Streptomyces cultures were grown at 30°C in conical flasks with metal springs to provide aeration, or 
on plates. Liquid cultures were shaken at 220 rpm for 72 hrs. Solid media cultures were incubated for 
3-14 days. For spore isolation cultures were grown on solid SFM media for 14 days. Spores were 
collected by the addition of 1-2 ml MilliQ water and agitation by sterilised cotton buds. The spore 
suspension was cleaned by filtration through cotton wool. 
 
2.2.3 Growth of Streptomyces for metabolite production 
 
For production of filipin, seed cultures of S. filipinensis were grown in 5 ml SFM for 48 hours at 30°C, 
200 rpm in 50 ml flasks with metal springs. 10% (v/v) of the seed medium was used to inoculate a 
larger culture of 50 ml SFM in a 250 ml flask with metal springs. The larger culture was incubated for 
up to 7 days at 30°C, 200 rpm. 
For production tests of a large number of S. filipinensis mutants, a 96 well plate with 2 ml wells 
was used. Each well was filled with 1 ml of SFM and a small glass bead was added to prevent clumping. 
The wells were inoculated with a small piece of sporulating mycelium grown on SFM agar for 7 days. 
The 96 well plates were incubated for 5-7 days at 30°C, 200 rpm. 
For production of pseudouridimycin, seed cultures of A980 were grown in 5 ml TSBY for 48 
hours at 30°C, 200 rpm in 50 ml flasks with metal springs. 10% (v/v) of the seed medium was used to 
inoculate a larger culture of 50 ml SFM in a 250 ml flask with metal springs. The larger culture was 
incubated for up to 7 days at 30°C, 200 rpm. 
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2.2.4 Preparation of chemically competent cells 
 
For the preparation of chemically competent cells an overnight culture of E. coli ET12567/pUZ8002 or 
DH10B was used as an inoculum (0.5 ml into 50 ml) of 2TY with the appropriate antibiotics. The culture 
was incubated at 37°C with shaking at 220 rpm until an optical density of A600 = 0.3-0.5 was achieved. 
The cells were pelleted by centrifugation and resuspended in 30 ml ice cold buffer A (Table 2.3). After 
1 hr incubation with occasional agitation the cells were pelleted by centrifugation and resuspended in 
1-3 ml ice cold buffer B. The culture was aliquoted (50-100 µl) in the cold room. All tips, cryotubes, 
and racks were pre-cooled in the cold room. Aliquots were frozen in dry ice and stored at -80°C. 
 
2.2.5 Transformation of E. coli 
 
An aliquot of E. coli ET12567/pUZ8002 or DH10B competent cells was thawed on ice for 20 mins. 1-5 
µl (2-200 ng) of DNA was added and the mixture was left of ice for 30 mins. Cells were submitted to 
heat shock for 30 s at 42°C and then placed on ice for 2 mins. 250-750 µl was added and the mixture 
was incubated at 37°C for 1 hr with shaking at 220 rpm. 50-200 µl was spread on an LB or 2TY plate 
with appropriate antibiotics and incubated at 37°C overnight. Successfully transformed colonies were 
identified through colony PCR (cPCR). 
 
2.2.6 Transformation of Streptomyces by conjugation 
 
Transformations of Streptomyces with integrative plasmids were carried out through intergenic 
conjugation with E. coli ET12567/pUZ8002 following protocols based on those in the laboratory 
manual “Practical Streptomyces Genetics”. 
Competent cells of E. coli ET12567/pUZ8002 were prepared and transformed with the 
integrative plasmid as described above. Single colonies were picked and used to inoculate 10 ml LB 
with chloramphenicol, kanamycin, and the desired selective antibiotic and were grown overnight at 
37°C, 220 rpm. Fresh LB (10 ml) containing half concentration of antibiotics was inoculated with 100 
µl of the overnight culture and grown at 37°C, 220 rpm until an A600 of 0.4-0.6 was reached. Meanwhile 
a culture of Streptomyces was grown in 50 ml TSBY for 48 to 72 hrs. E. coli and Streptomyces cells were 
harvested by centrifugation and were washed three times in LB. The Streptomyces pellet was 
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resuspended in 500 µl LB and the E. coli pellet was resuspended in 100 µl LB. 100 µl of the E. coli and 
the Streptomyces for each conjugation plate were mixed together before being spread on an SFM agar 
plate and incubated at 30°C for 12-20 hrs. The plates were overlaid with 1 ml of MilliQ water containing 
nalidixic acid and the selective antibiotic. The plates were then incubated at 30°C until colonies were 
visible. 
Conjugations using Streptomyces spores instead of a liquid culture were performed as above, 
except that before mixing with resuspended E. coli the spores were heat shocked at 50°C for 10 mins 
before incubation on ice for 10 mins. 
 
2.3 Molecular Biology Methods 
2.3.1 Isolation of Plasmid DNA from E. coli 
 
Plasmid DNA was isolated from 5-10 ml cultures grown overnight using the Plasmid Mini Kit I (Omega 
BioTek) following the manufacturer’s protocol. 
 
2.3.2 Isolation of Genomic DNA from Streptomyces 
 
Streptomyces genomic DNA was isolated using the salting out procedure outlined in the laboratory 
manual “Practical Streptomyces Genetics”. 
A culture of Streptomyces was grown in 10 ml TSBY at 30°C, 220 rpm for 48 hrs. The cells were 
then harvested by centrifugation. The pellet was resuspended in 5 ml SET buffer, 100 µl of lysozyme 
solution (50 mg/ml) was added and the mixture was incubated at 37°C for 1 hr. 140 µl proteinase K 
solution (20 mg/ml) was added, the mixture was mixed, then 600 µl SDS solution (10%), pre-warmed 
to 55°C, was added. The mixture was incubated at 55°C for 2 hrs with occasional inversion. 2 ml of 5M 
NaCl was added and the mixture was allowed to cool to 37°C. 5 ml chloroform was added, and the 
mixture was mixed for 30 mins at room temperature before being centrifuged for 15 mins at 5000 x 
g. The upper layer was transferred to a fresh tube, 0.6 volumes of isopropanol was added, and the 
tube was inverted until the DNA became visible. The DNA was spooled onto a pipette tip, transferred 
to a fresh tube and washed twice with 5 ml ethanol (70%). The DNA was then air dried and redissolved 




2.3.3 Polymerase Chain Reaction 
 
All polymerase chain reaction (PCR) reactions were carried out on a GeneAmp PCR system 9700 (PE 
Applied Biosystems). For cloning, a 2x Phusion Master Mix with GC buffer or a 2x Q5 High-fidelity 
Master Mix was used (Table 2.7, condition 1). For colony PCR a 2x Bioline BioMix with Taq polymerase 
(Table 2.7, condition 2) was used. Typical reactions conditions are shown in Table 2.7 and typical PCR 
temperature cycling conditions are shown in Table 2.8. 
 
Table 2.7: Components required for a single polymerase chain reaction 
Components Reaction conditions 1 (µl) Reactions conditions 2 (µl) 
Polymerase Mix 25 10 
DMSO 1.5 1 
Primer 1 (10 pM) 2.5 1 
Primer 2 (10 pM) 2.5 1 
Template DNA X X 
MilliQ water  Up to 50 µl Up to 20 µl 
 
Table 2.8: Thermal cycling conditions for PCR. The annealing temperature is dependent on the 
melting temperature of the primers 
PCR cycle stage (30 cycles) Temperature (°C) Time (sec) 
Initial denaturation 95 120 
Denaturation 95 10 
Annealing X  20 
Extension 72 (68 for Taq) 30-60 per kb 
Final extension 72 (68 for Taq) 300 
Rest 4 ∞ 
 
2.3.4 Colony PCR for E. coli 
 
Routine screening of transformed E. coli was performed by colony PCR (cPCR) of single colonies. 
Isolated colonies were picked with a toothpick and agitated in a 250 µl PCR tube containing 20 µl of 
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cPCR master mix. The toothpick was then streaked on an LB or 2TY plate containing appropriate 
antibiotics. The plates were incubated at 37°C overnight. The PCR tubes were incubated according to 
the conditions described above. 
 
2.3.5 Colony PCR for Streptomyces 
 
Screening of large numbers of transformed Streptomyces colonies was performed by a modified cPCR 
protocol. Small amounts of mycelium were scraped off each colony using a toothpick and agitated in 
a 250 µl PCR tube containing 20 µl of 1:1 DMSO:MilliQ water. The tubes were microwaved at a high 
setting for 30 s on, 30 s off for a total microwave times of 2 min. 1 µl of the mixture was used as the 
template DNA in the PCR protocol described above. 
 
2.3.6 Agarose Gel Electrophoresis 
 
DNA separation and visualisation was performed by agarose gel electrophoresis using a horizontal 
flow tank. Agarose was dissolved in 1x TAE buffer (4.85 g Tris, 1.14 ml glacial acetic acid, 2 ml 0.5M 
EDTA Ph 8.0) at 0.7% (w/v) and SYBR Safe gel stain (3 µl to 100ml buffer) was added for DNA 
visualisation. DNA samples were mixed with a 6x loading buffer (Fermentas) and GeneRuler 1kb Plus 
DNA ladder (Fermentas) was used as a molecular DNA length marker. DNA was visualised with a UV 
transilluminator (254 nm).  
 
2.3.7 Recovery of DNA from Agarose Gel 
 
For preparative purposed DNA fragments bands were cut from the gel and purified using a QIAquick 






2.3.8 Restriction Enzyme Digestion of DNA 
 
Analytical and preparative DNA digestion was performed using the following restriction endonuclease 
digestion protocol. The components and volumes are shown in Table 2.9. Digestion mixtures were 
incubated at 37°C for 0.5-1 hrs, then separated and visualised by gel electrophoresis. 
 
Table 2.9: Components required for DNA restriction digest 
Components Analytical digestion mix (µl) Preparative digestion mix (µl) 
DNA to be digested X (100 ng of DNA) X (1 µg of DNA) 
10x digestion buffer 1 5 
Restriction enzyme 0.2 1 
MilliQ water Up to 10 µl Up to 50 µl 
 
2.3.9 Ligation of DNA Fragments 
 
Ligations of DNA fragments were carried out using the protocol laid out in Table 2.10. The ligation 
reaction mixture was incubated at 16°C overnight, after which the entire reaction volume was used 
for transformation of E. coli. 
 
Table 2.10: Components required for DNA ligation 
Components Volume (µl) 
T4 DNA ligase 1 
10x ligation buffer 1 
Linearised vector DNA X (20-50 ng of DNA) 
Insert DNA Y (5x molar excess of insert DNA) 






2.3.10 Isothermal Assembly of DNA Fragments 
 
Isothermal assemblies of DNA fragments were performed using the NEBuilder HiFi DNA Assembly 
Master Mix (NEB) following the protocol laid out in Table 2.11. The reaction mixture was incubated at 
50°C for 1 hr, after which 10 µl of the reaction volume was used for transformation of E. coli. 
 
Table 2.11: Components required for isothermal assembly of DNA fragments 
Components Volume (µl) 
Assembly Master Mix 10 
Linearised vector DNA X (50-100 ng of DNA) 
Insert DNA Y (3x molar excess of insert DNA) 
MilliQ water Up to 20 µl 
 
2.3.11 DNA Sequencing 
 
All cloning was confirmed by sequencing. All routine sequencing reactions were carried out by the 
DNA Sequencing Facility in the Department of Biochemistry, University of Cambridge. 
Whole genome sequencing reactions were carried out by the DNA Sequencing Facility and 
assembly and automated annotation was performed by Dr Markiyan Samborskyy of the Leadlay Lab. 
 
2.3.12 Protein Expression in E. coli 
 
Protein expression was carried out by taking advantage of the T7 promoter in pET28a to express the 
target gene in the presence of Isopropyl-β-D-1-thiogalactopyranoside (IPTG). 
pET28a vectors containing the target gene downstream of the T7 promoter were constructed 
following the protocols described above and used to transform E. coli BL21(DE3) cells. A single colony 
was inoculated into LB (10 ml) with appropriate antibiotics and incubated overnight. This seed culture 
was then used to inoculate LB (1 L) with antibiotics and was incubated until A600 = 0.5-1.0 was reached. 
IPTG was added (final concentration 0.1-0.3 mM) and the culture was incubated at 16°C overnight.  
61 
 
2.3.13 Affinity Chromatography 
 
The pET28a expression system generates His tagged proteins, and so the target protein can be purified 
from the cell culture by Nickel-NTA affinity chromatography (nitrilotriacetic acid (NTA) is a chelating 
ligand coupled to a cross-linked 6% agarose resin that when charged with nickel can purify 6xHis 
tagged recombinant proteins). 
The overnight culture, as described above, was pelleted by centrifugation, the supernatant 
discarded, and the pellet resuspended in binding buffer (30 ml), see table 2.4. The resuspended culture 
was sonicated on ice and the lysate was centrifuged. This supernatant was then used for 
chromatography, the steps of which are summarised in Table 2.12. 
 
Table 2.12: Wash steps used in affinity chromatography 
Solutions added to column in order Volume (ml) 
MilliQ water 10 
NiCl2 (50 mM) 4 
MilliQ water 4 
Binding buffer 4 
Lysate All supernatant 
Wash buffer (0 mM Imidazole) 15 
Wash buffer (10 mM Imidazole) 15 
Wash buffer (40 mM Imidazole) 5 
Wash buffer (80 mM Imidazole) 2 
Wash buffer (100 mM Imidazole) 2 
Wash buffer (150 mM Imidazole) 2 
Wash buffer (200 mM Imidazole) 2 
Wash buffer (300 mM Imidazole) 2 
Strip buffer 5 
MilliQ water 20 
MilliQ water 20 




The lysate fraction, all wash fractions and a sample of the pellet were analysed by SDS-PAGE gel 
electrophoresis. A sample of each fraction (10 µl) was added to SDS-PAGE protein buffer (10 µl), see 
table 2.3. The mixture was boiled for 10 mins before being loaded onto the SDS-PAGE gel. 
The SDS-PAGE gels were visualised by the addition of InstantBlue, and incubation at room 
temperature until the bands were visible. 
 
2.4 Chemical and Analytical Methods 
2.4.1 Analysis of Polyketide Products 
 
For analysis of filipin, 1 ml was sampled from S. filipinensis production cultures and were extracted 
with 1-2 ml of ethyl acetate. The mixture was shaken vigorously for 5 mins before being separated by 
centrifugation. The upper layer was taken, and the solvent was removed by drying in air. The residue 
was redissolved in 500 µl of methanol. Samples were centrifuged before HPLC analysis. 
For analysis of pseudouridimycin and related molecules, 1 ml of A980 production cultures was 
sampled and the cells pelleted by centrifugation. The supernatant was collected and was centrifuged 
before HPLC analysis.  
 
2.4.2 Liquid Chromatography and Mass Spectrometry 
 
HPLC-MS analysis was performed using an HPLC (Hewlett Packard, Agilent Technologies 1200 series) 
coupled to a Finnigan MAT LTQ mass spectrometer (Thermo Finnigan) fitted with an electrospray 
ionisation (ESI) source. The mass spectrometer was run in positive ionisation mode, scanning from 
m/z 150 to 1800 with fragmentation at 12 % normalised collision energy. 
 
2.4.3 HPLC analysis 
 
The HPLC was fitted with a Prodigy C18 (250 mm × 4.6 mm, 5μm, Phenomenex) column. Filipin samples 
were eluted using a solvent system of solvent A (H2O + 0.1% FA) and solvent B (MeOH), with a linear 
gradient starting at 50% A for 3 mins, 50%-10% A over 9 mins, 10% A for 8 mins, 10%-0% A over 1 min, 
0% A for 2 mins, and 0%-50% A over 4 mins at a flow rate of 0.8 ml/min. Pseudouridimycin and related 
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standards and intermediates were eluted using a solvent system of solvent A (H2O + 0.1% TFA) and 
solvent B (CH3CN), with a linear gradient starting at 100% A for 5 mins, 100%-95% A over 10 mins, 
95%-0% A over 10 mins, 0% A for 4 mins, and 0%-100% A over 1 min at a flow rate of 0.4 ml/min. 
 
2.4.4 NMR analysis 
 
All samples for NMR spectroscopy were prepared with substrates as concentrations of 1 mM, and 
enzymes at a concentration of 10 µM, in 50 mM phosphate or HEPES buffer, pH 7.5, 100 mM NaCl, 
supplemented with 10% D2O (Sigma) and 0.0025% 3,3,3-trimethylsilylpropionate (Sigma) in 5 mm 
Ultra-Imperial grade NMR tubes (Wilmad). All spectra were recorded at 298 K on a Bruker Avance 
800 MHz spectrometer equipped with a z-shielded gradient triple resonance probe. One dimensional 
1H spectra were acquired by averaging 32 scans using the first row of a NOESY experiment with 
Watergate solvent suppression. 
 
2.4.5 Measurement of DNA and Protein Concentration 
 
For the measurement of concentrations of DNA and protein in samples, a Nanodrop 
spectrophotometer (ND-100 v3.2.1) was used. 
 
2.4.6 Bioinformatics and software 
 
Genome sequences were analysed and visualised with Artemis [ref], and genomes were annotated by 
AntiSMASH 4.0 178. BLAST 175 was used to search for DNA and protein homologues in public databases, 
and Clustal Omega 210 was used to align multiple DNA and protein sequences. SnapGene (GSL Biotech, 
Chicago, IL) was used to design vectors, and Primer3 211 was used to design primers. ChemDraw 
(PerkinElmer, CambridgeSoft) was used to draw chemical structures and calculate exact masses. 









Recently an attempt at using homologous recombination to carry out a conventional domain swap in 
the modular rapamycin PKS (Figure 3.1) led to the serendipitous discovery by Dr Steve Kendrew (then 
at Biotica Technology) of an efficient method to increase the structural diversity of a polyketide 
template following a single integration event 201. Instead of the expected product, the various progeny 
generated by the experiment produced a variety of unexpected rapalogs at comparable titres to the 
wild type production of rapamycin. Each of the progeny strains produced a single rapalog, and the 
various progeny, between them producing an array of different rapalogs, were generated from a single 
crossover event. Follow up studies isolated and characterised the rapalog compounds. It became clear 
that each rapalog was directly related to rapamycin but lacked between 2 or 12 carbon atoms from 
the rapamycin backbone, and in one case had 2 additional carbon atoms. The structures matched the 
predicted polyketide structures that would be produced by truncated or expanded rapamycin PKS 
multienzymes. This result was repeatable, and further investigation showed that the diversity was 
generated during the second crossover event. The second recombination event can occur between 
several homologous regions of DNA in the PKS gene cluster, leading to a mixture of recombinant 
strains with varying number of modules in the target PKS, as illustrated schematically in Figure 3.2. 
This integration leads to a high ratio of productive strains to non-productive strains, where the 
productive strains can be isolated and separated giving multiple individual strains each producing a 
specific novel polyketide (see Figure 3.3). The productivity of the recombinant strains was surprisingly 
not much reduced from the parent strain. This is unusual, as manipulations of PKS gene clusters, 
especially those creating hybrid PKSs, tend to lead to strains with low productivity 212. Analysis of the 
genome sequences for the rapalog producing strains revealed that all genomic changes were confined 
to the PKS region of the rapamycin BGC. For each rapalog producer the new PKS systems matched the 
predicted sequence of domains based on the rapalog structures. The architecture of the mutant PKSs 
was consistent with homologous recombination having occurred between modules at regions of high 
sequence similarity. Additionally, the apparent deletion of one or more modules was often more 
complex than might be expected. For example, sequence analysis of the mutant producing the 1-
module expanded rapalog revealed that the PKS had lost almost two modules (modules 2 and 3) and 
that three extra modules (modules 11, 12 and 13 from rapC) had been inserted into rapA. In the cases 
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where PKS architecture was similar, it was observed that the contractions had occurred at different 
junction points. Taking the data together, it appeared that the junction points tended to occur either 
in the coding sequences for the KS or AT domains, or in a region just upstream of the ACP. 
It is possible that this approach mimics how modular PKSs might have evolved, utilising 
processes involving gene duplication, module duplications, homologous recombination (both inter 
and intra-BGC) and horizontal transfer of genes or gene clusters 213. Due to the similarities between 




Figure 3.1: Schematic diagram of the rapamycin PKS multienzyme. Adapted from Wlodek et al. 201. CoL = CoA 
ligase like, hCHCA = trans-4-hydroxycyclohexanecarboxylic acid which is fed to the strain to initiate biosynthesis 





Figure 3.2: Schematic representation of the recombineering process. Primary integration uses entry point DNA 




Figure 3.3: Representation of the outputs from recombineering on the rapamycin PKS. In this example, initial 
recombination was into DNA encoding module 3 of the rapamycin PKS. Adapted from Wlodek et al. 201.  
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 AE differs from traditional engineering approaches by its apparent lack of target. Typically, a 
conventional attempt at engineering PKS would first decide upon a target molecule then, utilising the 
co-linearity principle, design a PKS system that could generate that polyketide. AE instead picks a 
system which could generate useful analogues, then introduces homologous DNA at a target site 
within the PKS which results in a library of analogous compounds. This principle is illustrated in Figure 
3.4. 
Wlodek and colleagues at Isomerase Therapeutics began optimising this process to further 
study it after the rapalogs were identified. To simplify the work, they used short regions of 
homologous DNA rather than the pairs of flanking DNA sequences that are used to remove or 
introduce DNA. When designing this entry point DNA, a desired initial integration site can be selected 
for. This marks a central point from where the second recombination event can occur between 
homologous regions in other modules, leading to the expanded or contracted macrocyclic ring or 
linear chain structures of the modified polyketide. The original work suggests a preferential target for 
the entry point DNA would be a sequence of >100 bases of homologous sequence which is >80% 
identical (but quickly a standard length of approximately 2 kb was adopted). This high sequence 
homology is common between comparable domains within PKS multi-enzymes and especially 
between domains of the same PKS. If the desired entry point lacks sufficient sequence identity, it is 
possible that the PKS could be prepared for the application of AE by increasing the homology of 
comparable domains using silent mutations of the sequence. Due to the clinical importance of many 
polyketide compounds, the ability to create libraries of analogues could lead to novel compounds with 
therapeutic activities. Replicating the success of AE with the rapamycin gene cluster in other systems 
would provide important evidence for the general use of this technique, even for the most well-known 
polyketides such as erythromycin and monensin. AE is still in its infancy, and so will require a thorough 
investigation of its mode of action, and optimisation of the protocol for each actinomycete strain may 






Figure 3.4: Comparison between the design logic of a traditional engineering-based approach and an 
accelerated evolution-based approach. 
 
 There are a number of factors to consider when designing an AE experiment. These are; the 
suitability of the PKS system for AE, the entry point DNA (the sequence of DNA homologous to the 
desired integration site), and the vector chosen to carry the entry point DNA into the cell and initiate 
the secondary recombination event. There are several characteristics which through an examination 
of the proposed mechanisms, experimental methods, and analytical techniques should determine 
whether a PKS system is suitable for engineering by AE: 
1. High production levels in wild type 
2. UV spectrum 
3. Low number of background peaks 
4. No tailoring enzymes 
5. High-quality whole genome sequence 
6. Co-linear arrangement of PKS genes 
7. Exotic unit required (conditional synthesis) 
8. Strain genetically tractable 
 Most of these characteristics are chosen to assist in characterisation of the fermentation 
products of any AE-generated strains. A high production level is helpful for any engineering method, 
and a characteristic UV spectrum allows for rapid analysis by HPLC and UV-vis spectrometry. Due to 
the nature of AE it will generate products that may have unpredictable molecular weights. Choosing 
systems that have a low number of background peaks and no post-PKS tailoring enzymes makes 
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identifying and characterising new mass signals easier. A high-quality whole genome sequence makes 
genetic analysis easier, and a co-linear arrangement of PKS genes refers to a linear arrangement of 
PKS genes. Using the rapamycin PKS as an example, a co-linear arrangement would involve the rapA 
gene followed by rapB and rapC. This is a common feature among PKS gene clusters, but not universal. 
The co-linear arrangement allows for the maximum possible range of contractions, while minimising 
the creation of any progeny that have inactive an PKS, through loss of a TE or starting KS domain. An 
exotic unit involved in the biosynthesis is not mandatory, but will make analysis easier, as it creates 
the possibility of conditional synthesis. The pathway required to generate the exotic unit can be 
knocked out, and then the exotic unit fed to the fermentation media to initiate production. The final 
characteristic, essential for any engineering attempt, is that the strain must be genetically tractable.  
 Once a system has been selected on these criteria, the choice of the entry point DNA is also 
an important consideration. It must be a sequence that has a high sequence similarity to multiple 
comparable domains within the PKS. The entry point DNA also determines the module where primary 
integration occurs. This is thought to mark the centre from which recombination can occur, although 
the above examples show that the recombination can also occur at locations some distance from the 
insertion module. Work by Wlodek and colleagues highlighted certain ‘hot-spots’ where the most 
common junction points are found. These were in the KS and AT domains, and in the interdomain 
region following the ACP domain. 
 A controllable origin of replication (for example temperature controlled) is known to be critical 
to the success of the second recombination event, but it must also contain selection markers for both 
the parent host (for example E. coli) and the PKS-producing hosts. There are a number of vectors with 
temperature sensitive origins of replication, such as pSG5 214 or pKC1139 207. pSG5 is found naturally 
as a temperature-sensitive plasmid in Streptomyces ghanaensis DSM 2932 which replicates only at 
temperatures below 34°C. The nucleotide sequence of its minimal replicon is the template for the 
pGM vector family. The naturally temperature-sensitive replication of pSG5 and its derivatives makes 
it ideal for this technique because the replication can be controlled to induce recombination events. 
The vector pKC1139 in particular contains the temperature sensitive replicon from pSG5, as well as an 
apramycin resistance gene, multiple cloning sites and an oriT fragment which allows for transfer of 
the plasmid to the PKS-producing host via conjugation 215. Assembly of the entry point DNA into the 
vector is typically achieved using Gibson isothermal ligation assembly 216 in E. coli DH10B.  
The work by Wlodek et al. is not the first recorded evidence of an AE-like modification of a 
PKS multienzyme, but it is the first to recognise its significant and to repeat and characterise the effect. 
In 2002 Sergey Zotchev and colleagues from the Norwegian Institute of Science and Technology 
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reported that an attempt to manipulate the nysC gene of the nystatin PKS yielded a recombinant strain 
that produced a hexaene nystatin derivative 217. Further investigation revealed that the hexaene 
compound was a 36-membered macrocycle (compared to the 38-membered nystatin backbone) and 
was fully decorated by the post-PKS enzymes. Sequence analysis of the recombinant strain revealed 
an in-frame deletion in the nysC gene that had resulted in the loss of an entire module. The 
recombination occurred between the KR domains of modules 4 and 5, which share 99.9% sequence 
similarity, and have a G+C% of 64%, much lower than the 74% found in the rest of the gene cluster, 
suggesting that those sequences were acquired from another organism through horizontal gene 
transfer. The Norwegian group came to similar conclusions that the modification was generated by 
homologous recombination between regions of highly similar DNA through a process that mimicked 
the evolution of the nystatin PKS cluster, however they did not repeat the experiment to investigate 
whether this was a random and deleterious occurrence, or a process that could be replicated and 
made useful. 
 The significance of AE technology is that from a single exconjugant (primary), representing a 
single integration event, a wealth of diversity can be generated via the random truncations. The 
technique appears to overcome the limitations of conventional PKS engineering, namely the 
interference of domain boundaries resulting in poor productivity, by removing the need to artificially 
determine domain boundaries and instead allowing recombination processes to occur and the 
selecting for the productive strains. Furthermore, as a single strain can undergo a series of 
recombination events between different sites in the PKS gene sequence one can potentially create 
multiple stable strains that have had one or more module inserted or deleted during a single 
experiment. The analysis of AE-generated hybrid PKS modules could provide valuable insights to guide 
the rational engineering of modular PKS. Additionally, AE has the potential to become a standard 
approach to the engineering of PKS in its own right. Compared to rational PKS engineering, where the 
design of a single DNA construct is aimed at the production of a single strain that produces a single 
desired compound, AE allows for the rapid parallel creation of a number of strains each producing a 
member of a family of novel compounds. This work was done with kind advice from scientists at 







3.2: Results and Discussion 
3.2.1: Nystatin Gene Cluster Rearrangement 
 
The first recorded instance of an AE-like deletion of a PKS module was in the nystatin PKS. Therefore, 
it made sense to evaluate the nystatin producer S. noursei as a possible testbed for extension of AE, 
since the machinery for homologous recombination could be assumed present in this strain. Other 
integration sites would be tested in the nystatin PKS, with the aim of eventually generating a library 
of compounds. The nystatin gene cluster spans 267 kbp. There are six core PKS genes; nysA,B,C,I,J,K 









Figure 3.5: Nystatin PKS biosynthesis. (A) Nystatin gene cluster: NysA/B/C/I/J/K: PKS genes, nysL: P450 
monooxygenase, nysM: ferredoxin, nysM: P450 monooxygenase, nysDII: amino transferase, nysDI: 
glycosyltransferase. (B) Nystatin PKS biosynthetic pathway and completed nystatin structure. 
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As Figure 3.5 illustrates, the nystatin PKS genes are not co-linear with the arrangement of the 
genes in the cluster, and while there are large regions where homologous recombination can occur 
harmlessly, the location of nysA and nysK, which are essential to production of nystatin, presents the 
risk of generating recombinant nystatin BGCs that are inactive. To maximise the chances of generating 
novel nystatin derivatives an experiment based on CRISPR/Cas9 engineering was designed to 
rearrange the nystatin gene cluster. 
 To obtain the nystatin gene cluster rearrangement, a vector was constructed that contained 
the cassette necessary to make two accurate cuts to cleave nysA, B, and C (nysCBA) from the genome, 
and to re-join the digested ends. The protocol for designing and creating the vector was based on the 
protocol outlined in the supplementary materials of Cobb et al. 218. The nysCBA PKS genes were chosen 
for mobilisation, as this region is flanked by larger regions of non-coding DNA than the nysIJK genes. 
Once the vector had been designed, it would be transferred into the host through intergeneric 
conjugation and the desired cleavage performed. The next step would be to design a second vector 
that contained a cassette with nysCBA, and the required homologous arms to induce homologous 
recombination and insert nysCBA into a co-linear position within the nystatin BGC. This vector would 
be inserted, and progeny would be screened for the desired insertion. Figure 3.6 illustrates the 
targeted rearrangement of the nystatin BGC. 
 
 
Figure 3.6: The scheme for the rearrangement the nystatin biosynthetic gene cluster. NysABC is deleted by two 
targeted double stranded breaks mediated by the CRISPR-Cas9 complex. The nysABC cassette is then 





The S. noursei genome was sequenced and assembled by the Department of Biochemistry 
DNA Sequencing Facility, and the sequence of the nystatin gene cluster was fully checked and 
confirmed (Figure 3.5). The genes nysCBA were to be deleted and reinserted in sequential order 
adjacent to nysKJI. The template sequence was created by amplifying 1kbp of genomic DNA on either 
side of nysCBA to provide flanking arms. The flanking arms were purified by gel electrophoresis and 
were ligated together with pCRISPomyces2, previously linearised by digestion with the restriction 
enzyme XbaI, by using Gibson isothermal assembly (Figure 3.7) 216. 
Candidate crRNA sites were identified using an online tool 219 and target sites were chosen 
based on the 21bp target sequence and the position relative to nysCBA. These crRNA sites were 
included in the sgRNA sequence containing appropriate promoters and terminators (Figure 3.8). The 
designed sgRNA was bought as a gene fragment from Eurofins Genomics and ligated into 
pCRISPomyces2 via Golden Gate assembly (Figure 3.9). The completed pC2-nysCBA plasmid was 
verified by PCR amplification of the region containing the sgRNA and template inserts, and by 
sequencing. 
Transformation of pC2-nysCBA into S. noursei was attempted through conjugation with 
chemically competent ET12567/pUZ8002 cells which had previously been transformed with pC2-
nysCBA. Conjugations were performed on several different media; SFM, MAM, ABB13 and R6, varying 
concentration of MgCl2, using both mycelium and spores of S. noursei and varying incubation times 
before overlaying the conjugation plate with antibiotics (summarized in Table 3.1).  
CRISPR/Cas9 gene editing has been used successfully to edit Streptomyces spp. genomes218,220 
and so a deletion of approximately 40 kb in the nystatin gene cluster was considered achievable. This 
deletion would be the first step in a large-scale rearrangement of the nystatin cluster, an achievement 
in its own right, and one which would allow a more efficient and extensive application of AE 
technology. Despite many attempts at optimising the conjugation of ET12567/pUZ8002 with S. noursei 







Figure 3.7: Scheme for three-fragment assembly of the nysCBA flanking arms into pCRISPomyces2 to form the 
template sequence. pCRISPomyces2 was linearised by digestion with the restriction enzyme XbaI. PCR primers 










BbsI-Spacer 1-tracrRNA tail-T7 Terminator-gapdhp(EL)-Spacer 2-BbSI 
 
Figure 3.8: Design of sgRNA. BbsI indicates the sticky ends, complementary to the sticky ends left by BbsI 
digestion of pCRISPomyces2. Spacers 1 and 2 are the crRNAs that will guide Cas9 to the target sequences. The 
tracrRNA tail is the second part of the sgRNA and forms a scaffold to bind to Cas9. T7 is a terminator and 
gapdhp(EL) is a promoter. The missing promoter for Spacer 1 and the tracrRNA tail and terminator for Spacer 2 





Figure 3.9: Golden gate assembly of sgRNA into pCRISPomyces2 linearised by digestion with the restriction 
enzyme BbsI. BbsI cuts outside its recognition sequence and so the arrows above indicate the direction in which 
BbsI cuts, allowing for a seamless insertion of the sgRNA fragment. 
 
Table 3.1: Conditions attempted for conjugation between ET12567/pUZ8002 and S. noursei. 
 
Medium MgCl2 concentration S. noursei cell type Incubation time Antibiotic 
concentrations 
SFM 10mM Mycelium 20hrs (Nal + Apr) Nal: 25ng/µl 
MAM 20mM Spores 14hrs (Nal + Apr) Apr: 50ng/µl 
ABB13 
R6 







3.2.2: Nystatin Accelerated Evolution 
 
Accelerated Evolution is a new technology. It is known that entry point DNA requires high homology 
to comparable sequences in the PKS gene cluster, and that in the case of rapamycin most new 
junctions were found within the KS and AT domains, and C-terminal of the ACP domain. Besides that, 
there are few guidelines for choosing a suitable site for the entry point DNA. In this case, the entry 
point DNA was chosen by aligning all modules against one another and choosing the region of highest 
mutual percentage identity to counterparts in all other modules. (see Figure 3.10). It was believed that 
this should maximise the chance of recombination with sites in neighbouring modules after initial 
integration at the entry point.  
 
 
Figure 3.10: Sequence homology between KS domains in the nystatin PKS gene cluster. The highlighted column 
shows the sequence similarity between the KS in module 9 and all other KS domains. The KS domain in module 
9 was chosen as the entry point for AE as it has the highest sequence similarity compared to all other KS domains. 
 
The region with the highest identity contained most of the KS domain of module 6, therefore 
the whole KS6 domain (1383 bp) was chosen as the entry point DNA. The KS6 domain was amplified 
by PCR and purified using gel electrophoresis. This fragment was then inserted into pKC1139 which 
had been linearised by the restriction enzymes XbaI and EcoRI using Gibson isothermal assembly, to 
create the plasmid pKC1139-nysKS6. Figure 3.11 shows a general scheme for the creation of all 
pKC1139 derived vectors used in this work and Figure 3.12 shows the PCR amplification of the entry 
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point DNA and bands confirming the presence of the entry point DNA insert in pKC1139 generated by 
cPCR. 
 Transformation of pKC1139-nysKS6 into S. noursei was attempted through conjugation at 37°C 
with chemically competent ET12567/pUZ8002 cells which had previously been transformed with 
pKC1139-nysKS6. The same conditions as described in Table 3.1 were used, but once again failed to 
produce exconjugants despite attempts at optimisation using literature precedents as a guide 221. The 
difficulty of conjugating into S. noursei could have been overcome through further attempts at 
optimisation, or though other methods of transformation such as electroporation or transduction. 
However, due to the difficulties presented, it was decided that rather than continue working with 
nystatin, focus would be shifted to other strains which are known to be easily conjugatable, and where 
the natural arrangement of the PKS genes favours AE. 
Accordingly, three other modular PKS systems were evaluated for AE: filipin, erythromycin 
and monensin. Each of these systems have their PKS genes organized sequentially in the cluster and 
in the case of erythromycin and monensin they had been extensively characterised and effective 
conjugation protocols were well known. 
 
 
Figure 3.11: General scheme of amplification and ligation of entry point DNA into pKC1139. The primers 
include 20bp overhangs that are complementary to the ends of the linearised pKC1139. pKC1139 is linearised 





Figure 3.12: Gel images showing amplification of entry point DNA and screening of the pCK1139-nysKS6 
vector. (A) Amplification of entry point DNA; (B) Screening of pCK1139-nysKS vector by cPCR. The ‘Ladder’ lane 
contains the DNA ladder (1 Kb Plus DNA Ladder). The numbers to the side of each ladder refer to the size of each 
relevant band in the ladder. Each numbered lane refers to a colony of E. coli that was screened for the correct 
vector. 
 
3.2.3: Filipin, Erythromycin and Monensin Accelerated Evolution. 
 
Erythromycin and monensin are well known polyketide compounds with useful therapeutic activity, 
and their biosynthesis has been well characterised over many years. Filipin is not useful as a 
therapeutic agent, but its biosynthesis, along with other macrolide polyenes, such as amphotericin 
and nystatin, is well characterised. They were chosen for several reasons, the first criterion being the 
ease with which the strains can be manipulated, but each gene cluster also presents characteristics 
that make it a plausible candidate system for AE. All three antibiotics are produced at easily detectable 
production levels, accompanied by a low number of background peaks. Filipin biosynthesis involves 
few tailoring enzymes, and for monensin a mutant strain of S. cinnamonensis was available in which 
the gene monCI was knocked out, preventing oxidative cyclisation of the linear polyketide backbone 
and instead producing the simple triene shunt product, premonensin 222. . High quality genome 
sequences were already available for the erythromycin and monensin producers, and the filipin-
producing strain, S. filipinensis had been acquired and was submitted for whole genome sequencing 
and assembly. Finally, in all three gene clusters the PKS genes were aligned in the same direction in 
the order in which their encoded enzymes act, maximising the scope for productive recombination. 
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Filipin had the additional advantage of a distinctive UV spectrum and an exotic hexylmalonyl-CoA 
extender unit, the synthesis of which could potentially be knocked out and used as a basis for 
conditional synthesis of filipin analogs. Figure 3.13 shows the polyketide biosynthetic pathway for the 
three chosen PKS systems and highlights the chosen entry points in the PKS genes and structures. 
 The initial entry point DNA for erythromycin and monensin AE was designed using the same 
method as described above for nystatin, and once again KS domains (KS6 for erythromycin and KS2 
for monensin) were chosen as they held the highest sequence similarity between modules. Meanwhile 
the S. filipinensis genome was sequenced, assembled and annotated by the Department of 
Biochemistry DNA Sequencing Facility staff. Once the assembly was completed the entry point DNA, 
also a KS domain (KS11), was chosen for filipin. KS11 was chosen on the basis of its high sequence 
similarity with the KS domain of other modules, and because module 11 is involved in biosynthesis of 
part of the polyol region of filipin. The reasoning was that if contractions were generated, they would 
be more likely to leave the characteristic UV signature of filipin intact, which would help detection of 
novel filipin analogues. The entry point DNA for all three clusters was amplified by PCR and purified 
using gel electrophoresis. The fragments were then inserted into pKC1139, which had been linearised 
by the restriction enzymes XbaI and EcoRI, through Gibson isothermal assembly to create the plasmids 
pKC1139-eryKS6, pKC1139-preKS2 and pKC1139-filKS11 for the erythromycin cluster, monensin and 
filipin gene clusters, respectively (Figure 3.11). Successful assemblies were screened for using cPCR. 
Constructs were used to transform the S. erythraea, S. cinnamonensis, and S. filipinensis hosts was 
attempted through intergeneric conjugation at 37°C with chemically competent ET12567/pUZ8002 
cells which had previously been transformed with each construct. The initial conjugation attempts 
failed to produce exconjugants. Standard conjugation protocols were known to be effective in these 
strains 127,223,224 and so there must have been another issue, such as the vector, the entry point DNA, 
or the modifications to the conjugation protocol. The AE protocol requires conjugations to occur at 
37°C. Exconjugants are restreaked to ensure no contamination is carried over, and once confirmed as 
clean they are analysed by PCR to confirm the presence of the vector in the host genome. Only at this 
point are the cells grown at 30°C, which was described as vital to the success of AE in the original 
experimental protocol. The importance of the initial higher temperature is due to the pSG5 origin of 
the pKC1129 vector. This origin of replication is non-permissive at temperatures higher than 34°C, 
therefore the plasmid cannot replicate and must integrate into the genome to survive. The pKC1139 
vector is commonly used as a suicide vector for transformation of Streptomyces spp. 225. Why the 
temperature control is so vital to success is currently unknown but if the pSG5 origin were responsible 











Figure 3.13: PKS biosynthetic pathways of erythromycin, monensin, and filipin. The PKS biosynthetic pathways, 
intermediates and completed structures for; (A) erythromycin (B) monensin (the simple shunt compound 
"premonensin" was the target for the AE work) (C) filipin. 
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One hypothesis is that lowering the temperature initiates replication from the pSG5 origin within the 
host genome. This would generate single stranded DNA, which is known to be highly recombinogenic 
226 and could start strand invasion and recombination at neighbouring regions of homology, creating 
a recombination event between the entry point and the site of secondary integration, that truncates 
the PKS-encoding region between the two sites. An alternative hypothesis instead suggests might be 
that the temperature sensitive origin is just an efficient means to transform DNA into Streptomyces 
spp., and that the inter-module recombination is the secondary effect of the induced stress of 
repairing double stranded breaks, or other DNA damage caused by the integration of the pKC1139 
vector. 
 The modified protocol appeared to interfere with the growth of exconjugants. A larger-scale 
conjugation was attempted to overcome the reduced probability of generating exconjugants. This 
work resulted in exconjugants which grew when patched onto selective media. Consultation with our 
collaborators at Isomerase Therapeutics at this point confirmed that this approach did reduce the 
likelihood of generating exconjugants, and more importantly the ‘hot-spots’ within rapamycin PKS 
modules that were discussed in the introduction of this chapter had been identified, and their 
importance in generating mutants was highlighted. This indicated the need to evaluate several 
constructs for each system, covering an entire module, and to carry out conjugations on a larger scale.  
The AE experiments were therefore repeated for a new series of constructs. Entry point DNA 
for the new constructs was designed using the same module within each of the three gene clusters as 
in the initial experiments with the KS region only. For each chosen module, four constructs were 
designed to cover the entire module from the ACP domain in the previous module, to the KR domain 
in the chosen module. Figure 3.14 shows the sequence similarity across each module in the respective 
PKS gene clusters and Figure 3.15 shows the region each construct covers within the chosen module. 
The sequence similarity plots show that across the three PKS systems, the regions of highest sequence 
similarity consistently lie within the KS domains, although additional regions of high similarity can be 








The entry point DNA for each construct was amplified by PCR and purified using gel 
electrophoresis. The fragments were then inserted into pKC1139, which had been pre-linearised by 
the restriction enzymes XbaI and EcoRI, by Gibson isothermal assembly, to create each construct 
(Table 2.2). Transformation of each construct was attempted via conjugation between 
ET12567/pUZ8002 and the host strains at 37°C. Figure 3.16 shows the PCR amplification of the entry 
point DNA and bands confirming the presence of each entry point DNA insert in pKC1139 vectors for 
the filipin entry point constructs. 
 
Table 3.2: pKC1139-based plasmids for AE recombineering 
 
Plasmid Entry point DNA Length (bp) 
pKC1139-filKS11 Filipin domain KS11 1284 
pKC1139-filKS-AT11 Filipin domains KS-AT11 2056 
pKC1139-filAT-KR11 Filipin domains AT-KR11 2023 
pKC1139-filACP-KS11 Filipin domains ACP10-KS11 1945 
pKC1139-eryKS6 Erythromycin domain KS6 1278 
pKC1139-eryKS-AT6 Erythromycin domains KS-AT6 2031 
pKC1139-eryAT-KR6 Erythromycin domains AT-KS6 2062 
pKC1139-pryACP-KS6 Erythromycin domains ACP5-KS6 1560 
pKC1139-preKS2 Premonensin domain KS2 1278 
pKC1139-preKS-AT2 Premonensin domains KS-AT2 1890 
pKC1139-preACP-KS2 Premonensin domains ACP1-KS2 1727 






Figure 3.14: Sequence similarity between each module in the respective PKS gene clusters. (A) Erythromycin 
(B) Monensin (C) Filipin. The charts were created by aligning all module sequences from each PKS system and 
plotting sequence similarity using Plotcon (http://emboss.bioinformatics.nl/cgi-bin/emboss/plotcon). The 














Figure 3.15: Entry point DNA constructs covering the length of the chosen modules in each gene cluster. (A) 






Figure 3.16: Gel images showing amplification of entry point DNA and screening of the pCK1139-derived 
vectors for the filipin constructs. (A) Amplification of entry point DNA; (B) Screening of pCK1139 filipin vectors. 
The ‘Ladder’ lane contains the DNA ladder (1 Kb Plus DNA Ladder). The numbers to the side of each ladder refer 
to the size of each relevant band in the ladder. Each set of 4 lanes in (B) are from a colony of E. coli that was 
screened for the correct expression vector. 
 
 
Figure 3.17: Scheme for cPCR screening of exconjugants for primaries. A successful primary will have the 
pKC1139 plasmid integrated within the target region of the PKS module. To screen for this pairs of primers were 
designed that would amplify a sequence of DNA across the junction of the integration point. As long as one 
primer is on the plasmid and one is on upstream of the target region, a DNA fragment should be amplified 








Figure 3.18: Confirmation of primary exconjugants by colony PCR. Each set of three bands show PCR 
amplification of the junction regions between inserted vectors and genomic DNA. Each band observed is of the 
expected size, however many lanes do not any bands. This is an intrinsic issue with Streptomyces colony PCR. It 
is unknown whether lanes are missing bands due to a failure of the PCR, or due to the vector not being present 
in the host genome.  
 
This attempt produced several exconjugants for each strain. These were restreaked onto SFM plates 
containing nalidixic acid and apramycin. The exconjugant was cleared of contamination by several 
rounds of restreaking on fresh SFM plates containing antibiotics. The presence of the pKC1139 derived 
construct in the cells was confirmed using Streptomyces cPCR and sequencing. Figure 3.17 shows the 
scheme for screening of primary exconjugants and Figure 3.18 shows the results of the screening.  
 The effectiveness of colony PCR of sporulating Streptomyces colonies was investigated for this 
screening process. A small amount of mycelium was picked, the cells were lysed by boiling in a 50% 
DMSO solution, and the resulting mixture was used as the template for a PCR reaction. While initially 
promising, cPCR required several rounds of optimisation before it could produce products observable 
by gel electrophoresis in the majority of samples. As can be seen in Figure 3.18, the observable bands 
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are clear and of the expected size. However further optimisation is required before Streptomyces cPCR 
can reliably detect successful integration events. 
 The screening revealed only one erythromycin and two monensin primary exconjugants. In 
contrast, every one of the filipin conjugations produced colonies resistance to apramycin, and of those 
all but the FilKS-AT11 construct were confirmed as primaries. Once exconjugants were confirmed, the 
selective pressure of an antibiotic was removed to induce a secondary recombination event and 
removed the integrated plasmid. This is referred to a relaxing and was achieved by inoculating colonies 
into liquid TSBY medium without antibiotics and incubating the cultures at 30°C. Each culture was re-
inoculated after 48 hrs incubation, three times, then finally the cultures were diluted and streaked out 
to single colonies on an SFM plate without antibiotics. The loss of antibiotic resistance was confirmed 
by patching single colonies onto pairs of SFM plates, one without apramycin and one with apramycin. 
The only colonies that lost their resistance to apramycin were derived from S. filipinensis. It is unclear 
whether the relative success of the filipin constructs compared to those of erythromycin and 
monensin is due to chance, or some property of S. filipinensis which lends itself to success with AE. 
 In addition to the loss of apramycin resistance, conferred by the integrated pKC1139 vector, 
putative filipin mutants were screened by PCR. The reasoning behind the PCR screen is outlined in 
Figure 3.19 and the results of the screen are presented in Figure 3.20. This screen is not ideal as it 
relies on the disappearance of a band to identify recombinant DNA. However, considering the number 




Figure 3.19: Scheme for relaxant screening of putative filipin recombinant strains. By using primer pairs that 
amplify across the target region, a wild type strain can be identified. A recombinant strain would not give a 
product. This method is obviously not a reliable way to confirm a recombinant strain but provided a starting 




Figure 3.20: Gel images showing the screening for filipin recombinant strains. This screening approach 
identifies all 12 samples of the FilKS-AT relaxant strains and 9 of the FilAT-KR relaxant strains as being putative 
recombinants. In contrast the screening of the PreKS-AT relaxant strains identifies all 12 samples as being wild 
type. 
 
 The first batch of experiments resulted in 53 putative recombinant strains. These were grown 
following the protocol outlined in Chapter 2. After 5 to 7 days of growth the fermentation culture was 
sampled by extraction of 1 ml of culture with 2 ml of ethyl acetate. The ethyl acetate was evaporated 
off, and the remaining residue was dissolved in methanol. The samples were then analysed by LCMS, 
following the procedure in Chapter 2. All but one sample appeared to produce wildtype filipin. The 
remaining sample (sample 2.8.2) gave an LCMS spectrum that showed a profile with the characteristics 
of a filipin-like UV signature, a non-filipin mass, and a shorter retention time than filipin. Figure 3.21 
illustrates the differences between wildtype S. filipinensis, a characteristic sample of a putative 
recombinants, and sample 2.8.2. The shorter retention time of sample 2.8.2 is indicative of a filipin-
related analogue, perhaps generated by a contraction in the number of modules, and the reduction 
in yield is commonly seen in recombinant strains. To test whether this might be a novel filipin 
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derivative I reinoculated the strain from the plate it had been stored on, to repeat the fermentation 
at a larger volume and confirm the result.  
 Unfortunately, despite multiple attempts using liquid media and on SFM agar the strain did 
not grow. The reasons for this are unknown and might be wholly unconnected with filipin biosynthesis. 
It did however raise the possibility that an altered filipin analogue might be toxic to the cells. The 
reduction in the yield I observed in sample 2.8.2 was also a serious concern. To address this a 
production screen was set up using 13 different media. All media were inoculated with 0.5 ml of the 
same seed culture and incubated at 30°C for 5 days. There was an approximately 200-fold difference 
in the production level of filipin between the lowest and highest producing media, with SFM being the 
highest yielding medium. Ethyl acetate extractions of SFM cultures had a strong yellow colour, 
indicative of a high concentration of filipin. The differences are shown in Figure 3.22. Once SFM had 
been identified as the best medium for producing filipin it was used for all further fermentations of S. 
filipinensis. 
Further work focussed on repeating the attempts at AE of S. filipinensis and on maximising the 
output of potential recombinant strains and trying to shorten the time required for analysis. 
Approximately five to ten exconjugants were generated for each of the filipin constructs and these 
were relaxed to generate hundreds of putative recombinants. To maximise the number of putative 
recombinants that could be screened for loss of apramycin resistance, 96 deep-well plates (2ml in 
each well) were adopted for the relaxation stage. These plates contained 1 ml of SFM and a single 
glass bead to prevent clumping. The wells were inoculated from a seed culture from a confirmed 
primary exconjugant, and after several rounds of reinoculation into fresh non-selective media the 
cultures were diluted and spread out to obtain single colonies. These in turn were screened for loss of 
apramycin resistance. Primary exconjugants were screened for loss of production of filipin, resistance 
to apramycin and were also screened by cPCR. Loss of production of filipin is expected if the target 
region has been interrupted by the integrated vector. Figure 3.23 illustrates the loss of production in 















Figure 3.21: LCMS analysis of putative recombinant strains. (A) Wildtype S. filipinensis production (B) S. 




Figure 3.22: LCMS analysis of the filipin production screen. Based on the relative intensity of the UV signature 




Figure 3.23: LCMS analysis of the loss of filipin production in a primary. The characteristic peak at 13.9 mins 
has been lost, indicating a loss of filipin production. The peak at 16 mins was always observed with filipin 
production and is most likely a filipin related compound. 
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 Unfortunately, despite the new screening protocols, and the large number of potential 
recombinant strains being fermented and analysed by LCMS no other potential filipin derivatives were 
observed. Perhaps one reason for this was the lack of processing capacity in the lab, which was not 
really set up for such high throughput screening. The total number of potential recombinant strains 
that were generated from the last batch of primaries was approximately 900. Of those only 128 were 
analysed by LCMS. Except for 14 samples, all 128 appeared to produce filipin, matching the molecular 
weight and retention time of wildtype filipin. The remaining 14 samples appeared to have lost filipin 
production, without gaining the ability to make an altered product. This effect has also been observed 
with AE experiments on the antibiotic tylosin 201.  
 
3.3: Concluding Remarks 
 
The work described in this chapter was an attempt to widen the application of AE in Streptomyces spp. 
It began with the optimistic target of applying AE to the nystatin, erythromycin, premonensin, and 
filipin PKS systems, however the scale of that original goal, and the issues found with conjugation into 
the nystatin and to a lesser extent the erythromycin and premonensin producing strains led to a focus 
of the work on the filipin PKS system. Despite this focus, and the large number of putative 
recombinants generated and screened, no new filipin derivatives were characterised. 
 In future work, it would be highly advantageous to mutate S. filipinensis to produce filipin only 
when supplemented. One possible route to this might be through blocking the strain's ability to 
produce the hexylmalonyl-CoA building block required for the last chain-extension step on the PKS. 
FilB has been identified as a 2-octenoyl-CoA reductase that supplies the hexylmalonyl-CoA for filipin 
biosynthesis 227. Knocking out this gene would provide the basis for conditional synthesis, through 
feeding a cell-permeable precursor of hexylmalonyl-CoA to the strain. Having an S. filipinensis strain 
with conditional filipin synthesis would address concerns about generating toxic metabolites and 
would greatly ease analysis of any recombinant strains. 
 A significant barrier to the wider application of AE is that the underlying mechanism behind 
its generation of derivatives is not understood. It is possible that there is a specific requirement for AE 
to function correctly that happens to be found in the rapamycin producing strain, and not in others. 
The fact that this effect has only been recorded once, other than the paper by Wlodek et al. suggests 
that AE is possible in other strains but is extremely rare. This would also explain why a possible filipin 
derivative was observed in sample 2.8.2 but was never repeated. With the benefit of hindsight, it was 
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perhaps premature to begin trying to generalise the technology. The success of AE with rapamycin is 
undeniable, but I believe in the absence of a better understanding of the mechanism, it relied too 
heavily on luck to achieve an effect that had only been observed in a very small number of polyketide 
producing strains. The study of homologous recombination in Streptomyces is decades behind 
research focussing on E. coli 228,229 which makes it difficult to identify the similarities or differences 
required to make a strain amenable to AE. One way to explore this initially would be to continue AE 
on S. rapamycinicus, aimed at another of the metabolites of that strain, such as the long chain linear 
polyene clethramycin 230. It would be of great interest to know whether AE on a different metabolite 
was equally productive.  
 AE is a fascinating technology that if generalised has the potential to bring about a paradigm 
shift in the field of polyketide biosynthesis. The ability to rapidly generate a library of derivatives from 
a single experiment could lead to therapeutic agents with novel activities, improved efficacies, or 
agents that are able to overcome antibacterial resistance, especially if the generation of mutants could 

















Chapter 4: Genome-level analysis of the pseudouridimycin producing 




As discussed in the introduction, advances in DNA sequencing and genome annotation have provided 
huge benefits to the study of bacterial natural products. Streptomyces and allied genera have 
exceptionally large genomes (8-12 Mbp) and their high G+C % content and frequent regions of 
repetitive DNA pose significant technical problems for sequence analysis. This is reflected in the fact 
that the vast majority of publicly deposited draft genomes are highly fragmented and poorly 
interpretable. However, high-quality, well-annotated, genome sequences are afforded by the in-
house Department of Biochemistry Sequencing Facility and the customised assembly and automated 
annotation pipeline developed by Dr Markiyan Samborskyy. Together with the cluster-finding 
software AntiSMASH this provides an accurate estimate of the biosynthetic potential of a given strain 
and allows recovery of the full sequence of even the largest gene clusters. Their work has confirmed 
that on average a Streptomyces strain houses 20-25 clusters, although an exceptional strain such as 
Streptomyces malaysiensis DSM 4137 has 53 annotated clusters (Samborskyy et al., ms in 
preparation). Typically, most of these clusters do not give rise to detectable products under standard 
laboratory growth conditions. This genomics-based approach is now the method of choice for helping 
identify species and assessing the biosynthetic potential of a strain. However, it is only the first step 
in correctly matching a gene cluster to its product. 
 Pseudouridimycin (PUM) (Figure 4.1) is a nucleoside antibiotic first isolated under the name 
strepturidin in 1993. It was identified through the antibacterial activity of an extract of Streptomyces 
albus culture against the Gram-negative nitrogen-fixing soil bacterium Azotobacter chroococcum 231, 
and tests proved positive for guanidine groups, sugars and amino sugars, and negative for aromatic 
amines, organic acids, amino acids and peptides. A proposal for its structure was made in 2014 232, 
together with a tentative proposal for its biosynthetic pathway. The structure was initially 
characterised using HPLC-HR-ESI-(+)-Orbitrap-MS and IR spectroscopy. A molecular formula of 
C17H27O9N8 was identified by high-resolution mass spectroscopy, and IR spectroscopy revealed the 
presence of amine groups, hydroxyl groups, and amide carbonyls. UV spectroscopy showed 
characteristic absorptions for heterocycles. These insights were combined with the results of 
extensive 1H and 1H-13C 2D-NMR spectroscopy, which identified four distinct spin systems, to complete 
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the structural elucidation. The first spin system was identified as Nα-hydroxylated glutamine, the 
second was a triol-containing carbon chain, supposedly derived from diamino aldopentose, the third 
spin system was identified as 2-aminoimidazole-5-one, and the final spin system was identified as 
uracil. Signals indicative of the connection between these spin systems were also observed, identifying 
the structure seen in Figure 4.1 as strepturidin. 
 PUM was also independently reported by Ebright, Donadio, and colleagues in 2017 233 through 
screening a library of 3,000 actinobacterial and fungal culture extracts for inhibitory activity against E. 
coli RNA polymerase (RNAP) 234. PUM was isolated from two culture extracts with antibacterial activity, 
and it was shown to selectively inhibit bacterial RNAP in both Gram-negative and Gram-positive 
bacterial strains, and against both drug-sensitive and drug-resistant strains. It also showed no cross-
resistance with the potent, and broad-spectrum bacterial RNAP inhibitor rifampicin, exhibiting 
additive antibacterial activity when co-administered with rifampicin (a constituent of the standard 
DOTS treatment for TB). This suggests that PUM acts through a different mechanism to rifampicin, 
which makes it an exciting target for study, and a possible drug lead. 
 
 
Figure 4.1: Structures of (1) strepturidin and (2) pseudouridimycin. Deoxy-pseudouridimycin refers to a loss of 
the N-hydroxyl group. 
 
 The PUM structure shown in Figure 4.1 was independently established 233 by high-field NMR 
but additional 15N-HSQC spectroscopy indicated the uracil moiety was C-linked to C1’ of 6’-amino-
ribose, which HMBC spectra indicated was linked in turn to the glutaminyl moiety at the N6’ of 6’-
amino-ribose. Further data indicated the presence of glycine C-linked to the glutamine Nα, and of 
formamidine C-linked to the glycine Nα. The structure was completed when the absence of a 
glutaminyl Nα signal in the N-HSQC spectrum suggested the presence of a hydroxamic acid, which was 
confirmed by reduction of PUM with TiCl3, yielding deoxy-PUM (Figure 4.1). The stereochemistry of 
PUM shown in Figure 4.1 was identified through hydrolysis and a comparison of the products with 
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commercial standards using GC-MS. The work to characterise PUM structure does not acknowledge 
the earlier report, but it seems likely that strepturidin is actually mischaracterised PUM. 
 The fully elucidated structure of PUM shows several interesting features. Most strikingly it is 
a C-nucleoside, meaning that the uracil base is connected to the sugar through a C-C rather than a N-
C bond. Dr Hui Hong in this laboratory has recently analysed the biosynthetic pathway to the C-
nucleoside malayamycin A and has shown that it is derived from pseudouridine 5'-monophosphate 
(-MP) (Hong et al. (2018) ms. in the press). The other interesting feature is its modular nature, 
apparently the result of a convergent pathway in which 6’-amino-pseudouridine, N-hydroxylated 
glutamine, and guanidinoacetate moieties are then linked together. The work in this Chapter describes 
a genome mining approach to uncovering the PUM gene cluster, with a view to examining the 
biochemistry of the pathway compared to that of malayamycin and exploring the potential for 
preparing analogues of the PUM molecule. At the same time, the genome mining approach would 
allow a detailed overview of the unexplored biosynthetic potential of this strain. 
 
4.2 Results and Discussion 
4.2.1 Whole-genome sequencing of Streptomyces albus DSM40763 
Streptomyces albus DSM40763 was obtained from the DSMZ collection. Whole-genome sequence was 
obtained in-house by Shilo Dickens and colleagues at the NextGen DNA Sequencing Facility in the 
Department of Biochemistry using a combination of shotgun MiSeq and long-range mate-pair MiSeq 
data. Sequence data was assembled into scaffolds, using an in-house pipeline, by Dr. Markiyan 
Samborskyy. Open reading frames were identified and visualised by the genome browser Artemis 235. 
Streptomyces albus DSM40763 is coded as A980 in the Leadlay laboratory strain collection. A980 has 
a genome size of 8.01 Mbp with 6774 putative protein-coding sequences (Figure 4.2). The final 
assembly has a single large scaffold, A980_AS6_SC1, containing 97% of the genome and housing all 
but one of the biosynthetic gene clusters. Seven small scaffolds of decreasing size, which could not be 
mapped to the core sequence due to a lack of overlapping regions, were also obtained. These are 
named A980_AS6_SC2, A980_AS6_SC3, A980_AS6_SC4, A980_AS6_SC5, A980_AS6_SC6, 
A980_AS6_SC7, and A980_AS6_SC8. The final biosynthetic gene is found in A980_AS6_SC2. The G+C 






Figure 4.2: Map of the linear Streptomyces A980 chromosome scaffold 1, comprising 97.5% of the total 
genome. The scale is numbered in megabases. The outermost two rings show genes on the forwards and reverse 
strands, respectively. The coloured bands represent the class of gene; red, secondary metabolism, black, energy 
metabolism, pale blue, regulators, yellow, central metabolism, cyan, degradation of large molecules, magenta, 
degradation of small molecules, dark green, surface associated, orange, conserved hypothetical, pale green, 
unknown, grey, miscellaneous. The third ring shows the essential genes for cell division, DNA replication, 
transcription, translation, and amino acid biosynthesis. The fourth ring shows the genes of secondary 
metabolism. The large gene cluster around the 7 Mbp mark is discussed below. The fifth ring shows the mobile 
genetic elements (blue, transposases, red, prophages or integrated plasmids). The black sixth ring shows the GC 






4.2.2 Phylogenetic studies and whole genome comparisons 
 
To explore the phylogenetic context of A980 a BLAST 175 comparison was made of its 16S rRNA 
sequence to that of other Streptomyces spp. in the NCBI database. This revealed that A980 is correctly 
assigned as S. albus, however the 16S rRNA nearest neighbours were too closely related to produce a 
dendrogram that gave any meaningful information on the phylogeny. Instead a multilocus sequence 
alignment (MLSA) was performed using the sequence of the five housekeeping genes, atpD, gyrB, 
recA, rpoB and trpB 236. The phylogenetic tree in Figure 4.3 shows that A980 is closely related to S. 
albus type strains.  
 
 
Figure 4.3: Phylogenetic tree based on MLSA of five housekeeping gene sequences of A980 and other 
Streptomyces spp. Evolutionary history was inferred using the Maximum Likelihood Method 237. All positions 
containing gaps were eliminated and there were 2514 nucleotides in the final dataset. Evolutionary analysis was 
conducted by MEGA7 238.  
 
Comparisons of 16S rRNA and housekeeping genes offer useful information on the phylogeny 
of an organism but give little information on the differences across the rest of the genome. To address 
this MUMmer3, a bioinformatics software for the rapid alignment of whole or draft genome 
sequences 239, was used to compare the genome sequence of A980 against those of the type strains 
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S. albus NRRL B-1811 and S. albus NBRC 13014. The alignments were generated and visualised as dot 
plots by Dr. Markiyan Samborskyy (Figure 4.4). The genome comparisons illustrated by Figure 4.4 show 
that both the type strains NRRL B-1811 and NBRC13014 are highly homologous to A980, with no major 
DNA rearrangements. The only difference of any significance occurs at the 3’ end of the genome. A980 
is slightly longer at the 3’ end, and there is a break in the homology between A980 and the type strains, 
where A980 has additional nucleotides not found in the other two strains. This is probably the large 
gene cluster highlighted in Figure 4.3. The genomes for both NRRL B-1811 and NBRC13014 were 
contained within over 100 scaffolds which had to be aligned against the A980 sequence before the 
comparison could be made. 
 
 
Figure 4.4: Whole-genome sequence alignments of A980. The analysis was conducted in MUMmer3 with a 
minimum value of 128 base pairs. Red, forwards strand match, blue, reverse strand match. (A) Comparison 
against NBRC13014. (B) Comparison against NRRL B-1881. 
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4.2.3 Annotation of the genome of Streptomyces albus DSM40763 
 
After sequencing and assembly of the A980 genome an initial detection and annotation of gene 
clusters was carried out using AntiSMASH 4.0 178. This analysis revealed 27 gene clusters across two 
scaffolds. The biosynthetic gene clusters tend to be located at either end of the linear chromosome, a 
feature observed in other Streptomyces spp. 173. The putative pseudouridimycin gene cluster was not 
directly identified by AntiSMASH. However, screening of the A980 genome sequence with a 
biosynthetic gene, TruD, from the pathway to the C-nucleoside malayamycin A, identified a likely 
candidate, as described later in this Chapter, which had been listed by AntiSMASH under "Other". The 
full list of annotated gene clusters is shown in Table 4.1. 
 The 27 gene clusters revealed by AntiSMASH analysis were manually investigated to further 
elucidate the biosynthetic potential of A980. Six gene clusters were annotated as terpene biosynthetic 
gene clusters. The putative products of five of the clusters, 2,3,8,14, and 19 were identified as 
phytoene, geranylgeranyl pyrophosphate, dehydrosqualene, geosmin, and selinadiene, respectively, 
by comparison against the PDB database. The final cluster annotated as a terpene, cluster 26, 
contained several putative biosynthetic genes including a putative cyclodipeptide synthase and a 
putative phytoene synthase. Homologous gene clusters with this combination of genes have 
previously been identified and proposed to generate a fused cyclodipeptide-terpene product 240.  
 Two putative siderophore gene clusters were identified; clusters 11 and 18. When analysing 
cluster 11 with BLAST, none of the three biosynthetic genes had a high similarity with any sequences 
in the PDB database. Cluster 18 however, contains four genes which when compared to the PDB 
database with BLAST showed high similarity to the four genes responsible for the biosynthesis of the 
iron chelator, desferrioxamine 241. 
 Cluster 9 is annotated as a putative bacteriocin biosynthetic gene cluster. However, the cluster 
does not contain any genes which might encode a core peptide, or any posttranslational modification 
enzymes expected in a true bacteriocin gene cluster. Further analysis using BAGEL3, an online platform 
for identification of genes encoding bacteriocins and bactericidal post-translationally modified 
peptides 242, found no evidence of bacteriocin biosynthetic genes in the region identified by 
AntiSMASH. 
Upon comparison against the PDB database cluster 17 appears to contain the three genes 
necessary for ectoine biosynthesis; diaminobutyric acid acetyltransferase, diaminobutyric acid 
transaminase, and ectoine synthase 243. 
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 AntiSMASH identified two putative lanthipeptide gene clusters; cluster 4 and 7. Cluster 4 is 
likely a class I lanthipeptide due to the presence of LanB dehydratase and LanC cyclase homologues 
responsible for the formation of a carbon-carbon double bond and the cyclisation of the precursor 
peptide 244. Cluster 7 contains a gene, ORF01056, with a central kinase-like domain and a C-terminal 
LanC-like domain, indicative of a class III lanthipeptide.  
 Two putative lassopeptide gene clusters were identified; clusters 12 and 27. However a closer 
examination of the gene clusters indicated that neither would be capable of generating lassopaptides. 
The genetic architecture required for lassopeptide biosynthesis is well known, composed of three 
genes that are strictly necessary for the biosynthesis 245. A precursor peptide encoded by the A gene 
is processed by the B and C maturation enzymes to generate the lasso fold. All lassopeptide gene 
clusters share homologues of these genes. Neither cluster 12 nor 27 held homologues of these genes, 
suggesting that they have been erroneously annotated. 
 AntiSMASH identified four nonribosomal peptide synthase (NRPS) gene clusters; clusters 1, 
13, 21, and 25. Cluster 1 encodes an unknown tripeptide. Cluster 13 contains a single NRPS gene 
containing single condensation, adenylation, peptidyl carrier (PCP) and thioesterase domains, 
suggesting a putative iterative NRPS. A second gene is a putative methyltransferase. Cluster 21 
appears to encode an unknown dipeptide. AntiSMASH predicts cluster 25 to generate a pentapeptide, 
however the cluster is not as well organised as expected for a functional NRPS gene cluster. The NRPS 
genes are separated by at least 10 kb of unrelated genes, there are two genes with adenylation 
domains and no PCP domains, and no clear initiation module. Biochemical and genetic investigation 
will be required to better elucidate this gene cluster. 
 Two polyketide synthase (PKS) gene clusters were identified by AntiSMASH; clusters 16 and 
23. Cluster 16 is annotated as a Type II PKS. A BLAST analysis against the PDB database identifies two 
genes; ORF08410 and ORF08411 as homologues for the KSα and KSβ required for actinorhodin 
biosynthesis 92,246. Cluster 23 encodes an unknown type 1 PKS with one loading module and seven 
extension modules, the last including a thioesterase (TE) domain. Each extension module contains a 
ketoreductase (KR) domain, and modules 1 and 2 contain dehydratase (DH) domains. Assuming the 
colinearity principle of PKSs, this gene cluster encodes a polyene/ol. 
 AntiSMASH also identified four type 1 PKS hybrids. Cluster 10 is annotated as a PKS-NRPS 
hybrid, cluster 15 as a PKS-lanthipeptide, cluster 20 as a PKS-oligosaccharide, and cluster 24 is 
annotated as a PKS-terpene hybrid. Cluster 10 encodes two putative functional PKS genes, two 
putative functional NRPS genes, and two genes containing lone adenylation domains. The two PKS 
genes include one loading module and 3 extension modules, while the two NRPS genes include one 
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loading module and one extension module. The PKS and NRPS genes are held in separate genes, so 
there is unlikely to be direct functional hybridisation between the NRPS and PKS proteins. Instead a 
possible biosynthetic pathways could include the PKS and NRPS components being synthesised 
individually, then coupled together by a ligase, or in a cyclosporin-like pathway 247, the PKS could be 
converted to an amino acid before being incorporated into the natural product by the NRPS enzyme. 
Cluster 15 contains an interesting mixture of PKS genes and lanthipeptide biosynthetic genes. It is 
annotated as a lanthipeptide-PKS hybrid; however, this hybrid cluster is most likely several clusters, 
incorrectly annotated. It contains two genes that encode precursor peptides, only one of which has 
local LanB dehydratase and LanC cyclase homologues. There is also a gene encoding a PKS loading 
module, and several other genes that encode independent putative PKS biosynthetic enzymes.   
Cluster 20 appears to encode the biosynthetic genes for a large polyketide. It contains seven 
putative PKS genes containing one loading module and 20 extension modules, the last containing a TE 
domain. There are also two putative glycosyltransferase enzymes, suggesting that this polyketide is 
glycosylated. The final hybrid gene cluster is cluster 24. The more interesting biosynthetic genes of 
this cluster are a putative PKS gene that appears to be a single extension module, and a 
squalene/phytoene-like terpene synthase. The lack of a loading module hints that this PKS gene could 
encode a single module iterative type I PKS such as the PKS responsible for the biosynthesis of phenolic 
moiety in avilamycin 248, or for the biosynthesis of the enediyne in calicheamicin 249. The cluster also 
contains a putative oxidoreductase, aminotransferase and carboxylate-amine ligase, which could be 
responsible for the amination of either the terpene or the iterative PKS product and subsequent 
ligation with the other compound to give the final product. 
Clusters 5, 6, and 22 were annotated as "Other". At first glance, none of the three appear to 
be functional biosynthetic gene clusters. However closer investigation of cluster 6 reveals several 










Table 4.1: Biosynthetic gene clusters found in A980. Clusters were analysed using AntiSMASH 4.0. 
Gene cluster limits were kept from AntiSMASH predictions. Annotated gene clusters were manually 
identified from key biosynthetic genes using BLAST 175. 
 
Cluster AntiSMASH 4.0 
prediction 
Nucleotide  Gene ID  Annotation 
 From To From To  
A980_AS6_SC1      
1 NRPS 75234 128829 114 190 Unknown 
2 Terpene 148468 172932 219 262 Phytoene 
3 Terpene 221673 243559 338 373 Geranylgeranyl 
Pyrophosphate 
4 Lanthipeptide 345987 370632 535 567 Unknown 
5 Other 408817 449653 616 671 - 
6 Other 634198 675436 955 1016 PUM  
7 Lanthipeptide 691897 725605 1042 1090 Unknown 
8 Terpene 939670 966374 1423 1463 Dehydrosqualene 
9 Bacteriocin 1434686 1445516 2150 2167 Unknown 
10 Type I PKS-NRPS 1577987 1641100 2369 2440 Unknown 
11 Siderophore 1782846 1798150 2602 2620 Unknown 
12 Lassopeptide 2545416 2568398 3702 3731 Unknown 
13 NRPS 2718705 2762826 3953 4012 Unknown 
14 Terpene 5505171 5527402 7965 7999 Geosmin 
15 Lanthipeptide-Type I 
PKS 
5746467 5797885 8324 8399 Unknown 
16 Type II PKS 5783012 5825590 8372 8441 Actinorhodin-like Type II 
PKS 
17 Ectoine 5995802 6006206 8685 8697 Ectoine 
18 Siderophore 6074265 6086076 8811 8819 Desferrioxamine 
19 Terpene 6247497 6284125 9080 9144 Selinadiene 
20 Type I PKS-
Oligosaccharide 
6883231 7074071 10057 10199 Unknown 
21 NRPS 7394703 7441235 10671 10738 Unknown 
22 Other 7455353 7498613 10763 10815 - 
23 Type I PKS 7486455 7567810 10802 10885 Unknown 
24 Type I PKS-Terpene 7586501 7642165 10916 11006 Unknown 
25 NRPS 7632513 7711931 10992 11094 Unknown 
26 Terpene 7728151 7760470 11113 11161 Unknown 
A980_AS6_SC3      
27 Lassopeptide 9383 31822 10 38 Unknown 
104 
 
4.2.4 Bioinformatic analysis of uncharacterised gene clusters 
 
Four uncharacterised biosynthetic gene clusters were identified from the AntiSMASH 4.0 
analysis of the whole-genome sequence of A980. These clusters were chosen for their potential to 
generate novel compounds, or because their annotated gene cluster required further deconvolution 
to understand the biosynthetic potential. In the following section clusters 15 (a lanthipeptide-PKS 
hybrid), 16 (an actinorhodin-like type II PKS), 20 (a large type I PKS-oligosaccharide), and 26 (a terpene) 
are analysed bioinformatically to assess their potential to generate novel chemical diversity. The 
analysis and predictions were reasoned from comparative sequence analysis with homologous genes 
and gene clusters and where possible by study of enzyme active sites. 
 
Cluster 15: a novel lanthipeptide-PKS hybrid natural product? 
 
AntiSMASH identifies cluster 15 as a lanthipeptide-PKS hybrid gene cluster. This would certainly 
generate novel chemical diversity and have intriguing biosynthesis. Gene clusters containing 
lanthipeptide and PKS elements have been identified before, such as the GCF133 family of 
biosynthetic clusters where a LanKC homologue appears beside type II PKS genes 250. Cluster 15 spans 
a region of 51.4 kbp and contains 47 contiguous open reading frames encoding two precursor 
peptides, one pair of LanB and LanC homologues, another smaller LanB homologue, and one PKS 
enzyme. There are also ORFs encoding an acyl-CoA synthetase, two acyl-CoA dehydrogenases, a FabH-
like protein, an FkbH-like protein, an ACP, a TE, and a P450. There is also a 4’-phosphopantetheinyl 
transferase, an uncharacterised FAD-binding enzyme, one transport related enzyme, four regulatory 
enzymes and 21 ORFs annotated as ‘other’. The gene organisation of cluster 15 is shown in figure 4.5. 
 
 
Figure 4.5: Organisation of the core biosynthetic gene cluster 15 in A980 
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It becomes clear that AntiSMASH has picked up two distinct biosynthetic gene clusters. Cluster 
15a encodes a putative class I Lanthipeptide where the LanB and LanC homologues services two 
precursor peptides. One of those peptides, ORF08368, has been embedded in the middle of another 
cluster. It is unlikely that the products of the two clusters interact, but the location of ORF08368 raises 
questions regarding the origin of this genetic architecture. Cluster 15b appears to encode a natural 
product made up of products from polyketide and fatty acid synthases. The PKS gene encodes only 
one module containing one KS domain, one AT domain and an ACP domain. The substrate specificity 
of the AT domain is predicted to be malonyl-CoA by AntiSMASH, using the Minowa substrate 
specificity predictor 251. The PKS modules is unlikely to be a type II iterative system, due to the lack of 
the two ketosynthase domains, KSα and KSβ, typical of such systems 252. The product generated by this 
gene cluster will probably only have a single malonyl moiety.  
 The FabH and FkbH homologues give further clues as to what class of compound this gene 
cluster might generate. FabH is involved in type II fatty acid synthesis. It is known to condense malonyl-
ACP with acetyl-CoA, yielding acetoacetyl-CoA 253. The protein which gives its name to the FkbH family 
of enzymes is involved in the biosynthesis of the immunosuppressant FK520 254. It catalyses the 
formation of glyceryl-CoA, as part of the methoxymalonyl-CoA biosynthesis, an exotic building block 
used in the biosynthesis. The FkbH family of enzymes contain a central domain that is highly 
homologous to phosphatases from the haloacid dehalogenase family 255. When FkbH homologues are 
aligned a subfamily of enzymes with an additional N-terminal extension appear. Tmn16 is an FkbH 
family enzyme with this N-terminal extension. It catalyses the first step in the formation of the 
tetronate moiety in the tetronomycin biosynthesis 256. When the N-terminal extension was removed, 
the truncated Tmn16 was unable to transfer the glyceryl moiety to the downstream ACP, halting 
synthesis 256. Investigation of FkbH homologues with the N-terminal extension reveals that they are 
all involved in tetronate formation, providing a useful marker to identify the subfamily of FkbH family 
enzymes and the class of natural product they are used to generate. When the FkbH homologue in 
cluster 15b is aligned with several FkbH family enzymes of both types it clearly shows a N-terminal 
extension, indicating it is involved in tetronate formation (Figure 4.6). Tetronate ring formation 
requires several genes; an FabH-like protein, an FbkH-like protein and an ACP. All of these are present 




Figure 4.6: Sequence alignment of ORF08367 from A980 with FkbH homologues. The presence of an N-terminal 
extension indicates enzymes involved in tetronate formation. The N-terminal extension is highlighted in yellow. 
Sequences were aligned with Clustal Omega. 
 
Cluster 16: an actinorhodin-like type II PKS? 
 
Cluster 16 is an uncharacterised biosynthetic gene cluster which appears to encode an actinorhodin-
like type II PKS. The cluster spans 42.6 kbp and contains 47 contiguous open reading frames. The core 
biosynthetic genes in this cluster (orf08400, orf08410, and orf08411) encode an ACP and two beta-
ketoacyl synthases, which share high identity scores with the KSα and KSβ domains from actinorhodin 
biosynthesis, respectively. The rest of the biosynthetic genes in cluster 16 consist of; a type II TE, three 
dehydrogenases, two cyclases, one of which is identical to the F2 cyclase in tetracenomycin 
biosynthesis 257, and two acetyl-CoA carboxylases. There are also two SARP family transcriptional 
regulators and a multidrug efflux enzyme, similar to the actinorhodin transporter form S. coelicolor. 
The gene cluster organisation is shown in Figure 4.7. A section of the gene cluster (orf08398 to 
orf08423) containing the core biosynthetic genes is conserved across several other Streptomyces spp 
as identified by a BLAST homology search. The homologues can be found in Streptomyces sp. 
HPH0547, Streptomyces sp. AA1529 and Streptomyces flavogriseus, the xantholipin producer 258 and 
show near identical gene arrangement, except for a set of five ORFs containing the ACP and cyclase, 
which is inverted. The conservation of this gene cluster across species encourages the view that the 






Figure 4.7: Organisation of the core biosynthetic gene cluster 16 in A980. 
 
 The genes contained by cluster 16 strongly implicate an aromatic type II polyketide product 
as the end product of the pathway. The extension unit used in the biosynthesis of this product is most 
likely malonyl-CoA, as indicated by the presence of acetyl-CoA carboxylases (though enzymes 
annotated as acetyl-CoA carboxylases often also accept propionyl-CoA). The number of extension 
units in the product is likely to closely resemble the actinorhodin biosynthetic pathway due to the 
similarity between the respective KSα and KSβ proteins of each pathway. KS-CLF didomains are known 
to have a series of ‘gates’ within the tunnel that the growing polyketide extrudes into. These gates can 
be open or closed depending on the size of the amino acid residues at those locations 259. The length 
of the growing chain is controlled by these gates, as the chain extension appears to halt once it reaches 
a closed gate. However, the true number is unsafe to predict, and biochemical evidence is needed.  
 Actinorhodin biosynthesis starts with the condensation of one starter unit and seven extender 
malonyl units into the octaketide PKS product. At the heptaketide stage the chain has reached the end 
of the tunnel, closed off by a gate. The final extension causes the chain to buckle, allowing for 
intramolecular cyclisation 92. This is followed by series of reduction and spontaneous and catalysed 
cyclisations. After the final cyclisation the scaffold is decorated by hydroxylation at the C-6 and C-8 







Figure 4.8: Actinorhodin biosynthetic pathway. (1) eight malonyl-CoA used to generate the polyketide 
backbone (2) bicyclic intermediate (3) (S)-DNPA (4) 6-deoxy-dihydrokalafungin (5) dihydrokalafungin (6) 8-oxy-
dihydrokalafungin (7) actinorhodin. 
 
The putative biosynthetic pathway encoded by cluster 16 appears to be an unremarkable type 
II PKS, however the presence of different enzymes with high sequence identity to genes found in 
different type II PKS gene clusters hints at an interesting evolution. Perhaps this is an example of a 
relatively new gene cluster formed by the combination of multiple other clusters and hasn’t had time 
for the individual genes to diverge. Whatever the case, this gene cluster warrants further investigation. 
 
Cluster 20: a novel PKS-oligosaccharide? 
 
Cluster 20 is annotated by AntiSMASH as a type I PKS oligosaccharide. The cluster appears to encode 
a large polyol tailored with multiple sugar moieties, indicated by the seven glycosyltransferase genes 
found in the cluster. Cluster 20 is huge, spanning 190.8 kbp. Its core biosynthetic genes consist of 
seven type I PKS genes encoding a starter module and 20 extension modules with a terminal type I TE 
domain. The cluster also contains many post-PKS tailoring enzymes; three aminotransferases, three 
epimerases, three monooxygenases, two oxidoreductases, and seven glycosyltransferases in addition 
to drug resistance transporters and several LuxR transcriptional regulators. Figure 4.9 shows the 








Figure 4.9: Organisation of the core biosynthetic gene cluster 20 in A980. 
 
From an understanding of the relationship between the sequence of amino acid residues and 
the function of PKS domains, as discussed in the introduction, the specificity of each domain can be 
predicted. There is one loading AT domain, and 20 extension AT domains. Nine of the AT domains are 
specific for methylmalonyl-CoA, having the characteristic YASH motif, the remaining 12 are specific 
for malonyl-CoA, as indicated by a HAFH motif 104,135. There are 19 KR domains, as module 14 lacks a 
KR, despite having a DH domain. Seven of the KR domains have the characteristic LDD motif, indicating 
they are B type KR domains 137. The remaining KR domains are A type, and three of the them are A2 
type, as indicated by the conserved WxxxxH motif in the catalytic site 137. The six DH domains found in 
this PKS all have the characteristic motifs required for activity 152, however the DH from module 14 
won’t have any activity due to the lack of a KR domain in that module to generate the necessary 
hydroxyl group. Module 16 also has a ER domain that appears to be active. The KS in the loading 
module was confirmed as a starting KS by the presence of the characteristic QASS motif. Figure 4.10 
summarises the sequence alignments and characteristic sequence motifs and Figure 4.11 shows the 




Figure 4.10: Sequence alignments of cluster 20 PKS domains and amino acid motifs conferring activity. The 
YASH motif indicates a methylmalonyl-CoA specific AT domain. The HAFH motif indicates a malonyl-CoA specific 
AT domain. The LDD motif indicates a B-type KR domain. The WxxxxH motif indicates an A2-type KR domain. 
Sequences were aligned with Clustal Omega. 
 
 





 The presence of a pair of dienes in the polyketide backbone at first suggested cluster 20 may 
encode a novel bafilomycin 261, however the polyketide generated by cluster 20 is far larger than any 
bafilomycin class molecule, and the dienes are too far apart to form the characteristic bafilomycin 
structure. The PKS genes do not have any known homologues so this cluster likely encodes a novel 
polyketide scaffold. The length of the polyketide backbone is longer than usual, but not unexpectedly 
large 179. The post-PKS tailoring enzymes however, are of interest. The cluster contains three 
aminotransferase genes that are labelled as eryC1 homologues (ORF10069, ORF10071 and 
ORF10132). EryC1 is involved in erythromycin biosynthesis either as a structural gene in the formation 
of the deoxyamino-sugar desosamine 66. On closer inspection only ORF10069 is a close homologue to 
eryC1, but the other two are homologous to enzymes involved in sugar biosynthesis. The cluster also 
contains several glycosyltransferases. At least one appears to be a true biosynthetic 
glycosyltransferase, while the others appear to be involved in antibiotic self-resistance. These 
glycosyltransferase enzymes will glycosylate sugar moieties on the molecule and once the product is 
transported outside the cell the molecule is converted back to the antibiotic by an extracellular 
hydrolysis enzyme 262. Cluster 20 also has an NDP hexose 2,3-dehydratase, and an NDP hexose 3-
ketoreductase, which are both involved in 2,6-dideoxysugar biosynthesis 263. There is also a putative 
epimerase, and a putative 3,4-ketoisomerase to further modify the sugar molecule, which may also 
be aminated by one of the aminotransferase enzymes. The putative sugar biosynthesis is summarised 
in Figure 4.12.  
Finally, there are also two genes that are implicated in polyisoprenoid biosynthesis. ORF 10113 
is a putative homologue of a polyisoprenoid binding protein from Thermus thermophilus and a 
member of the YceI family of enzymes that are involved in isoprenoid metabolism, transport, or 






Figure 4.12: TDP-deoxysugar biosynthesis. (1) 2,3-dehydratase (2) 3-ketoreductase (3) epimerase (4) 3,4-
ketoisomerase (5) aminotransferase. 
While the exact product of this gene cluster is difficult to predict, the product is definitely 
novel, as there are no similar PKS gene clusters in the database. It appears to be a novel combination 
of type I PKS and isoprenoid, but further investigation is required to properly characterise the cluster. 
The first attempts at studying this cluster should begin by ensuring the cluster is active under normal 
laboratory conditions. Knocking out or interrupting key biosynthetic genes and then comparing the 
fermentation profiles of the mutant and wildtype can be an effective method for this. It is also possible 
to take advantage of recent advances in overexpression mutants. The cluster has three LuxR family 
transcriptional regulators, two FscRIII homologues and one FscRIV homologue (from the candicidin 
biosynthetic pathway 265). These are positive regulatory genes, and can be overexpressed by 
introducing a strong promoter to boost expression of the gene cluster and increase the yield of the 
product 179.  
 
Cluster 26: a hybrid cyclodipeptide-terpene? 
 
Cluster 26 spans 14.0 kbp, however the core biosynthetic genes only cover 3.3 kbp. The core cluster 
contains a phytoene synthase, a cyclodipeptide synthase (a family of peptide bond-forming enzymes 
that utilise two amino acids activated as aminoacyl-tRNA for the synthesis of cyclodipeptides 266), and 
two methyltransferases. The extended cluster also has a hydrolase and oxidoreductase. The presence 
of a LuxR transcriptional regulator encourages the view that this is a real biosynthetic cluster that may 
be active or has the potential to be activated. Figure 4.13 shows the organisation of cluster. 
 
 




The presence of a cyclodipeptide synthase in close proximity to a phytoene synthase is 
unusual and hints at a novel hybrid structure. Cyclodipeptides are widespread in nature and exhibit a 
broad variety of biological activities 267. They are typically under the control of LuxR regulators, and 
are commonly associated with a range of tailoring enzymes such as oxidoreductases, hydrolases, 
methyltransferases and peptide ligases 267, however an association with terpene biosynthetic genes is 
unusual. One study by Skinnider et al. aimed to group genetically encoded cyclodipeptides in an effort 
to create an online tool to facilitate genome mining of cyclodipeptides. They identified a family of 
cyclodipeptide gene clusters that contained terpene biosynthetic machinery. This class of 
cyclodipeptide synthases had a methyltransferase domain fused to the C-terminus 240. When the 
cyclodipeptide synthase in cluster 26 is inspected by BLAST analysis, a methyltransferase domain is 
revealed in the C-terminus. This evidence strongly supports the view that the product of cluster 26 is 
a novel cyclodipeptide-terpene hybrid. 
 
4.2.5 Identification of the putative pseudouridimycin biosynthetic gene cluster 
 
Pseudouridine () has been referred to as the fifth base, because it is the most abundant post-
transcriptional alteration found in Nature 268. Several pseuduridine synthases have been identified, 
usually named from their counterparts in E. coli. The reaction they catalyse uses as substrate a 
preformed tRNA or other ncRNA, and each enzyme isomerises one or more specific uridine residues 
to pseudouridine () 269. The  moiety in the PUM structure could be generated through several ways, 
which will be discussed in detail in the next chapter. One of those could be through a dedicated 
pseudouridine synthase, such as the TruD-like 270 enzymes found by Dr Hui Hong in the recently-
characterised gene clusters for the C-nucleoside malayamycin A (Hong et al., (2018) ms. in the press) 
from Streptomyces malaysiensis DSM14702 and Streptomyces chromofuscus. The sequence of TruD 
from S. malaysiensis was used as a probe in a BLAST search of the S. albus DSM40763 (A980) genome, 
yielding only one significant hit (43% identity, 56% similarity). The sequence of this putative A980 TruD 
homologue was aligned with the authentic TruD enzymes using Clustal Omega (Figure 4.14). It shares 
regions of conserved sequence and possesses the essential active site aspartic acid residue within one 









Figure 4.14. Sequence alignment of TruD family of tRNA pseudouridine synthases. The sequences of TruDs 
[TruD_SM: TruD from Streptomyces malaysiensis; TruD_SC: TruD from Streptomyces chromofuscus; TruD_SA: 
TruD from Streptomyces albus A980; TruD_EC: TruD from E. coli (accession no. AQZ29382)] were aligned using 
Clustal Omega. The catalytic aspartate is denoted with an asterisk. 
  
Further evidence that this gene was involved in the biosynthesis of PUM came when the genes 
flanking the TruD homologue were investigated. In close proximity to the TruD gene are two putative 
ligases and an amidinotransferase. Retrobiosynthesis applied to the structure of PUM shows that 
similar enzymes would be appropriate to produce PUM. The pseudouridine moiety would require 
modification before it would be suitable for ligation. This gene cluster also contains a putative Glucose-
Methanol-Choline (GMC) oxidoreductase and an aminotransferase. This cluster is clearly a plausible 




4.3 Concluding remarks 
 
The whole-genome sequence of a putative pseudouridine producer, Streptomyces albus DSM40763 
(A980), has been obtained through shotgun DNA sequencing using the Illumina platform and 
assembled into three scaffolds, with the largest scaffold containing 97% of the whole genome. 
Phylogenetic analysis has clarified that A980 is a true S. albus and shares high similarity with both 
NBRC13014 and NRRL B-1881 S. albus type strains. 
Initial annotation was performed by AntiSMASH 4.0, and subsequent manual curation has 
revealed a number of novel biosynthetic gene clusters, including several clusters that appear to govern 
production of novel classes of natural products. The level to which this genome can be analysed for 
its potential to generate novel chemical diversity is due in large measure to the availability of a high-
quality genome sequence. Large biosynthetic gene clusters such as cluster 20 cover huge regions of 
the genome. Cluster 20 itself spans over 190 kbp, which is larger than many of the genome scaffolds 
often found in online databases. Proper genome-level analysis is impossible with such fragmented 
genomes. The number of biosynthetic gene clusters identified in this chapter that deserve further 
investigation illustrates the potential of genome mining and highlights how vital high-quality genome 
sequences are to the field. Finally, the pseudouridimycin gene cluster was identified with high 














Chapter 5: The Enzymology of Pseudouridimycin Biosynthesis 
 
5.1: Introduction 
5.1.1: Structure and Function of Nucleoside Antibiotics 
 
Nucleoside antibiotics are a large, diverse family of natural products derived from nucleosides and 
nucleotides, a number of these are illustrated in Figure 5.1. They are produced almost exclusively by 
Streptomyces and related actinomycetes. Nucleoside antibiotics exhibit a broad range of biological 
activities, such as antibacterial, antifungal, antiviral, immunosuppressive, and antitumor activities 271. 
Such a broad spectrum of activities is due to the involvement of nucleosides and nucleotides in almost 
all cellular metabolism 272. Nucleoside antibiotics can be classified into three major groups based on 
their biological functions; inhibitors of peptidoglycan biosynthesis, by competitively inhibiting MraY, 
the translocase that initiates the lipid cycle of peptidoglycan biosynthesis 273, inhibitors of fungal cell 
wall biosynthesis, by competitively inhibiting fungal chitin synthases, and inhibitors of protein 
biosynthesis, but competitively inhibiting peptidyl transferase 272. Nucleoside antibiotics often contain 
unusual structural features, arising from unusual enzymatic reactions. The rapid expansion of available 
genomic data has allowed biosynthetic studies of nucleoside antibiotics to accelerate, providing the 
foundation for engineering of the biosynthesis of these molecules. 
 Nikkomycins are potent competitive inhibitors of fungal chitin synthases as they mimic the 
natural substrate for the synthase, UDP-N-acetylglucosamine (Figure 5.2). Nikkomycin is nontoxic to 
mammals, making it a potentially valuable antifungal therapeutic agent. Phase I clinical trials have 
investigated the dosing effects of nikkomycin Z for the treatment of coccidioidomycosis 274. It is also 
an effective treatment for the ecologically significant fungal infection caused by Batrachochytrium 
dendrobatidis which is threatening several endangered species of frogs 275. Nikkomycins are composed 
of a di- or tri-peptide backbone containing a non-proteinogenic amino acid residue, hydroxypyridyl-
homothreonine (HPHT), and an aminohexuronic acid that is N-glycosidically linked to a uracil base (in 
nikkomycins Z and J) or to a 4-formyl-4-imidazolin-2-one base (in nikkomycins X and I) 272. The isolation 
of the nikkomycin biosynthetic cluster from S. tendae and its heterologous expression in S. lividans 
enabled a thorough investigation into the biosynthesis of this family of compounds 273. It has been 
postulated that the peptide and nucleoside fragments of nikkomycin are biosynthesised separately, 
then linked by a peptide bond 276. Analysis of the gene cluster led to the prediction of eleven enzymatic 
steps required for the generation of the peptide core 277, and feeding experiments indicated that the 
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HPHT moiety is generated from L-lysine 278. The exact biosynthetic pathway for the aminohexuronic 




Figure 5.1: Examples of nucleoside antibiotics from Streptomyces spp. (1) pacidamycin 1 (2) malayamycin A (3) 
sinefungin (4) amicetin. 
 
 





 Another class of nucleoside antibiotics targets bacterial RNA polymerase (RNAP) to inhibit 
RNA synthesis. RNAP is particularly suitable as a target for broad-spectrum antibacterial therapy as 
bacterial RNAP is an essential enzyme, bacterial RNAP subunit sequences are highly conserved, and 
the bacterial RNAP subunit sequences are not highly conserved in eukaryotic RNAP, which provides a 
basis for selectivity 280. Rifampin is a member of this class of molecules and is part of the rifamycin 
family of antibiotics. It is a potent and broad-spectrum semi-synthetic antibiotic whose precursor is 
obtained from the fermentation broth of S. mediterranei. It is active against most Gram-positive 
bacteria, some Gram-negative bacteria, and mycobacteria 281. The bacterial RNAP inhibitory activity 
was known to totally block formation of the second or third phosphodiester bond in the growing RNA 
chain 282, however it had no effect of RNAP which had already started synthesising a long transcript. 
These insights led to a hypothesis that rifampicin’s activity is conferred by a steric block of the path 
the RNA chain took, which was confirmed later by a crystal structure of rifampicin in complex with Taq 
RNAP from E. coli 283 (figure 5.3). Rifampin was shown to bind to the β subunit of the RNAP, adjacent 
to the RNAP active site, which also matched the findings that mutations conferring rifampin resistance 
are almost exclusively found on the rpoB gene, encoding the β subunit 284. 
 
Figure 5.3: Structure of rifampin and the three-dimensional structure of Taq RNA polymerase in complex with 
rifampin. Adapted from Campbell et al. 283. 
 Unfortunately, these mutations occur with high frequency, leading to rifampin-resistant 
strains of bacteria. This has led the medical community to a voluntary restriction of its use for 
treatment of TB or in emergencies 283, and to a search for alternative front-line drugs. The only other 
antibiotics currently in use targeting bacterial RNAP are the macrocyclic polyketides known as 
lipiarmycins (fidaxomicins) which function by binding to the end of the RNAP ‘clamp’, trapping the 
RNAP in an open state and therefore allosterically inhibiting RNAP-DNA interaction 285. Lipiarmycins 
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suffer from the same high frequency of mutations giving rise to bacterial resistance as rifampin. 
Therefore, there is an urgent need for new antibacterial drugs that inhibit this important target. 
 
5.1.2: Structure and Function of Pseudouridimycin 
 
As discussed in the previous chapter, one such molecule has been identified as a selective bacterial 
RNAP inhibitor. Pseudouridimycin (PUM) is a nucleoside antibiotic with the favourable characteristics 
of no cross-resistance with other bacterial RNAP inhibitors, additive antibacterial activity when co-
administered, and spontaneous resistance rates an order-of-magnitude lower than those of rifampin 
280. Initial studies of the biochemical basis for the RNAP inhibition by PUM conclude that PUM 
functions as a nucleoside-analogue inhibitor that competes with UTP for occupancy of the RNAP NTP 
addition site 280. Crystal studies rationalise the low spontaneous resistance rates to PUM and the 
selectivity for bacterial RNAP over human RNAP. PUM makes direct contact with ten functionally 
critical residues, the substitution of which would compromise RNAP activity, and all residues in contact 
with PUM are conserved in bacterial RNAP, while four important residues are not conserved in human 
RNAPs. 
Additionally, PUM has an interesting structure (Figure 5.4), enabling structure-based design of 
analogues with increased potency and selectivity, and its C-nucleoside structure hints at an unusual 
biosynthetic pathway involving one of the family of prolific pseudouridine synthases. 
 
 
Figure 5.4: Structure of pseudouridimycin. The uracil moiety is linked to the rest of the nucleoside sugar by the 





5.1.3: Pseudouridine and Pseudouridine Synthases 
 
The unusual C-C linked nucleotide found in pseudouridimycin is due to a pseudouridine moiety linked 
to the dipeptide that makes up the rest of pseudouridimycin. Pseudouridine is the most abundant 
posttranscriptional modification of RNA. In fact it is found in such abundance (4% of nucleotides in 
yeast tRNA) , that, as mentioned in Chapter 4, it was dubbed the fifth nucleotide when first discovered 
in 1957 286. The enzymatic reaction was characterised much later. Studies using RNase digestion and 
2D TLC analysis of an in vitro-transcribed 14C-uridine-labelled RNA found that E. coli cultural extracts 
would isomerise uridines that are incorporated into RNA chains, and that the modifications were only 
found on specific tRNA 287. Subsequent studies demonstrated that pseudouridine synthases require 
no cofactor, and the uridine base is not released during the isomerisation reaction 288–290. The reaction 
is proposed to proceed through a covalent intermediate formed between an aspartate residue and C6 
of uridine, allowing a 180° rotation of the pyrimidine and subsequent re-ligation, resulting in the C-C 
glycosidic bond. A number of pseudouridine synthases have been identified, the most recent being 
TruD that modifies U13 in glutamic acid tRNA 270,291. TruD is unique among the pseudouridine synthase 
family in that is shares no sequence homology with the rest of the family. In a database search, 58 
homologues were found, none of which had a previously known RNA-binding motif, indicating this 
class of enzymes had a novel RNA-binding sequence. The only conserved aspartate in the aligned 
homologues was mutated and shown to be essential for activity 292. Despite the lack of significant 
sequence homology, the catalytic domain of TruD is strikingly similar in its structure to the other 
members of pseudouridine synthases, with TruA being its closest structural homologue (Figure 5.5). 
The only structurally conserved residue in the active site is the catalytic aspartate, but there are other 
retained structural features involved in recognition and catalysis 291. TruD has an additional domain, 
unlike other pseudouridine synthases. This insertion domain has no significant structural similarities 
to any PDB entry and has a strong positive surface charge on the side facing the catalytic domain. This 
domain is most likely involved in RNA binding, and accounts for the lack of any other RNA binding 
motif in TruD. A catalytic cleft is formed in between the insertion and catalytic domains with the 
catalytic Asp protruding from one face of the cleft where, presumably, the tRNA binds into the 





Figure 5.5: Structure and catalytic activity of truD. (A) Superposition of TruD and its closest structural 
homologue, TruA. TruD is coloured in blue (catalytic domain) and beige (insertion domain) and TruA is coloured 
in pink. (B) A rigid docking model of TruD with tRNAGlu. The surface of the catalytic Asp80 is coloured in orange 
and the U13 to be modified is coloured in green. Adapted from Ericsson et al. 291. 
 
 The work in this Chapter describes an analysis of the biosynthetic pathway to PUM and in 
particular attempts to reconstitute parts of the pathway in vitro, to pave the way for future 
knowledge-based generation of analogues of this bioactive C-nucleoside. 
 
5.2: Results and Discussion 
5.2.1: Identification and Characterisation of the Pseudouridimycin Biosynthetic Gene Cluster 
 
The structure of PUM had been characterised by Maffioli et al. 280 in 2017. The obvious choice to probe 
for the PUM cluster in the genome sequence of S. albus A980 was therefore a pseudouridine synthase. 
As noted in Chapter 4, probing the A980 genome sequence with a TruD-like sequence from 
malayamycin producers being studied in this laboratory produced a single definite hit. The sequence 
of TruD from yeast was also used to probe the entire Leadlay lab strain collection. This returned five 
hits; Saccharopolyspora cavernae DSMZ 45825, Nocardia sp. NBRC 14326 (a thiolactomycin producer), 
the two malayamycin producers Streptomyces malaysiensis DSM 14702 and Streptomyces 
chromofuscus ATCC 49982, and Streptomyces albus DSM 40763 (A980). Looking at the genes 
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surrounding the TruD homologue in A980 revealed many biosynthetic genes that could be involved in 
PUM biosynthesis. The putative biosynthetic gene cluster (BGC) is illustrated in Figure 5.6. 
 
 
Figure 5.6: Organisation of the putative pseudouridimycin biosynthetic gene cluster. 
 
 Once the candidate bioynthetic gene cluster had been identified in A980, the encoded 
enzymes could be scrutinised for their fit with an initial proposal for the biosynthetic pathway. The 
structure of PUM revealed three units linked together by amide bonds (Figure 5.7); an N-terminal 
guanidinoacetate, N-hydroxylated glutamic acid, and C-terminal 5’-amino-pseudouridine (APU). If the 
N-hydroxylation occurs as the final step in the pathway, which is chemically reasonable, glutamic acid 
is recruited directly from primary metabolism. Guanidinoacetate is known to be the product of an 
amidinotransferase reaction between arginine and glycine 293 again directly from primary metabolism. 
The C-terminal component, APU, might be derived from pseudouridine () via oxidation of  at the 
5' position to form an aldehyde, coupled to the action of an aminotransferase to generate APU. 
Analogous oxidation-aminotransfer steps are widespread in aminoglycoside biosynthetic pathways 
294. The origin of the  substrate remains obscure. If a TruD homologue in A980 catalyses the 
conventional TruD-catalysed reaction, post-transcriptional modification of an ncRNA, there must be a 
mechanism by which  can be subsequently be released from the ncRNA. This could be as part of 
normal RNA turnover, but nothing is known in detail about this in Streptomyces. Alternatively, the  
required for PUM biosynthesis is generated by a different mechanism. At any rate, a coupled 
oxidoreductase, aminotransferase reaction on  remains a plausible way to generate APU. 
Alternatively, an Fe(II)-2-oxoglutarate-dependent oxygenase enzyme in capuramycin biosynthesis has 
been described that converts uridine 5'-monophosphate to uridine 5'-aldehyde in a single step 295. 
Conceivably an analogous enzyme could convert 5'-MP directly to the 5'-aldehyde. The three 
components of Figure 5.7 must be linked together, which likely requires two different two ligase 
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Figure 5.7: Retrobiosynthetic analysis of pseudouridimycin.  
  
The putative PUM cluster was manually curated. Its boundaries were provisionally defined 
when genes were encountered that were unlikely to be involved in PUM biosynthesis. The putative 
cluster covers 26 kbp and contains 22 protein coding sequences. It is summarised in Table 5.1. 
 
 
Table 5.1: Summary of the putative pseudouridimycin biosynthetic gene cluster. The function of 
each gene has been identified by comparing its sequence against the NCBI database using a BLAST 
search. Similarities to homologues of known functions have been included, as well as the predicted 
function of the gene in the PUM cluster. Pathway enzymatic activities are highlighted in bold. 
 









WP_030405507.1 99/100 export 
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WP_016471205.1 100/100 biosynthetic 
psmC 303 substrate-binding 




woesei DSM 14684 
ADB51680.1 47/62 export 




WP_030405504.1 99/99 export 
psmE 237 ABC transporter 
permease, 
Streptomyces sp. 
WP_030886564.1 96/96 export 




WP_030895287.1 93/95 export 
psmG 204 Hypothetical 
Protein 
- - - 








psmI 463 D-ala-D-ala ligase, 
Enterorhabdus 
mucosicola 








WP_031027667.1 99/99 export 
psmK 394 NikS-like protein, 
Actinomyces sp. Lu 
9419 





















psmN 212 adenylate kinase, 
Streptomyces 
mobaraensis 
WP_004951438.1 69/76 unknown 
psmO 440 aminotransferase, 
Streptomyces sp. 
NRRL F-6602 
KPC69014.1 99/100 Generates APU, 
C-terminal 
component 




WP_040908662.1 55/65 unknown 




WP_030405496.1 99/99 Glutamate N-
hydroxylation 
candidate 
psmR 264 UPF0317 protein, 
Streptomyces sp. 
HPH0547 
EPD92375.1 100/100 unknown 
psmS 685 peptidase M4, 
Streptomyces albus 
WP_037611685.1 100/100 unknown 





WP_031027676.1 99/100 regulator 
psmU 396 cytochrome P450, 
Streptomyces sp. 
CNT360 
WP_051352406.1 86/92 Glutamate N-
hydroxylation 
candidate 
psmV 72 cytochrome P450, 
Streptomyces 
varsoviensis 
WP_030874200.1 81/91 unknown 
 
 As noted in Table 5.1, there is an excellent fit between a number of the genes in the candidate 
cluster and the enzymology expected for the otlined PUM biosynthetic pathway. No other locus in the 
S. albus A980 genome matchedf these reqirements. With the biosynthetic gene cluster for PUM 
confidently identified, its sequence was used to design in vitro experiments to obtain biochemical 
evidence for the proposed pathway. While this was carried out, the Ebright and Donadio groups 
followed up their Cell paper (2017) on the PUM target by independently reporting in 2018 the PUM 
cluster from an unrelated Streptomyces spp., and they generated several deletions to investigate the 
sequence of biosynthesis.296 Their results will be discussed in full, in the context of my own results, 
later in this chapter. A comparison of the Sosio et al. PUM cluster 296 with that in A980 is summarised 
in Figure 5.8. It reveals an essentially identical, but inverted, core sequence of genes (psmG to psmQ), 




Figure 5.8: Comparative sequence analysis of the pseudouridimycin biosynthetic gene cluster in A980 with the 
biosynthetic gene cluster characterised by Sosio et al 296. The Sosio cluster is smaller, and the A980 gene cluster 
contains several biosynthetic genes that are only putatively involved in PUM biosynthesis. Further work is 
required to define the boundaries of this cluster. The clusters are not identical, the 5’ and 3’ ends hold different 
genes but the core biosynthetic genes, transporter genes, and other hypothetical genes (psmG to psmQ and 
pumE to pumO) are identical but inverted with respect to each other. 
 
5.2.2: In vitro Assays 
The in vivo biosynthesis of PUM appears to follow a convergent path: the building blocks 
guanidinoacetate and APU are synthesised and then ligated to glutamic acid (Figure 5.7). If the building 
blocks could be obtained enzymatically, it was hoped then to use recombinant candidate ligases PsmL 
and PsmK to generate deoxy-PUM in vitro (Figure 5.10). In vitro assays were designed to recapitulate 
formation of the building blocks other than glutamate. This would provide substrates for the putative 




Figure 5.9: Reactions between guanidinoacetate, glutamic acid, and 5’-aminopseudouridine catalysed by the 




Figure 5.10: Reaction between arginine and glycine catalysed by PsmH.  
 The production of guanidinoacetate from arginine and glycine is a well-known reaction. 297 
Testing whether PsmH catalyses this reaction (Figure 5.10) was expected to be straightforward. The 
recombinant PsmH required was obtained by cloning and expressing the gene in E. coli, and 
purification of the N-terminally His6-tagged enzyme by affinity chromatography, as detailed later in 
this section. The assay conditions were based on work by Li et al. 297. The conditions are summarised 
in Table 5.2, and the reaction was performed in a 0.05M phosphate buffer with 0.1M NaCl at pH 7.4. 
The reaction mixture was incubated at 30°C for 2 hours 
Table 5.2: Reaction conditions for PsmH assay 
Component Volume (µl) Final concentration 
PsmH 100 15 µM 
glycine 20 1 mM 
arginine 20 1 mM 
phosphate buffer 60 0.05 M 
 
Since the substrates and products have no chromophore, the products of the reaction were initially 
tested for using Marfey’s reagent. Marfey’s reagent (1-fluoro-2-4-dinitrophenyl-5-L-alanine amide) 
reacts with primary amines (Figure 5.11) and is commonly used as a derivatisation agent for the UV 
detection of amino acids and for the resolution of chiral mixtures of amino acids 298 
 The derivatisation worked well, and could be used to detect glycine, arginine, and one of the 
products, ornithine. However, after some trials using standard samples of the starting materials and 
products with TLC and HPLC (not shown) 1H NMR was used instead to visualise the progress of the 
reaction, with the major advantage that the reaction could be monitored in situ as it progressed. The 
1H NMR analysis was performed as described in section 2.4.4. Spectra for the starting materials 




Figure 5.11: Reaction between Marfey’s reagent and a primary amine. 
These spectra are shown in Figure 5.12. The CH2 region of the spectrum (Figure 5.12A) shows signals 
from arginine and ornithine, but not from glycine or guanidinoacetate, as expected. The difference in 
the chemical shifts of the arginine and ornithine signals could be used to track the reaction, but 
guanidinoacetate gives a unique singlet at 3.8 ppm in the Hα region (Figure 5.22B) which was the most 
convenient way to monitor its appearance (Figure 5.13). 
 
Figure 5.12: NMR spectra of starting materials and products in the arginine:glycine amidinotransferase-
catalysed reaction. Portions of the 1H NMR spectra of glycine, arginine, ornithine and guanidinoacetate are 






Figure 5.13: The psmH-catalysed reaction monitored by the appearance of a signal at 3.8 ppm. 1H NMR spectra 
showing the substrate glycine, the product guanidinoacetate and the spectra of the assay mixture at the first 
and last time points.  
 The NMR data showed that guanidinoacetate is indeed generated by the reaction between 
glycine and arginine catalysed by PsmH and confirms the identity of this building block. As 
guanidinoacetate is readily commercially available, there is obviously no need to use the recombinant 
PsmH to generate it. 
 If pseudouridine () is the correct starting material for biosynthesis of the APU building block, 
it can be converted to APU in a two step, coupled oxidation/transamination reaction. The oxidation of 
a hydroxy group followed by transamination is a well-known coupled reaction in Streptomyces 
biosynthesis (Figure 5.14). To produce the  starting material in vitro, advantage would be taken of a 
pathway already found useful in this laboratory in the study of malayamycin biosynthesis. YeiN from 
E. coli is a pseudouridine-5’-phosphate glycosidase, normally involved in recycling of . Recombinant 
YeiN (the kind gift of Dr Hui Hong) also catalyses the reverse reaction between ribose-5’-phosphate 
(R5P) and uracil and generates pseudouridine-5’-phosphate (5'-MP) 299 which may be subsequently 











Figure 5.15: Reaction between ribose-5’-phosphate and uracil catalysed by YeiN, followed by 
dephosphorylation using calf intestinal phosphatase. 
 
The use of recombinant PsmH has already been described above. Other recombinant enzymes 
required for the in vitro assays were: flavin-dependent GMC oxidase PsmM; aminotransferase PsmO; 
and putative ligases PsmK and PsmI. All these genes were cloned for E. coli expression in pET28a as 
follows (see also Figure 5.15). First, primers were designed to amplify each gene from the PUM 
cluster, and provide overhanging 5’ ends, homologous to the adjacent sequence when assembled. 
The purified PCR products were assembled together with linearized, NdeI- and EcoRI-cut pET28a 
using the Gibson isothermal assembly method. The products were used to transform E. coli DH10B, 





Figure 5.16: Cloning of psm genes in pET28a for expression in E. coli 
 
The identity of the PCR products and the final vector inserts was confirmed by gel electrophoresis and 
sequencing. The details of the procedure are given in section 2.3. Figure 5.17 and Figure 5.18 show 
images of the results of gel electrophoresis from the initial PCR and from the screening of E. coli clones, 
respectively, for the cloning of psmH into pET28a. The other genes cloned gave comparable results. 
Figure 5.19 shows the results of screening of E. coli clones from each of the five gene expression 
vectors constructed. The analogously-constructed pET28a-based vector for YeiN was the kind gift of 





Figure 5.17: Gel electrophoresis image of the psmH amplified PCR product. The ‘L’ lane contains the DNA ladder 
(1 Kb Plus DNA Ladder). The numbers to the side of the ladder refer to the size of each relevant band in the 
ladder. The psmH lane contains the PCR product amplified for the construction of the PsmH expression vector. 
 
 
Figure 5.18: Gel electrophoresis image of the cPCR screening to confirm correct assembly of the PsmH 
expression vector. The ‘Ladder’ lane contains the DNA ladder (1 Kb Plus DNA Ladder). The numbers to the side 
of each ladder refer to the size of each relevant band in the ladder. Each numbered lane refers to a colony of E. 
coli that was screened for the correct expression vector. The lanes 2,4,6-10, and 12 contain bands with the 





Figure 5.19: Gel electrophoresis images of the inserts from each of the four psm expression vectors. The ‘L’ 
lane contains the DNA ladder (1 Kb Plus DNA Ladder). The numbers to the side of each ladder refer to the size 
of each relevant band in the ladder. The psmH-O lanes contain the PCR product amplified for the construction 
of each expression vector. 
 
Once the inserts had been successfully cloned into pET28a vectors they could be transformed into E. 
coli BL21 and induced with IPTG to overexpress the desired protein, which was then recovered and 
purified as described in section 2.3.12,13. Figure 5.20 shows an SDS-PAGE gel of the purification of 
PsmM and Figure 5.21 shows the elution fractions collected and concentrated from each protein, to 
be used in the in vitro assays. 
 
Figure 5.20: SDS-PAGE gel image showing the process of purifying PsmM from the expression culture. The ‘L’ 
lane contains the protein size ladder (Precision Plus Protein Standards). The numbers to the side of the ladder 
refer to the size of each relevant band in the ladder. ‘P’ and ‘FT’ refer to the insoluble (pellet) and soluble (flow-
through) fractions of the purification, respectively. The numbers above each of the remaining lanes refer to the 





Figure 5.21: SDS-PAGE gel images showing the elution fractions collected for each of the six proteins for the 
in vitro assays. The ‘L’ lane contains the protein size ladder (Precision Plus Protein Standards). The numbers to 
the side of each ladder refer to the size of each relevant band in the ladder. The numbers above each pair of 
lanes refer to the concentration of imidazole in the buffer used to elute the fraction that has been loaded onto 
each lane. All enzymes were recovered in high yield. PsmM was recovered in the lowest yield, but could be 
concentrated to 50 µM, which is more than enough for the required assays. 
 
 Each protein eluted in 2 ml of the imidazole wash buffer. From the size of the bands on the 
SDS-PAGE gel, it is clear that some expressed better than others. YeiN consistently expressed very well 
and yielded higher concentrations of protein than the others, but this is unsurprising as it is an E. coli 
protein. PsmM tended to express poorly, and PsmO always eluted with another smaller protein of 
approximately 37 kDa. The smaller protein was not identified but may be a truncated version of PsmO. 
For the highly expressed proteins, such as YeiN, a single elution fraction was collected and 
concentrated using a 30K Merck Millipore centrifugal filter unit. For poorly-expressed proteins, several 
fractions were combined before concentration. The wash buffer was replaced with a suitable reaction 
buffer through a series of concentration and dilution steps using the desired buffer. Unfortunately, 
PsmK did not express in E. coli BL21, despite several attempts, using different expression conditions. 
Sequencing confirmed the cloning had been correct, so the reason for this is unclear. Figure 5.22 





Figure 5.22: SDS-PAGE gel image of the soluble and insoluble fractions of a culture of BL21 transformed with 
pET28a-psmK. The ‘L’ lane contains the protein size ladder (Precision Plus Protein Standards). The numbers to 
the side of each ladder refer to the size of each relevant band in the ladder. ‘NI’ and ‘I’ lanes refer to ‘Not Induced’ 
and ‘Induced’ with IPTG at the concentrations indicated (0.1 mM and 0.5 mM). The temperatures refer to the 














Attempted formation of 5'-amino-pseudouridine (APU) in vitro 
It was thought best to combine the action of the flavin-dependent GMC oxidase PsmM with that of 
aminotransferase PsmO, to prevent problems, such as over-oxidation or product inhibition, arising 
from the build-up of the reactive aldehyde product of the oxidase. Different amino acids needed to 
be tried as amino donors in the PsmO-catalysed reaction. The substrate for the oxidase would be 
generated in situ by the joint action of YeiN and calf intestinal phosphatase. The principle of the assay 
is summarised in Figures 5.11 and 5.12. The reaction conditions used are summarised in Table 5.3, and 
the reaction was performed in a 0.05M phosphate buffer with 0.1M NaCl at pH 7.4. The reaction 
mixture was incubated at 30°C for 2 hours for each step. Between each reaction chloroform was added 
to precipitate the protein. The supernatant was then removed and used in the next reaction. The 
progress of the reaction was monitored by following the UV absorbance of the nucleobase, and by 
NMR. Figures 5.23 to 5.27 summarise the results of the NMR and HPLC analysis of these reactions. 
 
Table 5.3: Reaction conditions for attempted enzymatic synthesis of APU 
Component Volume (µl) Final concentration 
YeiN reaction, illustrated in Figure 5.24. 
uracil 5 1 mM 
ribose-5’-phosphate 5 1 mM 
YeiN 5 7 µM 
Phosphate buffer 485 0.05 M 
   
Phosphatase reaction, illustrated in Figure 5.25. 
Calf intestinal phosphatase 5 50 units 
10X Reaction buffer 50 1X 
   
Coupled oxidation-aminotransferase reaction, illustrated in Figure 5.26 
PsmM 5 3 µM 
PLP 50 1 mM 
PsmO 5 5 µM 
Amino acid donor 
(Ala/Asp/Glu) 





Figure 5.23: NMR spectra of the reaction between uracil and ribose-5’-phosphate, catalysed by YeiN. The left-
hand panel shows the entire spectrum, while the right-hand panel focusses on the high field region where the 
aromatic protons signals can be found. (A) 1H NMR spectrum of uracil. (B) 1H NMR spectrum of R5P. (C) 1H NMR 
spectrum of uracil and R5P. (D) 1H NMR spectrum of uracil, R5P and YeiN.  
 
Figure 5.24: NMR spectra of the dephosphorylation reaction of pseudouridine-5’-phosphate, catalysed by Calf 
Intestinal Phosphatase. The left-hand panel shows the entire spectrum, while the right-hand panel focusses 
on the high field region where the aromatic protons signals can be found. (A) 1H NMR spectrum of uracil, R5P 
and yeiN. (B) 1H NMR spectrum of (A) after the subsequent addition of Calf Intestinal Phosphatase. The 





Figure 5.25: NMR spectra of the coupled oxidation and aminotransferase reaction of pseudouridine, catalysed 
by PsmM and PsmO, respectively. (A) 1H NMR spectrum of alanine; (B) 1H NMR spectrum of pyruvate; (C) 1H 
NMR spectrum of PLP (cofactor to PsmO); (D) 1H NMR spectrum of reaction mixture (see Table 5.3) using alanine 
as an amino donor. The small signal in (D) at approximately 2.5 ppm could potentially have been caused by the 
production of a small amount of pyruvate, indicating the coupled reaction worked to some extent. The large 























Figure 5.26: UV absorption spectrum showing the product of the reaction between ribose-5’-phosphate and 
uracil, catalysed by YeiN. (A) The peak at 5.62 min is  produced by the YeiN catalysed reaction. Absorbance 
measured at 262 nm; (B) The characteristic absorption signature of the uracil moiety at 262 nm is the basis for 





Figure 5.27: UV absorption spectra showing the product of the dephosphorylation reaction of pseudouridine-
5’-phosphate, catalysed by commercial phosphatases. (A) Dephosphorylation of P5P to  by antarctic 
phosphatase. P5P has not been fully converted. (B) Dephosphorylation of P5P to  by calf intestinal 
phosphatase. Absorbance measured at 262 nm. 
 
The NMR and HPLC results showed that the first two reactions, to generate P5P and  from 
uracil went to completion between combining the components and putting the sample into the NMR 
spectrometer. Figure 5.23 shows that when uracil and R5P are combined with YeiN, peaks at 5.8 ppm 
and 7.5 ppm disappear and in their place a peak at 7.95 ppm appears, consistent with the predicted 
changes in chemical shift. Figure 5.24 shows that when CIP is also present the signal at 7.95 ppm shifts 
to 7.85 ppm, consistent with  having been produced. This is also supported by the HPLC evidence in 
Figure 5.26 and 5.27, tracked by the shifts in retention time of peaks with an absorbance maximum of 
262 nm. Figure 5.25 shows that when alanine was used as an amino donor, there is potentially a small 
amount of pyruvate generated (peak at 2.5 ppm), indicative of an aminotransferase reaction having 
occurred. However, in the absence of an APU standard it is difficult to tell if any APU was generated 
at the same time. In contrast, there was no evidence from HPLC for conversion of  into the amine 
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APU. The HPLC spectra show some changes when PsmM and PsmO are added to the reaction mixture, 
however no mass associated with APU or any intermediate is observed. The additional signals that 
appear at 3.2 ppm and between 3.5 to 3.8 ppm in Figure 5.24B are due to the presence of the CutSmart 
buffer which contains Tris-acetate and the CIP which is in a Tris-HCl buffer with 50% glycerol. This 
makes the 1H NMR spectra messy and difficult to interpret in the affected region, however the buffer 
was used to maximise the chances of the dephosphorylation reaction to generate . The production 
of pyruvate in spectra D of Figure 5.25 should indicate that alanine has been turned over by an 
aminotransferase and was used as a measure of the progress of the coupled reaction. Pyruvate and 
alanine were used as standards in place of APU because of the lack of availability of APU from chemical 
suppliers. 
 
Kinetic studies of oxidoreductase, PsmM 
 
It was important to determine whether the recombinant GMC oxidase PsmM is enzymatically active 
in the absence of the aminotransferase. If the oxidase uses oxygen as the oxidant then H2O2 should be 
produced and can be detected using components of a commercial glucose oxidase assay kit, namely 
horseradish peroxidase (HRP) and the dye Amplex Red (AR). In the presence of H2O2 the horseradish 
peroxidase catalyses reaction between H2O2 and Amplex Red to form the red-fluorescent oxidation 
product resorufin. A range of substrate concentrations (25 mM to 0.05 mM final concentrations) for 
 were mixed with a solution containing HRP and AR. These mixtures were then added to PsmM and 
the absorption at 570 nm (A570) was measured at 30 second intervals over 5 minutes. To test whether 
the oxidase could also accept uridine as a substrate, the same experiment was done with uridine 
substituted for . The initial rates were calculated by plotting A570 against time, and those initial rates 
were plotted against substrate concentration to generate the plots in Figure 5.28. With the assistance 
of Elisabeth Chen, a Michaelis-Menten model was fitted to the data and the Vmax and Km values for 
PsmM with  and uridine were calculated, along with their associated standard errors. The values for 




Figure 5.28: Michaelis-Menten plots showing the rate of reaction for PsmM using pseudouridine and uridine 
as substrates. (A) Rate vs substrate concentration for the oxidation of pseudouridine by PsmM (0.6 µM final 
concentration). The five substrate concentrations between 5 mM and 25 mM were omitted from the Michaelis-
Menten model because at substrate concentrations higher than 1 mM substrate inhibition effects begin to 
reduce the rate of reaction. (B) Rate vs substrate concentration for the oxidation of uridine by PsmM (0.6 µM 
final concentration). The substrate concentration of 25 mM was omitted from the Michaelis-Menten model. 
 
Table 5.4: Michaelis-Menten kinetic analysis of the oxidation of pseudouridine and uridine by 
PsmM. 
Pseudouridine  Uridine 
Vmax (s-1) 1.05x10-3  Vmax (s-1) 1.13x10-3 
Standard error 4.23x10-5  Standard error 7.57x10-5 
Km (M) 5.70x10-5  Km (M) 4.32x10-3 
Standard error 1.00x10-5  Standard error 9.40 x10-4 
kcat (s-1) 1.75x103  kcat (s-1) 1.88x103 
kcat/Km (s-1M-1) 3.07x107  kcat/Km (s-1M-1) 4.37x105 
 
These data confirm that the recombinant GMC oxidase uses oxygen as the oxidant and that it 
has the appropriate activity against the pseudouridine substrate. Further, an analysis of the kinetics 
shows PsmM favours pseudouridine by a factor of almost 2 orders of magnitude compared to uridine. 
This suggests PsmM as a gatekeeper ensuring the specificity of PUM production by S. albus A980 even 
in the presence of intracellular uridine. However, it also suggests that if pseudouridine concentrations 
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were to fall there is a possibility that normal uridine might be utilised by the PUM biosynthetic 
pathway (see section 5.2.5 below). 
The success of this work to prove the activity of PsmM, with a  substrate, in isolation could 
be repeated with the remaining enzymes. This would further increase confidence in the in vitro 
approach, and the hypothesised function of each enzyme. This would require pure intermediate 
substrates, which could either be prepared by enzymatic reaction, or purchased from a chemical 
supplier. 
 
5.2.3: Attempted Inactivation of Genes in the PUM cluster  
 
The in-frame deletion of individual genes within a biosynthetic gene cluster is a powerful approach to 
gaining insight into their role. For example, it can be used to help define cluster boundaries; it can be 
used to confirm the predicted role of the gene; and if an intermediate or shunt product is produced 
instead of PUM its structure gives valuable mechanistic clues. It is also the best way to interrogate the 
role of genes which have only non-specific annotation. At the start of work on the PUM cluster, there 
was no information on whether the strain was transformable. I identified PsmQ and PsmU as 
candidates for the N-hydroxylation of deoxy-PUM; and PsmN, annotated as an adenylate kinase, as 
an enzyme potentially involved in the biosynthesis of APU. Finally, PsmB, annotated as a hydrolase, 
was selected for knockout studies to interrogate its role, if any, in PUM biosynthesis. 
 While my work was in progress, an investigation by Sosio et al. 296 into the biosynthesis of 
PUM by knocking out key biosynthetic genes was published. This reported PsmQ as the enzyme 
uniquely responsible for the N-amide hydroxylation of deoxy-PUM. Because of this finding I 
discontinued work on psmQ and continued with putative hydrolase psmB, cytochrome P450 psmU 
and adenylate kinase psmN. This section describes the construction of appropriate vectors and 
attempts - unfortunately unsuccessful - to complete the deletion of psmB, psmU and psmN. In parallel, 
Dr Hui Hong undertook the in-frame deletion of psmL, encoding the truD-like pseudouridine synthase. 
 For the creation of the ΔpsmN, ΔpsmB, and ΔpsmU mutants a homologous recombination-
based approach was used. The strategy is outlined in Figure 5.29. Primers were designed to amplify 2 
kbp regions of DNA either side of each target gene (left and right flanking arms). The primers were 
designed to have overhanging 5’ ends, homologous to the adjacent sequence when assembled. The 
amplified PCR products were purified and assembled together with linearized pYH7 using the Gibson 
isothermal assembly method. The mixtures were used to transform E. coli DH10B and colonies were 
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screened by PCR for the desired insert. The identity of the PCR products and the final vector inserts 
was confirmed by gel electrophoresis analysis (Figure 5.30 and Figure 5.31). The procedure is 
described in detail in section 2.3. Figure 5.32 shows the gel electrophoresis from step 6 from each of 
the cloned vectors.  
 
Figure 5.29: The strategy for inactivation of psmN, psmB, psmQ, and psmU in S. albus A980. 
 
Figure 5.30: Gel electrophoresis image of PCR products used to construct the psmB knockout vector. The 
‘Ladder’ lane contains the DNA ladder (1 Kb Plus DNA Ladder). The numbers to the side of the ladder refer to 






Figure 5.31: Gel electrophoresis image of the cPCR screening to confirm correct assembly of the psmB 
knockout vector. The ‘Ladder’ lane contains the DNA ladder (1 Kb Plus DNA Ladder). The numbers to the side of 
the ladder refer to the size of each relevant band in the ladder. Each numbered lane refers to a colony of E. coli 
that was screened for the correct knockout vector. The lanes 1,3-6,8,9,11, and 13 to 19 contain bands with the 
correct size for the psmB knockout vector. The circled lane (lane 11) indicates the colony used to purify the psmB 




Figure 5.32: Gel electrophoresis images of the inserts from each of the three psm knockout vectors. The ‘L’ 
lanes contains the DNA ladder (1 Kb Plus DNA Ladder). The numbers to the side of the ladder refer to the size of 
each relevant band in the ladder. The ‘S’ lanes refer to a colony used to confirm the size of the assembled insert 




Once the knockout vectors for psmN, psmU, and psmB had been obtained they were 
transformed into A980 by intergeneric conjugation following the protocol outlined in section 2.2.6. 
Each conjugation plate was incubated at 30°C for up to 1 week. By then several colonies had begun to 
grow. These were streaked onto selective media to confirm the presence of the vector. After two more 
rounds of restreaking on selective media the putative exconjugants were free of any contamination 
and ready for the relaxation step. At this point I attempted unsuccessfully to use Streptomyces cPCR 
to gain additional evidence that these exconjugants contained the integrated vector. I considered the 
growth of the colonies on selective media evidence enough for the integration of the vector and 
continued with the relaxation steps. Three apramycin resistant colonies were selected from each 
conjugation plate, and these were relaxed by three rounds of inoculation and growth in liquid SFM, 
incubated at 30°C. After the third round a sample of each culture was taken, diluted and streaked 
across 2TY agar. Single colonies (24 for each knockout) were selected. These were patched onto pairs 
of non-selective and selective plates to test of the loss of antibiotic resistance. All colonies tested had 
lost resistance. Each relaxant was then grown in liquid culture and genomic DNA was extracted from 
each relaxant. A screen for the presence of a second crossover identified that all colonies were 
wildtype. As this screen was performed towards the end of my PhD I did not have time to repeat the 
experiment.  
 Fortunately, Dr Hui Hong had meanwhile succeeded in obtaining an in-frame deletion in the 
psmL gene (the truD homologue). She analysed the fermentation culture by LCMS. The HPLC spectra 
from A980 wildtype and A980 ΔpsmL showed a clear reduction in the signal representing PUM (see 
Figure 5.33). Unexpectedly, the ΔpsmL spectrum also revealed a UV absorption signal corresponding 
to a molecule with the same mass as PUM, but with a different retention time. Further investigation 
of this unexpected peak by MS/MS analysis revealed similar fragmentation patterns to PUM, 





Figure 5.33: LCMS analysis of wild type A980 and A980 ΔpsmL. (Experiment carried out by Dr Hui Hong). The 
spectra are normalised to the wild type A980 spectrum. The residual PUM production in the ΔpsmL strain is likely 
due to free  found in the cell from primary metabolism. The small peak seen in the ΔpsmL spectrum at 

















Enhanced production of N-PUM in Streptomyces albus A980  
 
Sosio and colleagues 296 also created a truD mutant of their Streptomyces sp. strain, and they stated 
categorically that in this mutant PUM production was abolished and no N-linked PUM was produced, 
as might have been expected if pseudouridine production was abolished. When they fed uridine to 
the ΔpsmL mutant they did not see the accumulation of any compound. 
 In contrast, Dr Hui Hong's analysis appeared to show that in S. albus A980, there is detectable 
redirection of biosynthesis towards an N-linked version of PUM when the truD -like gene psmL is 
deleted. This was supported by the kinetic data obtained here on the key GMC oxidase enzyme which 
accepted uridine as a substrate, albeit with much lower efficiency. To confirm this finding of the 
tolerance of the PUM biosynthetic pathway in S. albus A980, I used the S. albus A980-psmL kindly 
provided by Dr Hong. A high concentration of uracil was fed to the ΔpsmL mutant strain: a 2-day pre-
culture of A980-ΔpsmL was used to inoculate 50 ml SFM containing 50 mg of uracil in a 250 ml flask 
with a spring to help aeration. After 5 days the cells were harvested by centrifugation and the 
supernatant was used for HPLC and MS analysis. Figure 5.34 shows the results of that analysis and 
compares them against wild type A980. The data shown in Figure 5.34 were kindly provided by Dr. Hui 
Hong. The peak at m/z = 259.36 is characteristic of the N-PUM isomer and is generated by a cleavage 
of the C-N nucleoside bond, cleavage of the guanidinoacetate-glutamate amide bond, and loss of 
ammonia. 
 The analysis clearly showed that formation of N-PUM in the S. albus A980-ΔpsmL mutant is 
boosted by feeding with uracil. It is difficult to be sure why Sosio and colleagues obtained different 
results. It might be a strain difference that means no N-PUM is visible in their truD mutant. Also, 
feeding of uridine may be less effective than feeding with uracil. Meanwhile, direct comparison of the 
intensity of the signals for PUM and N-PUM shows that the N-nucleoside is produced in levels lower 
than those of C-nucleoside in the wild type, but that it is present in quantities that should allow its 
future isolation and testing. This result encourages the view that there is some flexibility in the PUM 












Figure 5.34: HPLC spectra and mass spectrometry data comparing the fermentation products of wild type A980 
and A980-ΔpsmL. (A) LCMS analysis of PUM and its N-isomer. The spectra have been normalised to wild type 





5.3: Concluding remarks 
 
The work described in this chapter has identified the biosynthetic gene cluster for the remarkable N-
nucleoside antibiotic pseudouridimycin in Streptomyces albus DSM 40763 (A980). It has defined the 
key genes required for the biosynthesis of PUM and characterised the amidinotransferase by in vitro 
assay. A two-step in vitro enzymatic reaction combining a pseudouridine-5’-phosphate glycosidase 
followed by a dephosphorylation reaction by a commercial phosphatase successfully generated  
from R5P and uracil. Unfortunately, the in vitro assays for the remainder of the pathway to APU were 
unsuccessful. Nevertheless, it was possible to show that the GMC oxidase PsmM shows the predicted 
ability to oxidise . Further, the enzyme accepted uridine albeit with much lower efficiency. 
Unfortunately, knockouts of psmN, psmU, and psmB were not obtained. The publication by Sosio et 
al. implicates PsmQ as the enzyme responsible for the N-amide hydroxylation, but the hydrolase, 
PsmB, and the p450, PsmU, still have no defined role in the cluster. The adenylate kinase, PsmN, is still 
an enticing target for knockout studies as its role in the biosynthesis of PUM cannot be easily 
predicted, other than the possibility of its involvement in the generation of . 
 The recent work by Sosio et al. 296 offers complementary insights into the biosynthesis of PUM. 
The Sosio gene cluster has differences in both arrangement and type of genes present when compared 
to the PUM cluster in A980. The work by Sosio and colleagues matches my predictions of the functions 
of the psm cluster genes. However, there is an interesting difference between the Sosio PUM producer 
and A980. When the truD homologue is knocked out in the Sosio strain the only PUM related 
compound that is observed is guanidinoacetate, and when the mutant strain is fed with uridine, it is 
not incorporated into any PUM related compound. This is in contrast to A980, where the ΔTruD 
(ΔpsmL) is able to take up uracil and incorporate it into an N-PUM, a novel nucleoside. Identifying and 
understanding the differences between the two PUM clusters may help characterise the pathway 
more fully.  
The important question that remains unanswered regards the origin of  as a substrate for 
PsmM. The TruD homologue, psmL, has the function of generating  residues in tRNA polymers, but 
that  must be released from the tRNA before it can be incorporated into PUM. It is possible that 
PsmL is capable of converting a metabolite related to uridine into  but the direct conversion of 
uridine into  has been attempted by Dr Hong with recombinant enzyme without success (Hong et 
al., 2018, in the press). Another possibility is that the PUM cluster does not have a dedicated pathway 
to produce free  and must rely on primary metabolism to degrade converted  in tRNA before 
incorporating the nucleoside into PUM. It has been well documented that Streptomyces spp. 
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undergoes significant RNA degradation, coinciding with important morphological changes during 
transition to stationary phase. In E. coli, tRNA has been shown to become significantly unstable as a 
stress response 300, so it is plausible that the entry of Streptomyces into the stationary phase, which 
can trigger secondary metabolite production, might also accelerate tRNA breakdown. It may be 
possible to probe this idea by measuring production of PUM across several timepoints and comparing 























Chapter 6: Conclusions and Suggestions for Future Work 
 
The work described in this thesis has addressed the current paradigm for genome mining, biosynthetic 
gene cluster characterisation, and engineering of biosynthetic gene clusters towards generation of 
novel biologically active compounds in Streptomyces spp. It has also explored new approaches 
towards PKS bioengineering in the form of Accelerated Evolution.  
The main conclusion that can be drawn from the work in Chapter 3 is that while the 
engineering technology Accelerated Evolution shows promise in the rapamycin PKS system, further 
work is required to understand the mechanisms behind AE before it can be generalised and applied 
to other systems. In its current state, AE can produce a large library of rapamycin derived compounds, 
but besides a single putative exception, no derivative compounds were observed in the three systems 
AE was applied to in this work. The failure to produce the desired response may be due to the absence 
of an important factor found in the rapamycin producer, or it might be the result of an inadequate 
protocol that can’t produce the desired recombination effect. This effect has only been recorded once, 
other than the paper by Wlodek et al. suggests that AE is possible in other strains but is extremely 
rare. I believe in the absence of a better understanding of the mechanism, it relied too heavily on luck 
to achieve an effect that had only been observed in a very small number of polyketide producing 
strains. Future work must focus on characterising the mechanism behind AE in Streptomyces 
rapamycinicus. There are several approaches that could contribute to this goal. Identifying genes that 
may be involved in the homologous recombination between modules and systematically knocking 
them out in an effort to break AE in the knockouts may provide a starting point for identifying other 
strains to which AE can be applied. This may be difficult as homologous recombination is not as well 
understood in Streptomyces spp. as it is in other species, but it could provide vital information on the 
mechanism behind AE and so should still be pursued. Another approach would be to study the genome 
sequence of the recombinant S. rapamycinicus strains. The recombination points may provide clues 
on the most effective entry points to be targeted for future attempts at applying AE. 
In addition to understanding the mechanism behind AE, future work should aim to create 
several approaches that assist with screening. The nature of AE experiments, especially in the work 
described above, produce large number of exconjugant and recombinant strains. Screening for 
desired traits takes considerable time and effort. The application of colony PCR for Streptomyces 
colonies saved a lot of work, but it is far from perfect. Any method that can ease the screening process 
should be explored and if successful, embraced. 
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The work in Chapter 4 focused on the genome mining of S. albus DSM40763. The conclusions 
that can be made from this work are firstly that the strain appears to be rich in uncharacterised 
biosynthetic potential, including rarer clusters such as a putative hybrid cyclodipeptide-terpene and 
an enormous 21 module PKS. The second conclusion that can be made is that an essentially complete 
genome sequence allows significant advantages over the more widespread fragmented genomes in 
the time and effort required to identify clusters of interest. Assembly of shotgun fragments can be 
difficult in strains such as Streptomyces, known for their high GC% content and large repeating 
sequences, but it is essential to giving an accurate estimate of biosynthetic potential. A further 
conclusion is that automated annotation tools such as antiSMASH cannot be used without manual 
curation. The program tends to annotate much wider limits to gene clusters than would be annotated 
manually, leading to the tool predicting hybrid clusters, and other misleading results. The tool also 
failed to identify certain classes of clusters, for example the PUM cluster was not correctly identified 
by the latest version of antiSMASH (4.0). 
Chapter 5 discussed the in vitro and in vivo studies towards characterising the PUM 
biosynthetic gene cluster found in S. albus DSM40763. PUM is a potentially valuable therapeutic 
agent, and its biosynthetic pathway shows promise as a platform for generating a library of related 
compounds. This was shown by the ability of the PUM gene cluster to generate an N-nucleoside 
isomer of PUM. The in vivo work initially identified this compound, with feeding experiments showing 
the presence of uracil (1 mg/ml) increased production of N-PUM. The in vitro work complemented this 
observation by showing that the oxidoreductase PsmM, which is thought to be the first enzyme acting 
on the  substrate in the PUM biosynthetic pathway, could turnover both  and U, with an 
approximate hundred-fold preference for . The promiscuity of PsmM and presumably the 
downstream enzymes suggest they may be tolerant for other substrates. An attempt to reconstitute 
the entire PUM biosynthetic pathway in vitro was halted by a failure to generate the 5’-amino-
pseudouridine (APU) component of PUM, however the guanidinoacetate component was generated 
in vitro by PsmH, and PsmM was shown to convert , which generates the precursor to APU. Future 
work in this area should focus on proving the ability of the aminotransferase, PsmO, to turn over the 
product of PsmM. This would be helped greatly by access to pure substrates which could be prepared 
by scaling up the enzymatic reactions described above and purified by preparative HPLC. Finally, the 
heterologous expression of the ligase, PsmK, should be investigated as it would be the last barrier to 
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psmI-R ttgtcgacggagctcgaattccgctcagacgccggcct          
psmK-F ctggtgccgcgcggcagccatatggcgctgctgctgctcaa 


























psmNRcheck-R ccggttggtgggcggaggat  
psmBLcheck-F tcgggagggctcttcggtgc 
psmBLcheck-R tgaggtgagcgccccgtcga 
psmBRcheck-F gccctgcgccaccttctcct 
psmBRcheck-R tcggtgcagaaggtggcgtcc 
psmULcheck-F aacggctcgccctccaaccc 
psmULcheck-R acacgccgcggtccacttcg 
psmURcheck-F gccaagtgcgccccggtgta 
psmURcheck-R cggtgatctggaacgcgcgg 
psmNKO-F gttggtccagtggtcgtgcg 
psmNKO-R gagaacagcacacggtcggc 
psmUKO-F cgttcccgtaatcccgctgc 
psmUKO-R tccacttcgacacgccaggt 
psmBKO-F tgcgccaccttctccttcgt 
psmBKO-R agggccccggagatgttgtc 
 
 
